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ABSTRACT 
 
The ultimate goal of antitumor vaccines is to develop memory CD8
+
 cytotoxic T lymphocytes 
(CTLs), which are critical mediators of antitumor immunity. Previous work in our lab 
demonstrated that the ovalbumin (OVA)-specific CD4
+
 T cell-based (OVA-TEXO) vaccine 
generated using OVA-pulsed dendritic cell (DCOVA)-released exosomes (EXOOVA) stimulates 
CTL responses via interleukin (IL)-2 and costimulatory CD80 signaling. To assess the potential 
involvement of other costimulatory pathways and to define the key constituent of costimulation 
for memory CTL development, we first immunized wild-type (WT) C57BL/6 and gene-knockout 
mice with WT CD4
+
 OVA-TEXO cells or OVA-TEXO cells with various molecular deficiencies. 
We then assessed OVA-specific primary and recall CTL responses using PE-H-2K
b
/OVA257–264 
tetramer and FITC-anti-CD8 antibody staining by flow cytometry. We also examined antitumor 
immunity against the OVA-expressing B16 melanoma cell line BL6-10OVA. We demonstrate that 
CD4
+
 OVA-TEXO cells form immunological synapses with cognate CD8
+
 T cells in vitro. By 
assessment of the pattern of ex vivo interactions between OTI CD8
+
 T cells and OVA-TEXO or 
(K
b-/-
)TEXO cells lacking peptide/major histocompatibitity complex (pMHC)-I expression, we 
provide the first visible evidence on the critical role of exosomal pMHC-I in targeting OVA-
TEXO to cognate CD8
+
 T cells using two-photon microscopy. By assessing primary and recall 
CTL responses in mice immunized with OVA-TEXO cells or with OVA-TEXO cells lacking the 
costimulatory molecules CD40L, 4-1BBL or OX40L, we demonstrated that these costimulatory 
signals are dispensable for CTL priming by OVA-TEXO cells. Interestingly, CD40L, but not 4-
1BBL or OX40L, plays a crucial role in the development of functional memory CTLs against 
BL6-10OVA tumors. Overall, this work suggests that a novel CD4
+
 T cell-based vaccine that is 
capable of stimulating long-term functional CTL memory via CD40L signaling may represent a 
novel, efficient approach to antitumor vaccination. 
 
Breast cancer is the most common cancer among women in the western world. Approximately 
20-30% of invasive breast carcinomas are proto-oncogene human epidermal growth factor 
receptor (HER)-2 positive and associated with increased metastatic potential and poor prognosis. 
The survival benefit of anti-HER2 driven therapies demonstrated in clinical trials indicates that 
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HER2 is one of the most promising molecules for targeted therapy to date. Above results prompt 
us to assess whether CD4
+
 T-cell-based vaccine can stimulate efficient HER2-specific CD8
+
 
CTL responses and antitumor immunity in transgenic mice with HER2-specific self-immune 
tolerance. We prepared HER2-specific HER2-TEXO using ConA-stimulated CD4
+
 T cells with 
uptake of exosomes released from HER2-expressing AdVHER2-transfected DCs. We found that 
HER2-TEXO vaccine is capable of inducing HER2-specific CTL responses and protective 
immunity against transgene HLA-A2/HER2-expressing B16 melanoma BL6-10HLA-A2/HER2 in 2/8 
double transgenic HLA-A2/HER2 mice with HER2-specific self-immune tolerance. The 
remaining 6/8 mice had significantly prolonged survival. Therefore, the novel T cell-based 
HER2-TEXO vaccine may provide a new therapeutic alternative for women with HER2
+
 breast 
cancer.  
 
In contrast to CD4
+
CD25
+
 regulatory T cells (Tregs), mechanisms of CD8
+
CD25
+
 Treg-mediated 
immunosuppression are not well understood. In this study, we purified polyclonal CD8
+
CD25
+
 
Tregs from C57BL/6 mouse splenocytes and expanded them in culture medium containing 
CD3/CD28 microbeads. By using these amplified CD8
+
CD25
+
 Tregs, we demonstrated that 
CD8
+
CD25
+
 Tregs inhibit naive CD4
+
 T-cell proliferation and induce naive T-cell anergy by up-
regulating T-cell anergy-associated early growth response 2 (EGR2), and by decreasing T-cell 
proliferation and IL-2-secretion upon stimulation. They also impact the expression of perforin on 
effector CTLs and directly induce perforin-mediated CTL apoptosis. CD8
+
CD25
+
 Tregs, when 
pulsed with OVA323-339 peptide, exert an enhanced inhibition. Interestingly, CD8
+
CD25
+
 Tregs, 
when pulsed with myelin oligodendrocyte glycoprotein (MOG)35-55 peptide, become capable of 
inhibiting MOG35-55-induced experimental autoimmune encephalomyelitis (EAE). Two-photon 
microscopic observations suggest that OVA323-339-pulsed (armed) CD8
+
CD25
+
 Tregs reduce the 
interactions between DCs and cognate CD4
+
 T cells ex vivo by increasing velocities of T cells in 
mouse lymph nodes. Therefore, redirecting antigen-specificity to nonspecific CD8
+
CD25
+
 Tregs 
can be achieved for enhanced immunosuppression through their arming with the antigen-specific 
pMHC-II complexes. This approach may have great impact on improvement of endogenous 
polyclonal Treg-mediated immunotherapy for autoimmune diseases.  
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Taken together, our studies demonstrate that nonspecific polyclonal CD4
+
 T cells and 
CD8
+
CD25
+
 Tregs, when armed with HER2 and MOG antigen-specific pMHC-I and -II 
complexes, become capable of stimulating enhanced HER2-specific CTL responses and 
antitumor immunity in double transgenic HLA-A2/HER2 mice and inducing enhanced MOG-
specific immunosuppression in MOG-induced EAE mice, respectively. Therefore, redirecting 
antigen specificity to nonspecific CD4
+
 T and CD8
+
CD25
+
 Tregs by pMHC complex arming 
may have great impact in development of novel T cell-based vaccines for treatment of cancer 
and autoimmune diseases. 
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CHAPTER 1 LITERATURE REVIEWS 
 
1.1 Cells of the Immune System 
 
1.1.1 Overview of immune responses 
 
Immunity results from a complex interplay between the antigen-nonspecific innate immune 
responses and antigen-specific adaptive immune responses. Innate immunity provides the early 
line of defense against microbes using non-clonal recognition receptors, including Toll-like 
receptors (TLRs), NOD-like receptors (NLRs), lectins and helicases. The principal effector cells 
of innate immunity are mononuclear phagocytes (monocytes, dendritic cells (DCs) and 
macrophages), neutrophils and natural killer (NK) cells. Among all those cells, DCs are 
considered as an essential bridge between the innate and adaptive immune responses, since they 
are linked to their environment through a serial of molecular sensors that allow them to capture 
invading microbes and to transmit the resulting information to lymphocytes. In contrast to innate 
immunity, adaptive immunity develops as a response to successive exposure to a particular 
microbe and adapts to this infection. There are two types of adaptive immune responses called 
humoral immunity and cellular immunity, which are mediated by different components of the 
immune system and function to eliminate different types of microbes. Humoral immunity is 
mediated by antibodies (Abs), which can bind to the microbes and toxin, and assist in their 
elimination. B lymphocytes are the only cells capable of producing Abs, thus functioning as the 
mediators of humoral immunity. Cellular immunity is mediated by T lymphocytes, which 
recognize the antigens of microbes and function to destroy these microbes or the infected cells. T 
lymphocytes have a restricted specificity for antigens that attach to host major histocompatibility 
complex (MHC) and express on the surfaces of other cells, thus only recognizing and responding 
to cell surface-associated but not soluble antigens. Antigen-presenting cells (APCs) are also 
required during the initiation and development of adaptive immune responses to capture and 
display antigens to specific lymphocytes, thus the elimination of antigens often requires the 
participation of various types of cells. Here, only a few immune cell types will be discussed.  
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1.1.2 DC subsets 
 
DCs play important roles in coordinating innate and adaptive immune responses. They have long 
membranous projections and are related in lineage to mononuclear phagocytes. They also 
express pattern recognition receptors and respond to microbes by secreting cytokines. On the 
other hand, as professional APCs, DCs are critical for induction of adaptive immunity and 
tolerance. DCs comprise a heterogeneous population, which displays different surface markers, 
functions and origins across various organs in the body. DC subsets can be classified in several 
ways based on many criterions reviewed by Steinman and Idoyaga (1). Here, DCs are classified 
based on the precursor populations from which the various DC subsets originate. DCs derived 
from common DC progenitor (CDP) and precursor DC (pre-DC) populations are classified as 
conventional DCs, while monocyte-derived DCs and plasmacytoid DCs (pDCs) are classified as 
non-conventional DCs. Notably, although pDCs are derived from CDP, they are still be 
classified as non-conventional DCs due to their distinct function in secreting large amount of 
type I interferon.  
 
1.1.2.1 Conventional steady-state DCs 
 
Steady-state conventional DCs derived from CDP and pre-DCs can be further divided into 
migratory and lymphoid DCs. Migratory DCs, which have been found in the skin, lung, intestinal 
tract, liver and kidneys, migrate from peripheral tissues to lymphoid organs, whereas lymphoid 
DCs reside in the lymphoid organs without migratory function.  
 
1.1.2.1.1 CDP and pre-DCs derived migratory DCs 
 
Migratory DCs derived from CDP and pre-DCs have been characterized based on their different 
organ origin. Dermal langerin
+
 CD103
+
 DCs have been shown to play crucial role in cross-
presentation of self and viral antigens (2). CD103
+
 CD11c
high
 CD11b
-
 DCs in the lung have been 
found to migrate to the draining lymph nodes, produce interleukin (IL)-12 and cross-present 
antigens to CD8
+
 T cells (3, 4). In the intestinal tract, CD103
+
 DCs have also been found in 
Peyer’s patches (PP) and lamina propria (LP). CD103+ CX3CR1- CD11b+ (CD103+ LP) DCs can 
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recognize pathogenic intestinal bacteria via TLR5 (5) and drive induction of gut homing CD8
+
 T 
cells (6, 7), thus making it the major DC subset responsible for initiating adaptive immune 
responses in the intestinal tract. Additionally, they can also serve a regulatory role (8). Hepatic 
CD103
+
 CD11b
-
 DCs have been shown to highly express FMS-like tyrosine kinase 3 (Flt3), 
pointing to their pre-DCs origin (9). The pre-DC derived renal CD103
+
 DCs have been shown to 
mediate tolerance to kidney allografts (10). 
 
1.1.2.1.2 Lymphoid DCs 
 
Lymphoid DCs have been found in lymphoid organs such as lymph nodes, spleen and thymus, 
and lack migratory properties. They have been further divided into CD8
+
 CD4
+
 DCs, CD8
-
 CD4
-
 
DCs and CD8
-
 CD4
+
 DCs. Since CD8
-
 CD4
-
 DCs and CD8
-
 CD4
+
 DCs share a high degree of 
similarity, they will be referred to as CD8
-
 DCs.  
 
CD8
+
 DCs 
 
CD8
+
 DCs were initially thought to express the complete CD8αβ heterodimer found on T cells, 
however, later it became apparent CD8
+
 DCs express the CD8αα homodimer instead. CD8+ DCs 
have been found to play a key role in viral immune responses to intracellular pathogens in the 
spleen and the lymph nodes (11). They are the most potent interferon (IFN)-α producers among 
lymphoid DCs, which contribute to viral immunity through increasing cytotoxicity of NK and T 
cells (12). The expression of CD36 and C-type lectin domain family 9A (Clec9A) has been 
found to give CD8
+
 DCs the ability to phagocytose dead cells (13). The distinguishable feature 
of CD8
+
 DCs is their ability to cross-present exogenous antigens through an MHC class I 
pathway (14) and this process has been found not only mediated by phagocytosis of dead cells, 
but also mediated by uptake of soluble antigens (15). Stimulation of CD8
+
 DCs with a TLR 
ligand can induce CD40 expression, leading to an effector CD8
+
 T-cell response (16). Moreover, 
the high expression of CD205 on CD8
+
 DCs has been shown to mediate the efficient processing 
and presentation of antigens on MHC class II molecules (17), while neutralizing this CD8
+
 
CD205
+
 DCs has been found to induce CD8
+
 T-cell tolerance (18). 
 
 4 
CD8
-
 DCs 
 
Compared to CD8
+
 DCs, the understanding of CD8
-
 DCs is fairly limited. One functional 
significant difference between CD4
-
 CD8
-
 and CD4
+
 CD8
-
 DCs is their ability to secrete IL-
12p70 upon appropriate stimulation (19). The ability of CD8
-
 CD4
-
 DCs in driving T-cell 
response has been shown to depend on TLR9 signaling (20), whereas their ability in priming 
regulatory T cells (Tregs) has been found to relate to transforming growth factor (TGF)-β1 
secretion (21). On the other hand, the secretion of IL-10 by CD8
-
 CD4
+
 DCs have been found to 
reduce the severity of experimental autoimmune encephalitis (EAE) in murine models through 
their tolerizing effects on T helper (Th) cells (22). 
 
1.1.2.2 Non-conventional DCs 
 
Non-conventional DCs are usually not seen in steady state but originated in response to 
inflammatory stimuli. Plasmacytoid DCs, which are unique in their ability to secrete high 
amounts of IFN despite of their CDP origin, and monocyte-derived DCs are classified as non-
conventional DCs. However, the identification monocyte-derived DCs that arise under steady 
state conditions further complicates this classification. 
 
1.1.2.2.1 Plasmacytoid DCs 
 
Plasmacytoid DCs express TLR7 and TLR9, which recognize viral RNA and DNA, leading to 
the production of type I IFN production (23). In addition to serving as a source of IFN, they have 
also been shown to differentiate activated B cells into plasma cells via secretion of type I IFN 
and IL-6 (24). Moreover, MHC II synthesis did not down-regulate when pDCs undergo 
maturation and present antigens, thus providing pDCs with the ability to continuously present 
endogenous viral antigens in their activated state (25). Plasmacytoid DCs have also been 
associated with maintenance of peripheral tolerance by interacting with CD4
+
 T cells via MHC II, 
which promotes the induction of Treg expansion (26). In contrast, they have been associated with 
autoimmune responses due to the production of IFN after their recognition of microbial TLR9 
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(27). The differential ability of pDCs in driving immunity versus tolerance might be attributed to 
different pDC subsets. 
 
1.1.2.2.2 Monocyte-derived DCs 
 
Monocytes are derived from common myeloid progenitors (CMPs) and macrophage-DC 
progenitors (MDPs), and can give rise to DCs under both inflammatory and steady state 
conditions. Monocyte-derived DCs, which are found in peripheral tissues such as the skin, 
intestine, lung and kidneys, have the ability to uptake antigen followed by migrating to draining 
lymph nodes. Langerhans cells (LCs) arise from skin-localized Ly-6C
+
 monocyte precursors 
during inflammation. They possess a unique cellular organelle Langerin (CD207)-containing 
Birbeck granule as their main component, which plays a role in antigen uptake (28). Activation-
induced LCs have been shown to carry the antigen to the draining lymph nodes, where lymphoid 
CD8
+
 DCs take up the antigen followed by cross-presenting to CD4
+
 and CD8
+
 T cells (29, 30). 
E-cadherin
+
 intestinal DCs, which secret very high amounts of IL-23 and IL-12 upon stimulation 
(31), as well as CD103
-
 CX3CR1
+
 intestinal DCs, which mediate the initial innate immune 
response against pathogen (32), have also been shown their monocytic origin. In addition, 
pulmonary monocyte-derived CD103
-
 CD11c
hi
 CD11b
+
 DCs have been shown to play a critical 
role in airway inflammation by regulating Th2 (33) and Th17 (34) immune responses. Moreover, 
monocyte-derived CX3CR1
+
 CD11b
+
 DCs in kidney have been associated with the infiltration of 
T cells (35).  
 
1.1.3 CD4+ T lymphocyte subsets 
 
T lymphocytes, which mature in the thymus, are a type of lymphocytes that play a central role in 
cell-mediated immunity. They can be distinguished from other lymphocytes by the presence of a 
T-cell receptor (TCR) on the cell surface. CD4
+
 T cells, which possess TCR and CD4 molecules, 
help to eliminate microbes through secretion of cytokines and activation and through recruitment 
of other immune cells. Several subsets of CD4
+
 T cells have been identified based on their 
cytokine secretion and effector function.  
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1.1.3.1 Th1 and Th2 cells 
 
Th1 and Th2 subsets develop from the same naive CD4
+
 T lymphocytes precursors, and the 
pattern of differentiation is determined by stimuli present early during immune responses. Th1 
differentiation occurs in response to intracellular bacteria and parasites (36), and involves the 
cooperation among signals from TCR, cytokines IFN-γ and IL-12, and transcription factor T-bet, 
signal transduction and transcription (STAT) 1 and STAT4 (37, 38). They evoke cell-mediated 
immunity and phagocyte-dependent inflammation mainly by secreting cytokine products such as 
IFN-γ, lymphotoxin α (LTα), and IL-2. IFN-γ is essential for the activation of macrophages, thus 
resulting in enhanced phagocytic activity (39). LTα has been shown to be responsible for some 
of the Th1-induced autoimmune diseases (40). IL-2, as T cell growth factor, promotes 
proliferation of CD8
+
 T cells, as well as the development of CD8
+
 memory cells after antigen 
priming, thereby participating in robust secondary immune response (41). Besides, it also 
essential for the survival and activation of thymus-derived natural Tregs (42). 
 
Th2 differentiation occurs in response to some extracellular microbes, including helminthes and 
allergens (43), and involves the cooperation among signals from the TCR, the cytokine IL-4, and 
the transcription factor GATA-3 and STAT6 (44). They evoke strong Ab responses and 
eosinophil accumulation mainly by producing cytokines IL-4, IL-5, IL-9 and IL-13. IL-4 is a 
major cytokine involved in IgE switching and secretion by B cells, as well as in regulating other 
proinflammatory mediators (45, 46). IL-5 mainly targets eosinophils and their precursors, 
leading to their activation and release (47). Th1 and Th2 cells are considered terminally 
differentiated based on (i) lineage commitment of Th1 and Th2 require transcription factors T-
bet and GATA-3, respectively; (ii) their abilities to mutually inhibit one another’s activity 
through cytokine secretion. The concept of Th1/Th2 paradigm also provides an explanation of 
adaptive immunity against intracellular versus extracellular pathogens, and the pathogenesis of 
immune-mediated tissue damage in infection and allergy. 
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1.1.3.2 Th17 cells 
 
Th1 cells have been associated with several autoimmune diseases through the production of 
inflammatory IFN-γ and IL-12, however, mice with selective blockade of IFN-γ and IL-12 
function were still sensitive to some of the autoimmune diseases (48, 49), leading to discovery of 
a new CD4
+
 T cell subset-Th17. Th17 differentiation occurs in response to extracellular bacteria 
and fungi, and involves the interplay of signals from cytokines IL-6, IL-21, IL-23 and TGF-β, 
and transcription factor retinoic acid receptor-related orphan receptor gamma-T (RORγt) (50) 
and STAT3. They are also involved in the generation of autoimmune diseases by producing 
effector cytokines IL-17A, IL-17F, IL-21, and IL-22. IL-17 leads to the induction of 
proinflammatory cytokines and chemokines to ensure the chemotaxis of inflammatory cells to 
the sites of inflammation (50, 51). In addition to facilitating Th17 development, IL-21 has also 
been shown to activate T and NK cells, as well as to induce B cell differentiation (52, 53). IL-22 
is known to mediate inflammatory response in mucosal host defense against bacterial pathogens 
(54), and has been found its tissue protective property in limiting liver tissue damage (55).  
 
1.1.3.3 Regulatory CD4+ T cells 
 
CD4
+
 Tregs exist as natural thymus-derived and peripheral-induced subset. They play an 
important role in the maintenance of immunologic tolerance to self and foreign antigen after 
effector cell-mediated pathogens clearance, thereby protecting against immunopathology (56, 
57). The CD4
+
 Tregs differentiation involves the interplay of signals from cytokine TGF-β and 
transcription factor forkhead box P3 (Foxp3) and STAT5 (58, 59), while their main effector 
cytokines include IL-10, TGF-β, and IL-35. IL-10 is a potent inhibitory cytokine with the ability 
to suppress proinflammatory. TGF-β controls the differentiation of proinflammatory T cells. The 
combination effect of IL-10 and TGF-β has been shown to potently suppress IgE production, 
indicating their important roles in limiting tissue damage and attenuating allergic inflammation 
(58, 60).  
 
 8 
1.1.3.4 Follicular helper (Tfh) T cells.  
 
Tfh cells participate in the development of antigen-specific B-cell immunity in follicular areas of 
lymphoid tissue. Their differentiation involves the interplay of signals from cytokines IL-6 and 
IL-21, and transcription factor B-cell lymphoma 6 protein (Bcl6) and STAT3 (61, 62). Tfh cells 
express distinct surface marker C-X-C chemokine receptor-5 (CXCR5) after immunization and 
enter the pre-germinal centre for initial interactions with antigen-primed B cells (63). They later 
enter into the germinal area to further promote the development of long-live B memory cells.  
 
1.1.3.5 More CD4+ T-cell subsets: Th9 and Th22 cells 
 
Th2-produced IL-9 has been reported to play an important role in the pathogenesis of asthma, 
IgE class switching and parasite clearance (64). However, a new IL-9 producing CD4
+
 T-cell 
subset-Th9 was reported by two dependent group based on their studies of TCR stimulated naive 
CD4
+
 T cells in the presence of TGF-β and IL-4 (65, 66). The transcription factor that involved 
in Th9 cells differentiation was later identified as the ETS family transcription factor PU.1 and 
IFN regulatory factor 4 (IRF4) (67, 68). Despite IL-22 can be produced by Th17 cells and a 
subset of NK cells, three dependent groups showed a new IL-22 secreting CD4
+
 T subset-Th22, 
which can be generated by stimulating with pDCs in the presence of IL-6 and tumor necrosis 
factor-alpha (TNF-α) (69-71). Unlike other Th cells, no transcription factors have been identified 
for the development of Th22 cells yet. Only aryl hydrocarbon receptor was reported to play a 
role in IL-22 secreting by Th22 cells (69, 70).  
 
1.1.4 CD8+ T lymphocytes  
 
CD8
+
 cytotoxic T lymphocytes (CTLs), which can expand their number many thousand-fold at 
the peak of a primary immune response, are effector CD8
+
 cells and able to eliminate 
intracellular microbes mainly by killing infected cells. They kill targets that express the MHC-I-
associated antigen in a contact dependent way, and exert their cytolytic function mainly through 
perforin/granzyme-mediated or Fas ligand/Fas-mediated apoptosis (72). Following the 
elimination of the infected cells, effector CD8
+
 T cells undergo a precipitous contraction phase. 
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Only ~5-10% pathogen-specific effector CD8
+
 T cells will survive to further mature into 
memory CD8
+
 T cells, while the majority will go apoptotic cell death. Notably, not all effector 
CD8
+
 T cells have equal potential to form memory T cells, and their fates are based on the 
differences in gene and protein expression, effector functions and long-term proliferative 
capacity (73). Two broad phenotypes of memory T cells have been described, 
CD62L
high
CCR7
high
 (CC-chemokine receptor 7) central memory T cells and CD62L
low
CCR7
low
 
effector memory T cells (74, 75). Other CD8
+
 subpopulation, like CD8
+
 T cells with regulatory 
activities, will be further discussed in Section 1.6. 
 
1.1.5 Summary 
 
Except for the above mentioned cells, B lymphocytes, monocytes, macrophages, granulocytes 
(eosinophils, neutrophils, basophils), mast cells and NK cells are all indispensable for making up 
the cellular components of the innate and adaptive immune systems, thus constituting a dynamic 
communication network to protect body from foreign organisms. 
 
1.2 Exosome (EXO)-derived vaccines  
 
1.2.1 EXO biogenesis and composition 
 
EXOs, small membrane vesicles (40-100 nm), can be formed and secreted by the fusion of late 
endocytic compartments (multivesicular endosomes) (MVEs) containing intraluminal vesicles 
with plasma membrane via reverse-budding intracellular events (76). They were originally 
described as microvesicles containing ectoenzyme activity that were secreted by neoplastic cell 
lines (77). Their endocytic origin was reported a few years later (78, 79). Subsequent studies 
showed that EXOs can be constitutively or inductively secreted by a variety of cell types, 
including DCs, macrophages, mastocytes, T and B cells, epithelial cells (80), platelets, 
fibroblasts, schwann cells, adipocytes, neuronal cells  and numoerous tumor cell lines (76, 81-
84). In addition, EXOs can be purified without any mechanical dissociation from several 
biological fluids (84), such as human plasma, serum, bronchoalveolar fluid, urine, saliva, pleural 
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effusions of ascites, tumoral effusions, epididymal fluid, amniotic fluid and milk, indicating that 
EXOs can be released from several cell types and tissues in vivo.  
 
The biogenesis of EXOs is regulated by multiple signaling molecules and can be triggered by 
many factors including extracellular stimuli and stresses. EXOs can be released into the 
extracellular environment by the fusion of multivesicular bodies (MVBs) with the cell surface. 
Briefly, plasma membrane first contracts and draws MVBs membranes together with the help of 
soluble N-ethylmaleimide-sensitive factor attachment protein receptor complex (SNARE 
complex) followed by cleaving the membrane connection and releasing the vesicles into the 
extracellular space (85) in a process dependent on the activity of Ras-related GTPase Rab27A 
and Rab27B (86).  
  
EXOs have a lipid bilayer with a characteristic “saucer-like” morphology, which is consistent 
with the observed size and morphology of internal vesicles in MVEs (87), and float on sucrose 
gradients ranging from 1.13-1.19 g/mL. Based on the extensive proteomics and 
phosphoproteomics studies, EXOs are suggested to shuttle wide array of biologically relevant 
molecules, including proteins, lipids, carbohydrates and RNAs. In addition to the similarity of 
their morphology, EXOs are thought to be somewhat conservative in their protein and lipid 
composition. The ubiquitous proteins include cytoskeletal proteins, intracellular membrane 
fusion and transport proteins, signal transduction proteins, metabolic enzymes, heat-shock 
proteins (HSPs), tetraspanins, lipid-related proteins and phospholipases (88, 89). Certain raft-
associated lipids are also enriched in EXOs, such as ceramide (90), cholesterol, sphingolipids 
and phospoglycerides with long and saturated fatty-acyl chains (91). The finding of nucleic acid 
contents of EXOs, such as messenger RNAs (mRNAs), small non-coding microRNAs (miRNAs) 
and mitochondrial DNA (mtDNA), has been considered as a major breakthrough in EXO 
research.  
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1.2.2 EXO biological functions 
 
1.2.2.1 Elimination of obsolete proteins 
 
For many years, EXOs have been considered as organelles to remove cell debris or obsolete 
proteins out of the cell. During the maturation of erythrocytes, EXOs are released to eliminate of 
obsolete transferring receptors (TfR) (78, 79, 92, 93). TfR’s interaction with heat shock cognate 
protein 70 (HSC70) in secreted EXOs is required for the complete lost of TfR from the surface 
of the erythrocytes (94). Thus, EXOs was suggested as an effective alternative to lysosomal 
degradation, particularly in eliminating redundant plasma membrane proteins or other proteins 
that are resistant to degradation by lysosomal proteases. Therefore, the primary function of 
EXOs is postulated to clear away obsolete proteins during cell differentiation. 
 
1.2.2.2 Intercellular communication 
 
EXOs can affect the physiology of recipient cells in various ways via long-range membrane 
exchange. Recipient cells can induce intracellular signaling, as well as confer new functional 
properties after the acquisition of new receptors, enzymes or even genetic materials from the 
EXOs. Interactions between EXOs and recipient cells include (i) adhesion of EXOs to the 
surface of recipient cells via lipid or ligand-receptor conjunction followed by the direct fusion 
with recipient plasma membrane; (ii) internalization of EXOs into endocytic compartments 
followed by incorporation with endosomal membranes and further recycling to the recipient cell 
surface; (iii) degradation of endocytosed or phagocytosed EXOs followed by loading them onto 
the recipient MHC complex and further recycling to the recipient cell surface (84). Take DCs-
released EXOs for example, it has been reported that mature DC-derived intercellular adhesion 
molecule (ICAM)-1 bearing EXOs can be captured by activated T cells (95) and CD8
+
 DCs (96) 
via ICAM-1-LFA (lymphocyte function-associated antigen)-1 interaction. DC-derived EXOs 
have also be addressed specifically to both T cells and DCs through binding of exosomal αMβ2 
integrin to ICAM-1 on T cells and DCs (76). In addition, DC-derived EXOs bearing MFG-E8 
(lactadherin) can bind αvβ3/5 integrins expressed by DCs via Arginine-Glycine-Aspartic (RGD) 
domain (81, 97). Furthermore, tetraspanins on DC-derived EXOs have been shown related to 
 12 
their capture by DCs (97). Of note, DC- or T cell-derived EXOs can be captured by T cells or 
DCs via antigen-specific TCR-pMHC-I/II interaction (98-100). Finally, DC-released EXOs 
exposing phosphatidylserine (PS) on their surface. Therefore, they can be captured by activated 
lymphocytes or phagocytes that express PS receptors such as T-cell immunoglobulin- and 
mucin-domain-containing molecules T cell-immunoglobulin-mucin 1 (TIM1) and TIM4 (101).  
 
Besides targeting to recipient cells to exchange proteins and lipids or to trigger downstream 
signaling events, EXOs also deliver specific nucleic acid cargo to mediate intercellular 
communication (102-104) between widely separated locations in the body. Since miRNAs are 
short, non-coding RNAs that regulate the expression of complementary mRNAs, the shuttling of 
these molecules between cells aids in regulating the biology of target cells. The spread of 
oncogenes (105), mRNA, miRNA (106) and viruses (107, 108) has been reported.  
 
1.2.3 Modulation of immune responses 
 
1.2.3.1 Antigen presentation (Antigen-specific immune responses) 
 
EXOs derived from culture cells or body fluids contain whole or partially processed antigenic 
materials and peptide-MHC (pMHC) complexes, thus playing a critical role in triggering 
immune responses via antigen presentation. EXOs derived from virtually any cell type bear 
MHC-I molecules that could potentially induce CD8
+
 T-cell activation, in certain circumstances, 
could be directly presented to T cells via preformed peptide-MHC class I (pMHC-I) complex 
(109-111). Although preformed pMHC complexs on EXOs is functional, recipient DCs can also 
process MHC molecules and antigen from allogeneic DC-released EXOs to generate restriction 
peptides to reload onto their own MHC molecules, thus indirectly inducing antigen-specific 
CD8
+
 (112-114) and/or CD4
+ 
(112, 115, 116) T-cell responses. In addition, tumor-released EXOs 
purified from cultured tumor cells (117) or from ascites of patients with tumors (118) have been 
shown to bear tumor antigens and pMHC-I complex, leading the activation of antigen-specific T 
cells in vitro in the presence of recipient DCs. The antigen-specific immune responses of tumor-
derived EXOs are strictly dependent on recipient DCs, which may be due to the absence of 
costimulatory molecules on the surface of tumor cells and tumor cell-derived EXOs. Moreover, 
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intracellular pathogens infected macrophages-released EXOs have been shown to carry 
pathogen-derived antigens, which can be transferred to DCs leading to the activation of CD4
+
 
and CD8
+
 T cells, as well as the generation of memory CD4
+
 and CD8
+
 T cells (119). 
Furthermore, EXOs derived from endothelial cells infected with cytomegalovirus (CMV) also 
transfer virus-derived antigens to DCs for activation of CD4
+
 T cells, thus contributing to 
allograft rejection (120). Therefore, EXOs can directly or indirectly induce antigen-specific T-
cell responses, representing a potential cell-free vaccine for cancer immunotherapy. 
 
1.2.3.2 Antigen-independent roles in immune responses 
 
In addition to MHC molecule-mediated antigen-specific immune responses, EXOs can promote 
or inhibit immune responses in various antigen-independent ways. 
 
1.2.3.2.1 Antigen-independent immunostimulatory effects 
 
Mycoplasma-contaminated EXOs released by infected DCs have been shown to induce the 
polycolonal activation of B cells and promote immunoglobulin (Ig) secretion (121). HLA-B-
associated transcript-3 (BAT3) bearing EXOs derived from immature DCs can promote NK-cell 
activation and cytotoxicity (122). Furthermore, DC-derived EXOs containing both IL-15Rα and 
NKG2D ligands can contribute to NK-cell proliferation, activation and cytotoxicity in a IL-
15Rα- and NKG2D-dependent fashion (123), which is different from the NKG2D ligand-bearing 
tumor-derived EXO-mediated immunosuppressive effect. Although many studies reported that 
tumor-derived EXOs containing FasL and NKG2D ligand exert immunosuppressive effects, 
there are still many reports showing that tumor-derived EXOs are immunogenic. The 
discrepancy may be due to differences in the types of EXOs produced and microenvironment 
such as immunological conditions. EXOs from heat-shocked (stressed) tumor cells have been 
found to promote NK-cell cytolytic activity, TNF-α production by macrophages and DC 
maturation, and more efficiently induce CD4
+
 Th1-polarized and CD8
+
 CTL responses in MHC-
independent manner (124-127). EXOs released from macrophages infected with intracellular 
pathogens contain pathogen-associated molecular patterns (PAMPs) and can induce the secretion 
of proinflammatory cytokines such as TNF-α and IL-12 by recipient macrophages in a Toll-like 
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receptor (TLR)- and myeloid differentiation factor 88 (MyD88)-dependent manner (128, 129). 
Mast cell-derived EXOs harboring MHC-II, cell division cyclin 25 (Cdc25) and 
immunostimulatory molecules (such as CD86, LFA-1 and ICAM-1), can induce T cell 
activation, blast formation, cell proliferation and production of IL-2 and IFN-γ (130).  
 
1.2.3.2.2 Antigen-independent immunosuppressive effects 
 
Tumor-derived EXOs: EXOs derived from tumor cells such as melanoma and colorectal cancer 
cells can induce T-cell apoptosis via exosomal Fas ligand (FasL) (CD95L) and TNF-related 
apoptosis-inducing ligand (TRAIL)/APO2 ligand (APO2L) (131, 132), which is involved in 
tumor immune escape. Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma (NPC) 
cell- and NPC-bearing patient-derived EXOs contain high amounts of galectin-9, which can 
attenuate antitumor T-cell responses leading to immune evasion of tumor cells (133). In addition, 
mammary tumor-derived EXOs can inhibit IL-2-mediated activation, proliferation and cytotoxic 
activity of NK cells (134). Clayton et al. (135) reported that tumor-derived EXOs bearing 
membrane-bound TGF-β1 can impair IL-2-induced CD8+ T-cell and NK-cell proliferation as 
well as their killing function by enhancing the function of CD4
+
CD25
+
Foxp3
+
 Tregs via 
exosomal membrane-bound TGF-β1. The same group further reported that tumor-released EXOs 
can suppress the cytotoxic capacity of CD8
+
 T cells and NK cells through exosomal NKG2D 
ligand MHC class I polypeptide-related sequence A (MICA)- and TGF-β1-mediated 
downregulation of activating receptor NKG2D (136). Moreover, tumor-derived EXOs can impair 
the differentiation of myeloid precursors into DCs and induce the generation of myeloid-derived 
suppressor cells (MDSCs) via TGF-β (137-139). Remarkably, several breast cancer cell lines 
released EXOs, which contain human epidermal growth factor receptor 2 (HER2), have been 
shown to bind the trastuzumab Ab in vivo, thus reducing its therapeutic availability and 
increasing tumor aggressiveness (140). Thus, tumor-derived EXOs can subvert antitumor 
immune responses via multiple pathways.  
 
T cell-derived EXOs: Active T cells have been shown to release FasL and TRAIL/APO2L 
containing EXOs, which can rapidly induce apoptosis of bystander activated T cells via 
activation-induced cell death (AICD) (141, 142). The work in our lab further reported that DC-
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activated T cell-secreted EXOs bear antigen-specific TCR and FasL, thus inhibiting T-cell 
immune responses through downregulation of pMHC complex on antigen-loaded DCs and FasL-
mediated cytotoxicity (99, 100). 
 
Placenta- and milk-derived EXOs: Placenta of pregnant women secreted EXOs have been 
shown to bear NKG2D ligand UL-16 binding proteins (ULBP), which can induce down-
regulation of the NKG2D on NK and CD8
+
 T cells, leading to reduction of their in vitro 
cytotoxicity (143, 144). In addition, EXOs derived from human colostrum and mature breast 
milk can increase number of CD4
+
 CD25
+
 Foxp3
+
 Tregs and inhibit anti-CD3-induced 
production of IL-2 and IFN-γ from allogeneic and autologous peripheral blood mononuclear 
cells (PBMCs) (145). 
 
1.2.4 EXO-based immunotherapy 
 
It was initially reported in 1996 that B cell-derived EXOs could stimulate antigen- specific MHC 
II-dependent CD4
+
 T cells in vitro (87). Subsequent report showed that tumor peptide-loaded 
autologous DC-derived EXOs expressing functional pMHC-I/II complexes and T-cell 
costimulatory molecules could elicit the eradication of established tumors in vivo via antigen-
specific MHC class I-restricted CD8
+
 CTL responses in a mouse tumor model (146). The 
pioneering studies prompted investigation into the application of DC-derived EXOs (DEX) in 
antitumor immunotherapy. Notably, DEX from mature DC and immature DC exhibit distinct 
bioactivities in line with their differential protein composition. Although immature DCs secreted 
much more EXOs than mature DCs (81, 116), extensive studies have shown that mature DC-
derived EXOs (mDEX) bearing functional pMHC-I/II complexes and higher levels of 
costimulatory and adhesion molecules. Mature DEX can induce antigen-specific T-cell immune 
responses either directly by exposing exosomal pMHC complexes and costimulatory molecules 
to T cells (109-111, 147, 148) or indirectly by conveying pMHC complexes to recipient mature 
DCs (112-116). More recently, Qazi et al. (149) reported that OVA-pulsed DC-released EXOs 
could elicit OVA-specific Th1 cellular and immunoglobulin2a humoral immune responses via B 
cell-dependent mechanism. Importantly, DEX bearing can promote NK-cell proliferation, 
activation and cytotoxicity (122, 123), suggesting their modulating role in innate immune 
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responses. Injection of expression vector transfected targeted EXOs could possibly deliver 
siRNA to a mouse brain, thus postulating a potential therapeutic approach to Alzheimer’s disease 
(150, 151). Let-7a miRNA loaded EXOs can be used to target epidermal growth factor receptor 
(EGFR)-expressing breast cancer cells, thus represent a vehicle for conveying drugs to tumors 
(152).  
 
Preclinical studies in mouse models have shown that most of EXO-based vaccine can only 
induce a prophylactic (preventive) antitumor immunity but do not have significant therapeutic 
effect on established tumors. Some of factors that affect the bioactivity of EXOs have been 
addressed. Firstly, high dose level of EXOs and intradermal (i.d.) injection can induce more 
efficient CD8
+
 CTL responses and stronger antitumor immunity (114, 153). Additionally, DEX 
can be directly loaded with antigen peptides (112, 149) or indirectly via DC pulsed with antigen 
peptides (146) or immunogens (149, 154, 155). Moreover, the roles of CD4
+
CD25
+
 Tregs in the 
inhibition of CTL-mediated antitumor immunity have been increasingly recognized (156-158). 
Tumor microenvironment can facilitate prompt recruitment and expansion of CD4
+
CD25
+
 Tregs 
leading to the delayed rejection of tumors (156, 159). Chemotherapy drug cyclophosphamide can 
enhance the magnitude of tumor antigen-specific secondary CD8
+
 CTL responses induced by 
DEX via suppressing function of CD4
+
CD25
+
 Tregs (160). Furthermore, the immunogenicity of 
tumor-derived EXOs (TEX) can be improved via being exposed stress conditions and 
incorporating immunologic molecules. Heat-shocked or membrane-bound HSP70-engineered 
TEX can promote DC maturation, induce CD8
+
 CTL responses and antitumor immunity, and 
activate NK cells and macrophages (124-127, 161). Heat-treated malignant ascites can improve 
the immunogenicity of TEXs, promote DC maturation and induce tumor-specific CD8
+
 CTL 
responses (162). Oxidative stresses have also been shown to limit for solid tumor growth (163). 
Cytokine engineered TEX/IL-18 (164) or TEX/IL-12 (165) has been shown to more potentially 
induce CD8
+
 CTL responses and antitumor immunity. The increasing knowledge about the 
biological effects of EXOs and enhancement of their immunogenicity will provide exciting 
prospects for EXO vaccine development in cancer immunotherapy. 
 
Based on the knowledge that EXOs are well tolerated in humans and they have a long half-life in 
the blood, plus the established good manufacturing procedures in obtaining clinical-grade EXOs 
 17 
(166), several clinical trials has been carried out with DEX- and TEX- based cancer 
immunotherapy. The DEX-based initial two Phase I clinical trials involved patients with 
advanced stage melanomas or non-small cell lung cancers (167). The clinical outcomes were 
encouraging, showing (i) the safety of treatment by DEX with minimal side effect; (ii) transient 
stabilization of the diseases; (iii) detectable immune responses, particularly enhanced NK cell 
cytotoxicity. A Phase I clinical trial in colorectal cancer showed that using ascites-derived EXOs 
in conjunction with granulocyte macrophage-colony stimulating factor (GM-CSF) induced more 
antigen-specific T cells (168), indicating a feasible and safe immunotherapy strategy. In addition, 
ovarian cancer ascites-derived EXOs combined with TLR3 agonist PolyI:C as a adjuvant is 
being planned to clinically treat advanced ovarian cancer patients after chemotherapy (169). 
These clinical trials suggested that EXO-based cancer immunotherapy might be better combined 
with several already established therapies that enhance immune responses. The relative stability 
of TEXs in body fluids makes them as the most reliable source of biomarkers for detecting and 
monitoring cancer (170). At present, two clinical trials investigate TEX for their prognostic and 
predictive biomarker in breast cancer (NCT01344109) and gastric cancer patients 
(NCT01779583), respectively. More EXO-based regimens tested in clinical trials can be found 
on ClinicalTrails.gov website.  
 
1.2.5 Summary 
 
Although DC represents a promising cell-based strategy to elicit or enhance antitumor immune 
responses, the percentage of live DCs after freeze-thaw and unknown behaviours or fates of DCs 
after injection such as short-lived, sensitive to CTL-mediated killing (111) and elusive 
modification of pMHC complexes displayed on their surface currently limit DC-based adoptive 
cancer immunotherapy. DEX, relatively stable secreted membrane vesicles, harboring high 
levels of functional pMHC-I/II complexes and costimulatory and adhension molecules, thus 
theoretically, could at least complement DC-based immunotherapy. In fact, EXOs has been 
emerging as major players in intercellular communications in the past few years. EXOs have 
been shown to contain diverse biological molecules including virions, miRNAs, proteins and 
their complexes. The presenting of contents to recipient cells could either invoke or suppress 
immune responses, indicating potential therapeutic roles of EXOs. A lipid bilayer membrane 
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confers a high degree of stability, which makes EXO even more attractive as diagnostic markers. 
Although much progress has been made where EXOs are considered good vehicles to shuttle 
nucleic acid contents for therapeutic approaches, the miRNA-based trials in the context of EXOs 
have not been initiated. Hopefully, the development of EXO-based strategies will help to 
overcome the most challenging issue in cancer therapy. 
 
1.3 A new dynamic model of three cell interactions for CTL responses 
 
1.3.1 Three-cell and sequential two-cell model 
 
In the immune system, APCs such as DCs function by engulfing antigens, processing them, and 
subsequently presenting them to CD4
+
 and CD8
+
 T cells via MHC class II and MHC class I 
molecules, respectively, leading to CD8
+
 CTL responses. However, how these three rare cell 
populations precisely interact and how CD4
+
 T-helper cell signals are delivered to CD8
+
 T cells 
in vivo remains controversial. Based on the observation that the antigen recognized by CD4
+
 and 
CD8
+
 T cells must be carried by the same DC, several distinct models have been proposed. A 
“three-cell interaction model” was originally proposed for CD4+ T-cell dependent CTL 
responses (171), according to which antigen-specific CD4
+
 and CD8
+
 T-cell precursors must 
simultaneously interact with the same antigen-presenting DC (Figure 1.1A). However, as both 
antigen-specific CD4
+
 and CD8
+
 T-cell precursors are relatively rare, intuitively this three-cell 
interaction appears to be almost impossible. Later, Ridge et al. proposed a “dynamic model of 
sequential two-cell interactions by APCs” (172), according to which APCs must be first 
activated (licensed) by CD4
+
 T cells via CD40/CD40L interaction and then the licensed DCs can 
directly stimulate memory CTL responses (Figure 1.1B). However, this model has been 
challenged by the observation that efficient memory CTL responses require CD40 expression on 
CD8
+
 T cells but not on DCs (173), and as CD40L is mainly expressed by CD4
+
 T cells, thus 
implicating direct CD4
+
-CD8
+
 T-cell interactions in the development of memory CTLs.  
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Figure 1.1 A new, dynamic model of three-cell interactions. (A) The passive three-cell 
interaction model. A CD4
+
 T helper activated by an APC delivers cytokine (IL-2) required for 
CTL activation to a CD8
+
 T cell, which recognizes antigen on the same APC. (B) The dynamic 
model of sequential two-cell interactions by APCs. The cross-priming APC is activated 
(licensed) by an antigen-specific CD4
+
 T cell through CD40-CD40L interactions, and then, the 
fully licensed APC gets the ability to prime CTL directly. (C) The dynamic model of sequential 
two-cell interactions by CD4
+
 T-APCs. CD4
+
 T cells can acquire molecules (particularly pMHC-
I) from APCs by APC activation and thus, can stimulate CTL responses directly. (D) A new, 
dynamic model of three-cell interactions. The cross-priming DC first interacts with the antigen-
specific CD4
+
 T cell for the crucial first step in CTL responses, which are DC-CD4
+
 T 
interaction, resulting in DC licensing and CD4
+
 T cell activation (priming). Cognate CD8
+
 CTLs 
can then receive helper or stimulatory signals, not only from DC-CD4
+
 T clusters but also 
separately from fully licensed DCs and primed CD4
+
 T cells, even after their dissociation from 
DC-CD4
+
 T clusters. (E) A novel EXO-targeted CD4
+
 T vaccine. EXO-loaded CD4
+
 T cells 
stimulated CD8
+
 T-cell priming via pMHC-I-mediated targeting.  
 
1.3.2 Primed-CD4+ T cell model 
 
Trogocytosis (intercellular membrane protein transfer) is a ubiquitous phenomenon, when this 
involves immune cells, plays important roles in immune modulation (174). CD8
+
 and CD4
+
 T 
cells have been reported to acquire the immunological synapse (IS)-composed pMHC-I and 
pMHC-II complexes from activating DCs, respectively, via internalization and recycling of 
synapse components (175). As our lab was the first to discover that in addition to pMHC-II, 
CD4
+
 T cells also acquire pMHC-I and CD80 molecules from DCs, and the acquired antigen 
presenting machinery remains functional that help CD4
+
 T cells to directly stimulate cognate 
CD8
+
 T cells. This led to the proposal of a “new dynamic model of sequential two-cell 
interactions by CD4
+
 T cells” (Figure 1.1C), where primed-CD4+ T cells that have acquired 
antigen presenting machinery from DCs function as APCs themselves (T-APC) (176). This 
model is also supported by recent evidence from another lab (177). Interestingly, our lab also 
showed that T-APCs preferentially stimulate CD8
+
CD44
+
CD62L
high
CD127
+
 central memory 
CTL responses (178). However, physiological significance of T-APC concept in vivo remains an 
open question. Thus, the original question, that is, the mechanisms for functional delivery of 
CD4
+
 T-cell help, whether CD8
+
 T cells receive helper signals by forming a three-cell cluster 
(DC-CD4
+
-CD8
+
), indirectly through licensed DCs, or directly from primed CD4
+
 T cells, 
remains unresolved.  
 
 21 
To gain a better insight into the mechanisms that regulate CTL responses, novel immunization 
protocols have been developed in our lab, wherein antigen-presenting DCs (CD11c-diphtheria 
toxin (DT) receptor transgenic DCs, presenting ovalbumin (OVA) as a model antigen), CD4
+
 
and CD8
+
 T cells can be separately manipulated for dissecting their respective roles in the 
priming of CTL responses in vivo (179). In this experimental setup, CD4
+
 T cells and antigen-
presenting DCs were allowed to engage with one another in vivo, in the absence of cognate CD8
+
 
T cells (CD8
+
 T cell-depleted host). Thereafter, either the previously engaged CD4
+
 T cells 
(injecting the GK1.5 Ab) or DCs (injecting DT) can be selectively depleted before allowing the 
interaction of none, either or both of these populations with adoptively transferred naive CD8
+
 T 
cells. This protocol allowed us not only to clearly document the importance of CD4
+
 T cell-
licensed DCs and DC-primed CD4
+
 T cells in CTL responses, but also made possible the testing 
of previously proposed models in the same experimental setting. This study provided direct in 
vivo evidence that primed CD4
+
 T cells or licensed DCs can stimulate CTL and memory 
responses, independent of DC-CD4
+
 T-cell clusters. Remarkably, imaging study using intravital 
two-photon microscopy (TPM) provided first unequivocal ex vivo evidence for pMHC-I-
dependent direct CD4
+
-CD8
+
 T-cell interactions in the absence of DC-CD4
+
-CD8
+
 T cell ternary 
clusters. 
 
Thus, it provided for the first time physiologically relevant in vivo evidence that primed CD4
+
 T 
cells can directly orchestrate efficient CD8
+
 CTL responses, proposing a “new dynamic model of 
three-cell interactions for CTL responses” (Figure 1.1D) (179). According to such a dynamic 
model, CTL and memory responses do not depend on an antigen presenting DC simultaneously 
engaging cognate naive CD4
+
 and CD8
+
 T cells in an environment in which both of these latter 
cells are extremely rare. Directly attracting CD8
+
 T-cell targets to primed CD4
+
 T cells through 
acquired pMHC-I/TCR and CD40/CD40L engagement would also be expected to result in a 
more efficient delivery of IL-2 and hence a more efficient CTL memory induction. Altogether, 
this study revealed the coexistence of direct and indirect mechanisms of T cell help for CTL 
responses in non-inflammatory situations, thereby reconciling previous conflicting studies. In 
addition, the CTL programming derived from licensed DCs, primed CD4
+
 T cells and DC-CD4
+
 
T-cell clusters reflects microenvironments differing in signal strength, co-stimulation and 
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cytokine levels. Such subtle differences could be one of the reasons of the T-cell heterogeneity 
during memory T-cell development (180). 
 
1.3.3 A novel EXO-targeted CD4+ T cell vaccine 
 
Since immune cells also exchange various molecules through EXO release without any physical 
interaction, a variation on this theme has also been proposed in our lab. DCs process exogenous 
antigens in their endosomal compartments, which can later fuse with the plasma membrane, 
releasing antigen-presenting EXOs (146). Since the released EXOs can be captured by activated 
T cells (84), we propose that EXO-loaded activated T cells might be able to stimulate CTL 
responses similarly as DC-primed T cells. Interestingly, EXO-loaded CD4
+
 T cells have been 
found to stimulate CD8
+
 T-cell priming via pMHC-I-mediated targeting and via IL-2 and CD80 
signaling (Figure 1.1E) (181). Further study elucidate that the principle of EXO primed CD4
+
 T 
cell model can be applied as novel CD4
+
 T cell-based vaccine capable of stimulating long-term 
functional CTL memory via CD40L (182). This immune priming process has also been 
confirmed ex vivo using TPM, where cognate CD8
+
 T cells form stable contacts only when 
activated-T cells were loaded with antigen-specific DCs-released EXOs (183). 
 
1.3.4 Summary 
 
CTL immunity is orchestrated by dynamic interactions of antigen-presenting DCs, CD4
+
 T and 
CD8
+
 T cells, leading to the enhanced communications between rare antigen-specific immune 
precursors within a short window of time and to the efficient delivery of help signals. Although 
details remain to be explored, this concept may have a great impact for the design of vaccines 
and immunotherapy strategies against cancer and autoimmune diseases. 
 
1.4 Two-photon microscopy 
 
TPM has been introduced in immunology for almost a decade. The number of studies using this 
advanced technology has dramatically increased. The TPM allows long-term visualization of 
immune process hundreds of microns deep in the living tissue with minimal phototoxicity. From 
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imaging in explanted organs to performing the intravital studies in living animals, this 
technology reveals an elaborate cellular choreography of immune responses. 
 
1.4.1 Principles of two-photon excitation 
 
In traditional one-photon microscopy, such as confocal and fluorescent microscopy, one 
fluorochrome is excited by one high-energy photon. While in TPM, two lower-energy photons 
are absorbed nearly simultaneously by a single fluorochrome. As two photons excite one 
fluorochrome, each photon used in TPM harbors half of the energy used in one-photon 
microscopy. Therefore, the wavelength used in TPM is twice as long as in one-photon 
microscopy. The use of long wavelength excitation is particularly advantageous for imaging 
deep into highly scattering biological materials because scattering decreases with increasing 
wavelength (184), thus the infrared wavelengths used for two-photon imaging enable deeper 
tissue penetration (up to 1000 μm) than does one-photon imaging using visible wavelengths (185, 
186). However, as the trade-off, the resolution for two-photon imaging is proportionally worse in 
comparison to one-photon methods. Since fluorescence excitation is limited only to the region 
where photon flux is the highest (focus point), photobleaching and damages outside the focus 
point are minimized, thereby highly benefiting long-term imaging. High power, pulsed laser 
must be used as the excitation source because fluorochrome is only energized to an excited state 
when a simultaneously absorption of two photons occurs. Despite the intensity of light, less 
damage is produced because the light is off most of the time in between laser pulses. Another 
merit of two-photon excitation is its nonlinear optical effects such as second-harmonic 
generation (SHG) (187). High-intensity lasers passing through a coordinated material can lead 
the generation of a second-harmonic emission at precisely half the wavelength of the original 
light. Many intrinsic biological structures, including collagen fibers, brain, muscle, cornea, and 
bone, can induce SHG, thus these structures can be visualized without exogenous fluorescent 
labeling. In brief, TPM is an ideal tool for long-term intravital imaging because of its low 
phototoxicity and superior penetration depth.  
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1.4.2 Lymph node cellular dynamics 
 
1.4.2.1 Cellular dynamics within the lymph node 
 
One of the earliest applications of intravital two-photon imaging was performed in an explanted 
lymph node (186). Membrane-permeable fluorescent dyes labeled lymphocytes such as T and B 
cells were visualized in lymph nodes, revealing the rapid migration of naive T and B cells under 
the basal conditions, which challenge the previous belief that T and B cells were immobile in the 
resting state. T cells are able to crawl more rapidly (10-12 μm/min (188) for 2-D velocities and 
15 μm/min (189) for 3-D velocities) than any other cell type such as B cells (186), NK cells 
(190), neutrophils (191), and monocytes (192). All these cells have similar amoeboid actin-based 
motility. Therefore, they explore the environment using surface receptors and respond with 
altered dynamics when signals are transmitted. In contrast, APCs such as DCs (193, 194) and 
LCs (195) are generally sessile in tissue unless some microbial or inflammatory signals provided 
(196, 197).  
 
It has been long appreciated that T cell responses require direct cell-cell contact. In order to 
perform effective molecular communication, random cellular movement must be overcome to 
prevent partner cells from moving outside the range, leading to the change of cell motility. It 
becomes clear that naive T cells migrate rapidly along a network of fibroblastic reticular cells 
(FRCs), making brief and frequent contacts with DCs. The independent migration of T and B 
cells is overcome when specific antigen shows up. After exposure to antigen, T cells are arrested 
by DCs, leading to the formation of T cell clusters around individual DC (194, 198). B cells that 
have acquired antigen become activated APCs. Most of them stop wandering and form stable 
conjugates with antigen-specific T cells in SLAM-associated protein (SAP)-dependent manner 
(199). Others do not get strong stop signal and continue to migrate, dragging the T cell behind 
(200).  
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1.4.2.2 Lymphocytes trafficking in lymph node 
 
The process of lymphocyte homing and tissue localization have been extensively investigated 
using TPM, enlarging our current knowledge of how lymphocytes distribute from the blood to 
peripheral tissues and to lymphoid organs (201, 202). Lymph nodes, which are dispersed in the 
human body, are major sites for circulating naive lymphocytes to encounter with antigens and 
APCs. Recirculating of lymphocytes from the blood to lymphoid organs and back to the blood 
can be finished as quick as half day during homeostasis (203), allowing the extremely rare 
antigen specific lymphocytes to quickly survey the lymph for the presence of their target antigen. 
After homing from the blood into lymph nodes, lymphocytes spend several hours (T cells ~8-12 
hrs) to a day (B cells ~24 hrs) in a given lymph node (204). During this time, they search around, 
and most of them leave the lymph node via efferent lymphatic vessels without finding antigens. 
 
1.4.2.2.1 Entry of lymphocytes 
 
High endothelial venules (HEVs) have been considered as the major sites for migration of 
lymphocytes from the blood into lymph nodes. The entry of naive T and B cells is mainly 
through rolling along HEV walls, based on the attraction between the expression of CC-
chemokine ligand 21 (CCL21) on HEV endothelial cells and CCR7 expressed lymphocytes. 
Signaling through the CCR7, together with the shear force of blood flow, induce the activation of 
lymphocyte integrin LFA-1, leading the firm binding to ICAM-1 and ICAM-2 on the 
endothelium (205). After several minutes’ crawling on the HEV surface, T cells enter the 
abluminal side of HEVs, where a sheath of FRCs are surrounded. Lymphocytes are transiently 
trapped in this perivascular space, where the accumulation of DCs are also shown, increasing the 
likelihood of T cell-DC encounters (194). After the transient retention around HEVs, T cells 
rapidly migrate along the FRCs-the major constituents of the backbone structure of the T cell 
zone (206). The production of CCL21 and C-X-C chemokine ligand 12 (CXCL12) by T cell 
zone FRCs thus attract CCR7 and CXCR4 expressed naive T cells entering into T cell zone. On 
the other hand, rather than rapidly heading to the follicles, B cells remain confined close to 
HEVs for 3-4 hrs and search for local DCs (207). CCR7 ligands are not involved in retaining B 
cells since CCR7-deficient B cells show a similar motility pattern around HEVs to that of wild-
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type B cells (208). After leaving HEVs, B cells crawl on the FRC network in the T cell areas to 
reach the B cell follicles (206). The homing of naive B cells to the follicles depends on the 
expression of CXCR5 by B cells and CXCL13 by follicular dendritic cells (FDCs) (209). 
Notably, although the main function of HEVs is to recruit large numbers of naive B and T cells 
(also including central memory T cells and Tregs) into lymph nodes, they also mediate the entry 
of other important immune cell types during homeostasis such as pDCs (210) and the precursors 
of conventional DCs (pre-cDCs) (211).  
 
DCs have been shown to enter lymph nodes via afferent lymphatic vessels rather than through 
HEVs. Under both steady state and inflammatory conditions, CCR7 expressed DCs sense local 
CCL21 gradients, which are provided by terminal lymphatics, and directionally migrate towards, 
and eventually into, lymphatic vessels (212). Following lymphatic entry, DCs crawl in the 
direction of lymph flow and migrate through FRC stromal networks into the lymph node 
paracortex under the guide of CCR7 and its ligand CCL21. Unlike the entry of lymphocytes 
through HEVs, this process seems to be independent of integrins (213). Over time, lymph-
derived migratory DCs and HEV-derived pre-cDCs join and integrate into the network of 
resident DCs by internalization and/or desensitization of their CCR7, and start to continuously 
probe around.   
 
1.4.2.2.2 Egress of lymphocytes 
 
If naive lymphocytes do not encounter their target antigen after several hrs’ exploring, they will 
leave the lymph node through efferent lymphatics. Sphingosine-1-phosphate (S1P) and its 
receptor S1PR1 have been shown to be required for the egress of both B and T cells (214) based 
on the fact that a agonist of S1P receptors (FTY720) inhibits the egress of lymphocytes into 
lymph by down-regulating S1PR1 expression on lymphocytes (215, 216). Recent TPM analyses 
indicate that the exit of B and T cells from lymph nodes is mainly through cortical sinuses. By 
overcoming retention signals from CCR7, migrating T cells contact and probe on lymphatic 
vessel endothelial receptor 1 (LYVE1)
+
 cortical sinuses in the interfollicular areas. About one-
third of T cells then cross the lymphatic endothelium and enter the lymph node sinus system in a 
S1P-dependent manner (217). Similarly, B cells desensitize their chemokine receptors (CXCR5 
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and CCR7) and sense the S1P-mediated egress signal followed by egression from the B cell 
follicle into adjacent cortical sinuses (208, 218).  
 
1.4.3 Dynamics of DC-T cell interaction 
 
1.4.3.1 Contacts in the absence of antigen 
 
Because of the vigorous intranodal motility of naive T cells along stromal networks in lymph 
node T cell zone (206), roughly 500-5000 distinct T cells have been found to contact one DC per 
hour in the absence of antigen (193, 219). This process highly increases the change of initiating 
an immune response that rare antigen-presenting DCs encounter a low frequency of antigen-
specific T cells. Without presenting cognate antigen, only a few-minute contact is established 
between DCs and T cells. Although those contacts fail to induce calcium signaling in T cells 
(220), they are likely to be functionally important. There are also some non-random chemokine-
driven DC-T cell interactions in the absence of cognate antigen presentation. For example, 
CCL21 has been suggested to optimize the migration of CCR7-expressing T cells since this 
chemokine is bound to the surface of LN-resident DCs (221). CCL3 and CCL4 are produced at 
the site of DC-T conjugates, increasing the chance for CCR5-expressing CD8
+
 T cells migrating 
to contact DCs (222, 223), thereby favoring the formation of three-cell clusters and promoting 
collaboration between DCs and T cells.  
 
1.4.3.2 Contacts in the presence of antigen 
 
DC-T cell interactions in LNs during the priming of both naive CD8
+
 and CD4
+
 T cells have 
been widely studied (186, 193, 194, 224-226). Few models have been proposed to explain how 
DC-T contacts shift from transient to stable over time. One model suggests the maturation state 
of the DCs determines the timing of T cell arrest (227). Another model believes that there is a 
threshold of signal receiving by T cells. Once reaching this threshold, T cells gain the “memory” 
to establish long-lasting interaction with DCs (228). Several studies agree on a three-phase 
model of DC-T cell interactions based on the order of occurrence during an immune response. 
Within the first few hrs following naive T cells’ entry (phase 1), only brief contacts (< 10 min) 
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are established, which is hardly distinguishable from the situation that in the absence of antigen 
(194, 198). The second phase is characterized by a dramatic change in T cell behavior, including 
the decreased velocities and confined movements, resulting in stable DC-T cell interactions 
lasting 2-24 hrs depending on the different experiment settings. During this period, an increased 
in cytosolic calcium concentration has been found to associate with this stable DC-T cell 
interaction (220, 229). Finally, most clusters dissociate their stable interactions after 30 hrs 
(phase 3). T cells regain their velocities as well as their random movement pattern.  
 
The molecular mechanisms that lead to variations in contact duration in the three-phase model 
have been described. The amount and the quality of peptide-MHC complexes largely contribute 
to determine the nature of these contacts (193, 229). During the first phase of transient 
interactions, T cells are likely to up-regulate the early activation marker CD69 after receiving an 
activation signal (194, 226, 229). Accumulated brief contacts may collect additional signals to 
sufficiently activate DCs, leading to stabilize the interactions between DCs and T cells. ICAM-1 
is crucial for T-cell arrest on DCs following antigen recognition since ICAM-1 deficient DCs 
have been shown to establish only brief interactions with T cells (225). The expression of 
cytotoxic T lymphocyte antigen (CTLA)-4 on T cells, a receptor that normally down-regulates T-
cell activation, can also override T-cell arrest following antigen recognition (230). However, in a 
pancreatic islet self-antigen tolerance model, the blockade of CTLA-4 neither altered T cell 
mobility nor favored the establishment of a stable contact with antigen presenting DCs (231). In 
fact, the blockade of programmed death ligand 1 (PD-L1) in the same study showed the impaired 
T cell motility and enhanced cell-cell interactions. T cells detach from DCs and become more 
dynamic after the phase of stable DC-T cell contacts. Signals that involve in the termination of 
long-lasting contacts are less clear. One possibility is the down-regulation of pMHC complexes 
on DCs (232). The injection of anti-MHC-II Abs has been reported to promote the dissociation 
of established DC-T cell conjugates (233), indicating that low amount of pMHC complexes may 
lead to the detaching of T cells. By contrast, reinjection of the antigen couldn’t be able to 
prolong the phase of T cell arrests (226), suggesting that decreased antigen presentation by DC 
might not account for the phase three. The activation state of DCs might control the contact 
duration since encounter of DCs from phase three with T cells from phase two fails to restore 
stable DC-T cell interaction (226). The down-regulation of ICAM-1 has also been reported 
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during this late phase (225), suggesting that the variation in the expression of adhesion molecules 
by DCs could participate in the abrogation of long-lasting contacts.  
 
1.4.3.3 Contacts in the presence of Tregs  
 
Tregs modulate immune responses through mechanisms that may require direct contact between 
Tregs and DCs, T cells and/or bystander effects mediated by cytokines (234). Only few papers 
have applied imaging techniques to investigate these processes to date. Two in vivo imaging 
studies have provided direct evidence that Tregs interfere with the DC-T cell interaction. The 
reconstruction of naturally occurring antigen-specific Tregs has been shown to inhibit stable 
contacts between autoreactive myelin basic protein (MBP)-specific T cells and autoantigen 
loaded DCs in Treg-deficient mice (235). Similar suppressive effect of Tregs on the formation of 
stable clusters of diabetogenic T cells with DCs in isolated pancreatic LNs has also been reported 
(236). This paper has further demonstrated that Tregs are only detected to engage in long-lasting 
interactions with DCs rather than CD4
+
 T cells. A somehow different report of Tregs’ action has 
been obtained when imaging the interactions between CD8
+
 CTLs and antigen-presenting target 
B cells (237). The presence of Tregs can’t alter the recognition and stable interaction between 
CTL and target B cell, but profoundly inhibit the ability of CD8
+
 CTLs in releasing cytolytic 
granules and lysing the targets. Notably, no direct interaction has been found between Tregs and 
CD8
+
 CTLs in this study. All together, these results show that both initiation and effector phases 
of immune responses in lymph node may potentially be affected by Tregs. However, all the 
imaging experiments above performed with adoptive transferred, TCR-transgenic, high-affinity 
Tregs. In fact, more studies are focus on the endogenous polyclonal Tregs recently. One 
experiment has shown that the endogenous polyclonal Tregs could directly interact with DCs, 
and induce the death of DCs in tumor-draining lymph node through an antigen- and perforin-
dependent mechanism (238). In another experiment setting, the depletion of endogenous 
polyclonal Tregs has been shown to stabilize the interactions between antigen-presenting DCs 
and low-avidity T cells (239). The presence of endogenous Tregs has actually been suggested to 
increase the avidity of primary CD8
+
 T cell responses, thereby promoting effective memory.  
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1.4.4 Summary 
 
Since 2002, the in vivo two-photon imaging has been applied to visualize of immune cell 
dynamics in real-time within various intact tissues, including lymph node, thymus, spleen, lung, 
gastrointestinal tract, pancreas, skin, bone marrow, blood vessels, spinal cord, brain and tumors 
(240-246). It provides a unique perspective to our current knowledge of the immune system in 
health and disease conditions. Although current imaging techniques have several limitations, the 
progress in the development of laser technologies and the improvement in equipment sensitivity 
would benefit the immunoimaging. A closer interplay with computational modeling should also 
profit further imaging analysis. Even though current studies have only scratched the surface, 
there is no doubt that immunoimaging has a bright future ahead in unveiling the choreography of 
immune responses.  
 
1.5 The HER2 positive breast cancer 
 
HER2, also known as c-ErbB-2/neu, is a transmembrane receptor with tyrosine kinase activity. 
Unlike other ErbB family members that require ligand binding for activation, HER2 can adopt a 
fixed conformation resembling a ligand-activated state, permitting it to dimerize in the absence 
of a ligand (247), which results in activation of a potent cell signaling cascade predominately 
though the phosphatidylinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) 
pathway, leading to cell proliferation and survival. HER2 overexpression has been described in 
various human cancers, including ovary, prostate, gastric, lung, bladder, and kidney carcinomas 
(248, 249). Each year, breast cancer accounts for more than 400,000 new cancer cases and more 
than 130,000 cancer deaths in Europe. Approximately 20-30% of invasive breast carcinomas are 
HER2 positive and associated with increased metastatic potential and poor prognosis (250, 251). 
In the USA, approximately 5,000 patients with HER2-positive breast cancer die each year. In the 
last decades, several attempts have been made to develop strategies that could effectively 
recognize and eradicate cancer cells in HER2-positive breast cancer patients.  
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1.5.1 Passive immunotherapy 
 
Different approaches fall into this catalog, including (i) the infusion of monoclonal antibodies 
(mAbs) specific for a given tumor antigen or inhibitors; (ii) adoptive transfer of antigen-specific 
T lymphocytes expanded ex vivo; (iii) the functional inhibition or depletion of Tregs-elements 
that are able to down-modulate antitumor T-cell responses. 
 
1.5.1.1 mAbs specific for HER2 antigen or HER2 receptor inhibitors 
 
Trastuzumab (Herceptin, Roche, Switzerland) is a humanized mAb directed against the 
extracellular domain (ECD) of HER2. It was approved by food and drug administration (FDA) in 
1998 for metastatic HER2 over-expressing breast cancer combined with chemotherapy (252). 
The potential mechanisms for its antitumor action include antibody-dependent cell-mediated 
cytotoxicity (ADCC), blockade of HER2 ECD cleavage (253), inhibition of ligand-independent 
HER2 receptor dimerization, inhibition of downstream signal transduction pathways, induction 
of cell-cycle arrest, inhibition of angiogenesis, induction of apoptosis, and interference with 
DNA repair (254, 255). In early-stage disease, the addition of trastuzumab to adjuvant 
chemotherapy results in remarkably early and sustained improvement in disease-free survival 
and overall survival. However, drug resistance usually develops within one year from the 
beginning of the treatment in the metastatic setting (256, 257). Several mechanisms for inherent 
or acquired resistance have been proposed, including the loss of or increased HER2 expression; 
compensatory cross-talk with other ErbB receptors (eg. HER1 or HER3); increased TGF‑ α 
expression (a ligand for EGFR/HER1); steric hindrance of HER2 Abs interaction by membrane-
associated glycoproteins; inefficient trastuzumab binding by shedding of the HER2 ECD (258); 
and altered expression of downstream mediators of signaling pathways or constitutive activation 
of the PI3K/Akt signal pathway (259, 260). A better understanding of these mechanisms may 
help to design next-generation trastuzumab that can ameliorate or bypass tumor resistance.  
 
Lapatinib is a reversible tyrosine kinase inhibitor that targets the intracellular domains (ICD) of 
both HER1 and HER2. FDA approved the use of Lapatinib in 2007 for use in combination with 
capecitabine to treat patients with advanced breast cancer or HER2 overexpressing metastatic 
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breast cancer. Lapatinib has been shown to retain activity in tumor that overexpresses the 
truncated form of HER2 (p95HER2), which has been associated with resistance to trastuzumab 
(258). Dual anti-HER2 regimen combined lapatinib and trastuzumab has been shown superior to 
the use of lapatinib alone on trastuzumab-based therapy in HER2-positive metastatic breast 
cancer patients (261).  
 
Pertuzumab is a monoclonal Ab that blockades HER2:HER3 heterodimer formation and 
consequent downstream activation signals by binding to a distinct site on the HER2 ECD. It 
received FDA approval for the treatment of HER2-positive metastatic breast cancer in 2012. 
Similar to other HER2-targeted agents, pertuzumab demonstrates only modest activity as a single 
agent, while when administered with trastuzumab and chemotherapy, it is considered as the new 
standard of care for the first-line treatment of patients with HER2-positive metastatic breast 
cancer (262). 
 
Trastuzumab DM-1 (T-DM1) or trastuzumab emtansine, is an antibody-drug conjugate (ADC) 
consisting of trastuzumab linked to the microtubule cytotoxic maytansine, which enters cells and 
destroys them by binding to tubulin (263).  It received FDA approval for marketing on February 
22, 2013. T-DM1 is often given as a single agent since this drug is more similar to combination 
treatment. It demonstrates the high efficacy against trastuzumab-sensitive and -resistant HER2-
positive cell lines (264). The real benefit of T-DM1 lies in the potential to eliminate 
chemotherapy from therapeutic regimens. Therefore, it is becoming the new standard of care for 
refractory metastatic HER2-positive breast cancer after disease progression on trastuzumab. 
 
Many other novel anti-HER2 agents also show promise in treating HER2-positive breast cancer, 
inculding Tanespimycin (265) (an intravenously administered inhibitor of HSP90), 
Ertumaxomab (266) (a trifunctional Ab that targets HER2, CD3 and activating FCγ receptors, 
leading to phagocytosis of tumor cells), Neratinib (267) (an irreversible tyrosine kinase 
inhibitor), XL147 (268) (pan-PI3K inhibitor), etc. They can either be directed at HER2 receptor 
itself or can target downstream effectors and interact with compensatory signaling pathways. 
Therefore, these new treatments are likely to enter the adjuvant setting in the near future. 
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1.5.1.2 HER2-specific CTLs 
 
Increasing evidence shows that the presence of tumor-infiltrating T lymphocytes (TILs) is 
associated with a favorable prognosis of primary tumors. Non-responsive T cells may also be 
expanded due to the prevalence of antigen presentation and tolerance induction mediated by both 
the growing tumor and its surrounding stromal cells during tumor progression (269). Tumor-
reactive T cells can be increased in the blood and within the tumor site by taking out potential 
tumor-reactive T cells from the tumor-bearing host and stimulating them ex vivo (270). A study 
adoptively transferred ex vivo expanded HER2-specific CTLs in HER2-overexpressing breast 
cancer patients revealed that the transferred T cells accumulated in the patient’s bone marrow 
and migrated to the liver, but were unable to penetrate into the solid metastases (271).  
 
1.5.1.3 Inhibition or depletion of Tregs  
 
Another strategy in the context of passive immunotherapy is the functional inhibition or 
depletion of Tregs, leading to the up-regulation of T-cell responses. This can be achieved directly 
by using recombinant IL-2-DT fusion protein (also called ONTAK) to specifically target CD25
+
 
Tregs (272, 273). It also can be achieved indirectly by negative regulation of T-cell activation 
and function. CTLA-4 is physiologically expressed on both activated CD8
+
 T cell and Tregs, the 
blockade of CTLA-4 may enhance the activity of the former and down-regulate the inhibitory 
function of the latter, suggesting a particularly promising approach in this context. Clinical trials 
using anti-CTLA4 Abs (Tremelimumab) have shown promising results in cancer patients 
previously vaccinated with GM-CSF-expressing tumor vaccines (274, 275). Notably, since Tregs 
depletion could exacerbate autoimmunity, close monitoring is needed during immunotherapy 
trials.  
 
1.5.2 Active immunotherapy 
 
Active immunotherapy aims at activating patients’ own immune system through the 
administration of a therapeutic vaccine. Vaccine can elicit immune responses directed against 
antigens selectively expressed by tumor cells, sparing normal tissues with consequent low toxic 
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effect. HER2 over-expression has been linked to aggressive disease and poorer prognosis in 
node-positive breast cancer. Several investigations show that some patients develop spontaneous 
anti-HER2-specific immunity with high levels of both cellular and humoral responses (276, 277), 
suggesting that HER2 is a suitable target for active immunization. On the other hand, most 
patients only develop low or even a lack of immune response, strongly suggesting that immune 
tolerance to HER2 has been developed probably related to the oncofetal origin of HER2. Thus, 
the effective vaccine design should be able to circumvent tolerance and induce an integrated 
immune responses composed of CTLs, Abs and CD4
+
 T cells to overcome HER2-induced tumor 
resistance.  
 
1.5.2.1 Peptide-based vaccines 
 
Peptide-based vaccines are designed to induce immune responses using antigenic epitopes 
derived from tumor-associated antigens. Computer modeling programs are effective in predicting 
potential immunogenic epitopes of self-protein HER2. MHC class I-binding epitopes can be 
identified, and corresponding synthetic peptides have been tested for their capacity to induce 
tumor-specific CTLs (278). E75 (HER2 amino acid (aa) 369-377) derived from the ECD of 
HER2 and characterized by HLA-A2 restriction (279), is HLA class-I peptide that stimulates 
CTLs. Clinical studies using E75 as an anti-HER2 vaccine in combination with GM-CSF have 
shown that vaccination can induce a specific anti-peptide immune response with no associated 
toxicity (280). Patients expressing low levels of HER2 have more robust immunologic responses 
(281), and the disease free survival (DFS) rate is improved at 24-month follow-up (282). GP2 is 
HLA-A2-restricted peptide derived from the transmembrane domain of HER2 (aa 654-662). 
Preclinical evaluation of GP2 has confirmed its immunogenicity despite it is a subdominant 
HER2 epitope with lower affinity than E75 (283). A phase I clinical study using GP2 in 
combination with GM-CSF have shown that the vaccine is tolerable and able to effectively 
induce immunological responses in high-risk, lymph node-negative breast cancer patients (284). 
 
The design of multiple or long multivalent peptides is aiming at eliciting stronger and more 
complete responses, including HLA class-II restricted T-helper cells (285). AE37, constructed by 
fusing MHC-II peptide of HER2 (aa 776-779) (AE36) with a LRMK (li-Key) sequence to make 
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easier antigenic epitope presentation of the peptide with HLA class II molecules, has been found 
to augment the CD4
+
 T-cell response (286). Vaccination with AE37, with or without GM-CSF, 
has been shown to induce a dose-dependent cellular immune response specific to AE37. This is 
also the first study demonstrating the effectiveness of a peptide vaccine in the absence of an 
adjuvant according to the authors (287). 
 
Their easy manufacturing and capability of eliciting evaluable antigen-specific immune response 
entitle peptide-based vaccines a promising future. However, peptide vaccinations also present 
some potential limitations. For example, although epitope spreading has been found in some 
clinical settings (288), which could be correlated with clinical benefit, immune response is still 
mostly restricted to one or few epitopes, limiting the magnitude of response and effectiveness in 
fighting tumor cells. Besides, in order to generate a strong and sustained immunological 
memory, continued antigen exposure and stimulation by APCs are needed, whereas most peptide 
vaccines only stimulate a single CD8
+
 T-cell response.  
 
1.5.2.2 Protein-based vaccines 
 
In order to stimulate more complete immunological responses, including extending responses to 
different epitopes of HER2, protein-based vaccines has been developed consisting of the entire 
or truncated forms of HER2. A phase I clinical trial has been conducted in patients with HER2 
over-expressing breast or ovarian cancer using HER2 ICD (aa 676-1255) in combination with 
GM-CSF (289). HER2 ICD specific T-cell response, anti-HER2 IgG and maintained cellular 
immunity have been observed. Another clinical study using HER2 ECD and a portion of ICD 
fused protein vaccine has shown the development of HER2 ECD and ICD specific Abs after 
multiple immunizations (290). A protein-based vaccine by inserting a truncated HER2 protein 
(aa 1-146) into a delivery system consisting of cholesteryl pullulan nanogels (CHP) has also been 
designed. Induced CD4
+
 and/or CD8
+
 T-cell responses have been observed (291), as well as the 
production of truncated HER2-specific IgG (292). Protein-based vaccine has the theoretical 
advantage in including both HLA class I and II epitopes, however, exogenous soluble protein 
antigens stimulated APCs are in general efficient in sensitizing CD4
+
 T cells than in sensitizing 
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CD8
+
 T cells. Moreover, with this type of vaccines, it is more difficult to monitor the responses 
of patients. 
 
1.5.2.3 DNA-bases vaccines 
 
DNA vaccines have the advantage of being simple to construct, produce and administer. Besides, 
co-delivery of cytokine genes can increase their efficacy (293, 294). The goal of DNA vaccine is 
target gene being transferred into target cells, translated into protein and processed for 
presentation. As a result, antigen-specific T-cell response and Ab production will be generated. 
DNA is usually delivered in the form of expression plasmid, such as DNA coding for HER2 ICD 
cloned into pNGVL3 plasmid (NCT00363012, NCT00436254). Viral adenovirus vector 
(NCT00307229) has also been used in clinical trials. A modified vaccinia Ankara-based 
recombinant vaccine vector MVA-BN
®
-HER2, which encodes HER2 ECD and two promiscuous 
T helper cell epitopes from tetanus toxin, has shown improved immunogenicity in a tolerant 
environment (295). The administration of this modified vaccine has also been associated with 
HER2-specific Abs and T-cell responses in clinical trial (296). 
 
1.5.2.4 Tumor cell vaccines 
 
Tumor cell vaccine has the theoretical advantage of providing a pool of tumor antigens to 
develop effective and complete CD4
+
 and CD8
+
 T-cell responses. Non-specific co-stimulatory 
signals are needed to induce an antigen-specific immune response, however, most solid tumors 
do not express these co-stimulatory molecules. Therefore, they are unable to provide all the 
signals necessary for T-cell activation. Genetically modified tumor cells, which express co-
stimulatory molecules or immune-activating cytokines, may help to amplify immunological 
stimulation. Patients can be immunized with their own PBMCs (autologous) (297), which are 
activated in vitro by recombinant fusion protein (composed of HER2 ICD and ECD, as well as 
GM-CSF). They also can be immunized with HER2 overexpressing SKBR1 or SKBR3 cell-line 
(allogeneic) (298), which is genetically modified to secrete GM-CSF. Efficient immune response 
has been induced, and the results can be enhanced with Tregs depletion.  
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1.5.2.5 DC vaccines 
 
DC vaccine strategy has the theoretical advantage of promoting the presentation of the vaccine 
antigens to other cell types since DCs express high levels of both class I/II and co-stimulatory 
molecules, and produce cytokines that are necessary for T-cell activation. A preclinical study 
using HER2/neu modified DCs has shown the prevented or delayed onset of mammary 
carcinomas in a transgenic mouse model of breast cancer (299). Administration of DCs 
transfected with an adenovirus encoding both HER2/neu and IL-12 (300) or TNF-α (301) has 
been shown to induce tumor protection in FVB mice challenged with syngeneic HER2/neu over-
expressing tumor cells in other preclinical studies. DCs transfected with an adenovirus encoding 
HER2/neu has been found more efficient than the plasmid DNA vaccine (302). Later, a 
recombinant adenovirus was constructed, which encoded the HER2/neu protein and RGD motif. 
The addition of the RGD motif in the construct has been observed with increased expression of 
HER2/neu. DCs transfected with RGD motif modified HER2/neu adenovirus showed higher 
CTL and humoral responses and better anti-tumor protection than the ones only transfected with 
regular HER2/neu adenovirus (303). 
 
Mature DCs pulsed with HLA-A2-restricted HER2 peptide have been applied to patients with 
advanced ovarian and breast carcinoma in a clinical trial. Tumor-specific CTLs has been found 
in some patients with the ability to efficiently inhibit HER2 overexpressing cancer cell lines in 
vitro (304). More recently, patients with HER2 over-expressing ductal carcinoma in situ have 
been found to develop peptide specific immune responses and present high levels of CD4
+
 and 
CD8
+
 T cells after the injection of DCs, which are loaded with a mixture of HLA class I- and II-
restricted HER2 peptides (305). Another clinical trial used vaccine that consisted of both mature 
and immature autologous DCs loaded with HER2 ICD peptide in HER2-positive breast cancer 
patients who were disease free after surgery or adjuvant therapy. Most of the patients have been 
reported to develop immunological T-cell response against HER2 ICD and secret specific Abs 
(306). In addition, patients treated with Lapuleucel-T, a vaccine that used autologous PBMCs 
loaded ex vivo with a recombinant fusion antigen consisting of extensive HER2 sequence linked 
to GM-CSF domain, have also shown antigen-specific immune responses (307). 
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Although the use of DC vaccines seems promising, several things are still need to be further 
studied. Ex vivo expansion and activation of DCs are still technically challenging, which is 
crucial for optimal antigen presentation and T cell stimulation. The route of administration is 
also something that needs to be optimized in the future.  
 
1.5.3 Passive and active immunotherapy 
 
Although vaccines in HER2-positive breast cancer show an excellent safety profile and result in 
significant effectiveness, antigen variability and mechanisms of tumor cell immune escaping can 
impair effectiveness of active immunization. Combining tumor vaccines with passive 
immunotherapy is likely to increase the effectiveness of each approach. Different combination 
strategies have been used in clinical trials such as trastuzumab combined with HER2 peptide 
(308, 309), DNA (310) or allogeneic tumor cell vaccine (311), lapatinib concomitant with 
recombinant protein vaccine (312).  
 
1.5.4 Summary 
 
The survival benefit of anti-HER2 driven therapies demonstrated in clinical trials indicates that 
HER2 is one of the most promising molecules for targeted therapy to date. The recombinant 
humanized monoclonal Ab trastuzumab represents one of the most successful adjuvant 
treatments for patients with HER2-positive early stage breast cancer. Many new agents are in 
clinical development, including those directing at the HER2 receptor itself, and those targeting 
downstream effectors and interacting compensatory signaling pathways. Since the HER2 
blockade of tumor cell growth by trastuzumab can be circumvented through alternative growth 
signaling pathways, the antibody-drug conjugate (T-DM1) starts to represent a promising tool in 
the treatment of HER2-positive breast carcinoma. Although combining various chemotherapeutic 
drugs with anti-HER2 Ab is more efficient in clinical trials, it has limited efficacy over time and 
leads to significant increase in toxic effects.  
 
Several mechanisms have been proposed to explain the low clinical effectiveness. The main 
barrier is probably due to immune escaping mechanisms developed by cancer cells. The 
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depletion of Tregs or blockage of immune-checkpoints (e.g. CTLA-4, PD-1/PD-L1) may unleash 
the immune response. On the other hand, the paucity of specific T-cell precursors makes it 
difficult to efficiently elicit both humoral and cellular responses against tumor antigens. An 
increased presentation of HER2 peptides exceeding a critical threshold may break tolerance by 
efficiently stimulating low-avidity T-cell clones, which have escaped negative selection in the 
thymus. Moreover, deleterious impact of chemotherapy and radiotherapy might be another 
obstacle to translate the immunological responses into satisfactory clinical responses. Efforts 
should be made to conduct clinical trials in patients with low tumor burden, not heavily 
pretreated, and most likely to benefit from the vaccines. In conclusion, with the better 
understanding of the complexity of tumor progression, the improvement in technology and 
identification of the optimal clinical setting, defeating HER2-positive breast cancer would be 
challenging yet still plausible in the near future. 
 
1.6 CD8+ regulatory T cells 
 
The existence of T cells being capable of suppressing immune responses was first proposed in 
the 1970s (313), when Gershon et al. observed thymic lymphocytes mediating the adoptive 
transfer of tolerance in mice. Most of these cells with suppressive activities resided in CD8
+
 
compartment (314-316), but subsequent studies failed to identify the molecular basis of 
suppression due to technical limitations. Then it was neglected for many years and finally 
revived by the identification of natural CD4
+
CD25
+
 T cells as potent suppressors of 
autoimmunity (317). In the past decade, CD4
+
 Tregs have been extensively studied in various 
disease models. The key issue is finding specific marker to identify Tregs. Although many 
markers associated with Tregs have been reported, some of them are also activation markers and 
are not specific for Tregs. For example, CD25 has been widely used as a marker of Tregs, but its 
expression is not necessarily associated with Treg function. Similarly, the tumor necrosis factor 
family molecule glucocorticoid-induced tumor necrosis factor receptor (GITR) and CTLA-4 
have been reported as makers for Tregs (157), but they are also expressed on activated effector T 
cells. Foxp3 is the best marker identified to date for CD4
+
 Tregs (318). The elimination of 
Foxp3
+
 Tregs in healthy mice can lead to death resulting from multi-organ autoimmunity within 
10 days (319), and the mutation of Foxp3 gene can cause fatal autoimmune disease 
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immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) in human 
(320, 321). In addition, the reduction of Foxp3 amount can impair their suppressive function 
(322). A growing list of mechanisms is attributed to the suppressive action of CD4
+
Foxp3
+
 Tregs 
(318), but the mechanisms of immune regulation elaborated by regulatory CD8
+
 subsets remain 
less clear despite the fact that CD8
+
 T cells are the initial targets of work in this area. It is now 
widely accepted Tregs exist within both CD4
+
 and CD8
+
 compartments and constitute a 
heterogeneous class of cells with diverse mechanisms of action. Tregs that originate in the 
thymus through interactions between classical MHC molecules and the TCR (323-325) are often 
referred to as natural Tregs (nTregs), while those that arise in the periphery in response to 
antigenic stimulation (326-330) are termed adaptive/induced Tregs (iTregs). Although, in 
principle, functional and phenotypic similarities could be drawn from subsets of CD4
+
 and CD8
+
 
Tregs, no clear definition of mechanisms of action or phenotypes of CD8
+
 Tregs can be easily 
fitting into such categorization without potentially over-simplifying.  
 
1.6.1 Subsets of CD8+ Tregs and related autoimmune diseases 
 
Multiple subsets of thymus derived or peripherally induced CD8
+
 Tregs have been described in 
both humans and mice autoimmune diseases. No universal phenotypic marker has been defined 
based on the diverse origins from which they may have arisen in vivo or different experimental 
conditions to which they have been subjected prior to characterization. Each of these regulatory 
cells is known to possess distinct but sometimes overlapping phenotypes. 
 
1.6.1.1 Qa-1/HLA-E restricted CD8+ Tregs  
 
Mouse Qa-1 and its human homolog HLA-E belong to nonclassical MHC class I molecules 
(331). Qa-1 is preferentially expressed on activated but not resting T cells and thymocytes, 
thereby protecting unstimulated T cells from the effects of Qa-1-restricted CD8
+
-dependent 
suppression. Studies with Qa-1-restricted CD8
+
 Tregs showed that these cells suppress 
intermediate-avidity CD4
+
 T cell responses by sensing their self-peptides that are displayed by 
Qa-1, but enrich high or low avidity CD4
+
 T cell responses against foreign antigens (332). It has 
been shown that the protective effects of Qa-1-restricted CD8
+
 Tregs require perforin and the 
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presence of IFN-γ (333). Qa-1-restricted Tregs cloned from TCR peptide-vaccinated mice have 
also been characterized, revealing the expression of IL-7R, CD25, CD122, CD28, and 
NKG2/CD94 (334). 
 
Using the murine EAE model, several groups reported the involvement of Qa-1-restricted CD8
+
 
Tregs in the regulation of pathogenic self-reactive CD4
+
 T cells (335, 336). Vaccination of mice 
with activated MBP-specific CD4
+
 T cells (337) or anti-TCR mAbs (338) resulted in protection 
from the subsequent induction of EAE and the induction of Qa-1-restricted CD8
+
 Tregs. HLA-E-
restricted CD8
+
 Tregs have also been found in patients with multiple sclerosis (MS) treated with 
glatiramer acetate (GA), suggesting that treatment with GA might induce upregulation of HLA-
E-restricted CD8
+
 T cells, which in turn exert a regulatory/suppressor function and are capable of 
modulating in vivo immune responses by directly killing pathogenic CD4
+
 T cells (339-341). 
Therapeutic effect of GA-induced CD8
+
 Tregs has also been found in experimental inflammatory 
bowel diseases (IBDs) in mice (342). In addition to EAE/MS, beneficial effects of autoreactive 
T-cell induced Qa-1-restricted CD8
+
 Tregs have been observed in non-obese diabetic (NOD) 
mice (343) and collagen-induced arthritis (CIA) mice (344). Qa-1-restricted CD8
+
 T cells have 
also been shown to specifically suppress Qa-1 expressing follicular T-helper cells based on the 
fact that the genetic disruption of this inhibitory interaction promotes systemic lupus 
erythematosus (SLE)-like autoimmune disease in mice (345). 
 
1.6.1.2 CD8+CD25+ Tregs  
 
Human CD8
+
CD25
+
 (CD25: IL-2 receptor α chain) thymocytes sharing phenotype, functional 
features and mechanism of action with CD4
+
CD25
+
 Tregs have been shown to suppress 
autologous T cell responses in a cell contact-dependent manner (346). These cells constitutively 
express cytoplasmic CTLA-4, surface tumor necrosis factor receptor 2 (TNFR2), CCR8 as well 
as high levels of Foxp3 mRNA. When activated with long-term anti-CD3/CD28 treatment in 
vitro, they up-regulate surface expression of CTLA-4 and TGF-β1. Several reports documented 
the generation of CD8
+
CD25
+
 Tregs by culturing human peripheral blood in vitro (347-350). The 
CD25
-
 precursor cells up-regulated the expression of CD25, Foxp3, GITR, CD28 and CTLA-4 
after continuous antigen stimulation, thereby possessing the ability to inhibit CD4
+
 and CD8
+
 T-
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cell proliferation and cytokine production (349). A similar experiment further showed that 
continuous in vitro antigenic stimulated CD8
+
CD25
+
Foxp3
+
LAG-3
+
 Tregs suppress T cell 
responses via a CCL4 partially dependent mechanism (348). Co-culturing human PBMCs with 
autologous LPS-activated DCs can also generate CD8
+
CD25
+
Foxp3
+
 T cells with regulatory 
activity in a cell-cell contact and CTLA-4 dependent manner (350). In mice, a similar subset has 
been found in the thymus and periphery of MHC class II-deficient animals (351). CD44, GITR, 
LFA-1 and intracellular CTLA-4 expressing CD8
+
CD25
+
 T cells have been shown to suppress 
anti-CD3-stimulated CD25
-
 T cell responses in vitro in a contact-dependent, IL-10-independent 
manner. Notably, although both naturally occurring and induced CD8
+
Foxp3
+
 T cells have been 
demonstrated to express bona fide Treg markers including CD25, GITR, CTLA4 and CD103, 
induced CD8
+
Foxp3
+
 T cells have been shown to mildly suppress T-cell proliferation and IFN-γ 
production in mice (352). 
 
Treatment of diabetes mellitus (DM) patients with a modified anti-CD3 mAbs have been shown 
improved insulin secretion, an effect associated with an increase of CD8
+
CD25
+
Foxp3
+
CTLA-4
+
 
Tregs (353). Similarly, in NOD mice, glutamate decarboxylate 65 (GAD)-IgG-transduced 
splenocytes have been found to induce an antigen-specific CD8
+
CD25
+
Foxp3
+
 T cells with 
suppressive activity (354). 
 
1.6.1.3 CD8+CD122+ Tregs  
 
CD8
+
CD122
+
 (CD122: IL-2 receptor β chain) T cells are another type of naturally occurring 
Tregs found in the periphery of naive, unmanipulated mice. Mice genetically deficient for 
CD122 gene spontaneously develop severe hyperimmunity by abnormal expansion of activated 
T cells and differentiation of B cells into antibody-secreting plasma cells (355). This abnormal 
phenotype can be reversed by transfer of purified CD8
+
CD122
+
 T cells into CD122-deficient 
neonates, indicating that the CD8
+
CD122
+
 population includes naturally occurring CD8
+
 Tregs 
that control potentially dangerous T cells (356). Interestingly, the mechanism of suppressive 
function of CD8
+
CD122
+ 
Tregs has been shown independent of APC or cell-cell contact, but at 
least in part dependent on the secreting of regulatory cytokine IL-10 (357). A later study 
confirmed the important role of IL-10 in this suppression (358). Moreover, it has also been 
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shown that the costimulatory signals of both CD28 and PD-1 are required for their optimal IL-10 
production. The blockage of PD-1 inhibited the suppressive function of CD8
+
CD122
+
PD-1
+
 T 
cells, suggesting that the suppressive activity of this Treg subset resides within its PD-1 fraction. 
Like CD25 (which is also expressed in activated T cells) is not an exclusive marker for CD4
+
 
Tregs, CD122 cannot be an ideal marker for CD8
+
 Tregs either since it is also a marker of CD8
+
 
T memory cells.  
 
CD8
+
CD122
+
 Tregs have been identified in multiple autoimmune scenarios in murine models, 
including Graves’ disease (359), EAE (360) and CD4+ T cell-induced colitis (361). In the 
absence of CD8
+
CD122
+
 Tregs, the activation of autoreactive T cells in these models becomes 
aggressive, suggesting their importance in maintaining immune homeostasis. In addition, IL-10 
neutralization can largely reverse disease protection in all of these cases. Human CD8
+
CXCR3
+
 
T cells have been considered as the functional counterpart of the murine CD8
+
CD122
+
 T cells 
(362) as they demonstrate their regulatory activities of producing IL-10 and suppressing IFN-γ in 
vitro in a similar way. Moreover, treatment of NOD mice with disease-relevant peptide MHC 
nanoparticle complexes has been shown to mediate effective expansion of cognate low-avidity, 
memory-like CD8
+
CD122
+
CXCR3
+
 T cells in vivo, which abrogate disease by suppressing local 
presentation of autoantigens via IFN-γ, indoleamine 2,3-dioxygenase (IDO) and perforin-
dependent mechanisms (363).  
 
1.6.1.4 CD8+CD28- Tregs  
 
A series of studies on CD8
+
CD28
-
 T cells showed that they are able to suppress antigen specific 
CD4
+
 T cell responses in vitro (364-367). In the literature, this CD8
+
CD28
-
 T cell subset is 
commonly referred to as T suppressor (Ts). Some reports indicated that Foxp3 is a reliable 
marker for identification of CD8
+
CD28
-
 Ts (368), which express similar markers as CD4
+
CD25
+
 
Tregs, including Foxp3, GITR, CTLA-4, CD25, CD103, CD62L and 4-1BB (369), while others 
failed to identify the expression of Foxp3. Mechanistically, CD8
+
CD28
-
 Ts target DCs and other 
nonprofessional APCs either by down-regulating co-stimulatory molecules on APCs (364) or by 
up-regulating expression of the inhibitory receptors immunoglobulin-like transcript 3 (ILT3) and 
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ILT4 on APCs (370) or endothelial cells (371), thereby rendering these APCs tolerogenic, which 
in turn, conferring regulatory activity upon CD4
+
 T cells. 
 
The deficit of CD8
+
CD28
-
 T-cell population has been observed in numerous animal and human 
autoimmune diseases. CD8
-/-
CD28
-/-
 double knockout (KO) mice has been found susceptible to 
EAE, and adoptive transfer of in vitro-activated CD8
+
CD28
-
 T cells into MOG peptide-
immunized CD8
-/-
 mice can significant decrease the severity of EAE (372). The suppressive 
mechanism of CD8
+
CD28
-
 T cells is MHC class I-restricted and cell-cell contact dependent. A 
recent study using CD28 conditional KO mice, in which CD28 is deleted under the control of 
Foxp3 promoter, has shown that these animals accumulate large numbers of activated T cells, 
develop severe autoimmunity and fail to appropriately resolve induced EAE by dampening the 
expression of CTLA-4, PD-1 and CCR6 (373). In an experimental model of myasthenia gravis 
(MG), treatment with a dual-altered peptide ligand has been suggested to prevent disease through 
the expansion of CD8
+
CD28
-
Foxp3
+
 Tregs, which produce immunosuppressive cytokines such 
as IL-10 and TGF-β, thereby transferring the protection into MG-prone animals (374, 375). In 
vitro expanded CD8
+
CD28
-
CD56
+
 T cells have been shown to blunt synovitis in NOD-SCID 
(severe combined immunodeficiency) mice engrafted with synovial tissues from patients with 
rheumatoid arthritis (RA) (376). The suppressive activity of CD8
+
CD28
-
 T cells has also been 
demonstrated in patients with Hashimoto thyroiditis, Grave’s disease (377) and systemic 
sclerosis (378), but not in healthy individuals. Notably, the frequency and function of 
CD8
+
CD28
-
 Tregs has been shown to correlate with diseased states in type 1 DM (379), MS 
(379-381) and SLE patients (382). 
 
1.6.1.5 CD8+CD11c+ Tregs  
 
CD8
+
 T cells co-expressing CD11c are a new addition to the growing list of Tregs. CD8
+
CD11c
+
 
T cells exist in naive mice less than 3%, but they neither present appreciable suppressive activity 
in vitro nor substantially develop into mature CD8
+
CD11c
+
 T cells (383). Instead, CD11c
-
CD8
+
 
T cells when stimulate with antigen and anti-4-1BB Ab can develop into CD11c
+
CD8
+
 T cells in 
an antigen-specific manner. 4-1BB signaling other than CD3, CD28 or cytokines has been shown 
to effective support CD8
+
CD11c
+
 T cells expansion. The anti-4-1BB-expanded CD8
+
CD11c
+
 T 
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cells are characterized by strong expression of IFN-γ, which in turn primed DCs/macrophages to 
generate immunosuppressive IDO (384, 385). Such IDO
+
 APCs when collaborate with 
autoreactive CD4
+
 T cells can cause the suppression of CD4
+
 T cells (383-385). Notably, 
activated CD8
+
CD11c
+
 T cells have also been shown to function as immune effectors in viral 
infection models (386, 387). Therefore, it would be interested to explore the mechanism that 
switches between their proposed effector and regulatory roles in the future. 
 
Inducible expansion of CD8
+
CD11c
+
 T cells has been associated with the suppression of antigen-
specific CD4
+
 T-cell activity in autoimmune disease like CIA (385), experimental autoimmune 
uveoretinitis (EAU) (384) and IBD (388). A study in an animal model of CIA showed that the 
protective effect of CD8
+
CD11c
+
 T cells is linked to the production of IFN-γ and the activity of 
IDO, but failed to demonstrate whether it is a direct result of CD8
+
CD11c
+
 Tregs or not. The 
protective function of CD8
+
CD11c
+
 T cells has also been observed in EAU since the depletion of 
CD8α+ cells can partially neutralize the anti-4-1BB-mediated protective effects.  
 
1.6.1.6 CD8+CD103+ Tregs  
 
CD103 is the alpha chain of the integrin αEβ7 and provides tissue retention at sites enriched in E 
cadherin. Animal studies pointed that although the integrin CD103 is not necessary for the 
migration of T cells to sites of inflammation, it favored prolonged retention of Tregs at these 
sites (389, 390). Murine Tregs significantly differ with human Tregs in regard to CD103 
expression (391). In naive mice, up to 30% of CD25
+
Foxp3
+
 lymphocytes in fact express CD103. 
In contrast, cells with this marker are virtually absent among human CD25
high
Foxp3
+
 Tregs. 
However, CD103 expression is dramatically upregulated on alloreactive CD8
+
 T cells upon entry 
into a renal graft site or on CD8
+
 T cells within the gut epithelium (392) in a TGF-β1 and IL-2-
dependent manner (393). Although alloantigen induced CD8
+
CD103
+
 T cells were initially 
identified as an effector subset, these cells have also been addressed possessing regulatory 
activity (394). The increased CD103 expression on alloreactive CD8
+
 T cells has been shown in 
the presence of TGF-β, IL-4 and IL-10, but not in the presence of IL-12 in mixed lymphocyte 
cultures (MLCs). Their suppressive activity is antigen nonspecific and depends on cell-cell 
contact. In addition, TGF-β-based suppression has been suggested to depend completely upon 
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the CD8
+
 Tregs being capable of binding IFN-γ (395). CD8+CD103+ TGF-β-secreting T cells 
have also shown their protective function in a model of TNF-driven chronic ileitis (396) and in a 
liver allograft setting (397). However, the relationship between CD8
+
CD103
+
 Tregs and 
autoimmune disease remains to be determined. 
 
1.6.1.7 Other CD8+ Tregs 
 
CD8
+
HLA-G
+
 Tregs: HLA-G, a non-classical HLA class Ib molecule with immune-suppressive 
function (398-401), is mainly expressed on placental trophoblasts, ectopic expressed on small 
populations of peripheral blood CD4
+
 and CD8
+
 T cells and at sites of inflammation (402). 
CD8
+
HLA-G
+ 
Foxp3
-
 T cells are detectable in the human thymus and constitute on average 3.3% 
of the total CD8
+
 T cell population within human PBMCs. This HLA-G
+
 subset presents with an 
anergic phenotype in response to allogeneic and polyclonal stimuli, and has been shown to 
suppress both CD4
+
 and CD8
+
 T cell proliferation in vitro. Infiltrating or invading CD8
+
HLA-G
+
 
T cells has been found elevated in muscle biopsies from patients with inflammatory myopathies, 
and the frequencies of this population has been shown associated with the degree of cellular 
infiltrate in the muscle (402), suggesting their modulation role in inflamed tissue.  
 
CD8
+
LAP
+
 Tregs: Latency-associated peptide (LAP), a membrane bound form of TGF-β, has 
been reported expressed on approximately 3.3% of the splenic CD8
+
 T cell population in 
unmanipulated mice (403). Only a small fraction of CD8
+
LAP
+
 cells have been shown to express 
Foxp3 or CD25, although the expression level of Foxp3 for these cells are higher than their LAP
-
 
counterparts. CD8
+
LAP
+
 cells have been found to suppress EAE in an IFN-γ and TGF-β-
dependent manner based on the facts (i) In vivo neutralization of TGF-β significantly reverses the 
suppression of EAE mediated by CD8
+
LAP
+
 cells; (ii) The suppressive function of CD8
+
LAP
+
 
cells is markedly diminished when these cells are purified from IFN-γ-/- mice. Whether a 
counterpart of suppressive CD8
+
LAP
+
 cells, which play the suppressive role in human, remains 
to be determined. 
 
CD8
+
CD45RO
+
 Tregs: A subset of CD8
+
 T cells, which has been identified in patients that 
receive HLA-matched, minor histocompatibility antigen (HA-1)-mismatched renal transplants, 
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has shown suppressive ability on both cognate delayed-type hypersensitivity responses and 
responses towards a third party antigen via IL-10, TGF-β and CTLA-4-dependent mechanisms 
(404). These CD8
+
 cells consist mainly of CD45RO
+
CD62L
-
CCR7
-
 T cells of the memory 
effector type. Another subset of CD8
+
 T cells with the expression of CD45RO and CCR7
 
have 
also been found in patients with ovarian carcinoma. These tumor ascites pDCs induced cells 
have been observed to suppress tumor-antigen driven T cell responses in vitro by secreting IL-10 
(405).  
 
pCons-induced CD8
+
 Tregs: A nucleosomal histone peptide has been documented to treat 
lupus-prone animals by induction of regulatory CD8
+
 T cells. CD8
+
 Tregs, which produce and 
require TGF-β for immunosuppression, suppressed antigen-driven T cell responses in a contact-
independent manner (406). Similar subsets have been described in a model of murine systemic 
lupus, where treatment with a pConsensus (pCons) either by i.v. (407) or oral (408) 
administration induced a population of CD8
+
 T cells that suppress autoimmune responses. 
pCons-induced CD8
+
 Tregs have been shown to exert protective effects in lupus mice by 
differentially modulating the activity of different T cell subsets (409) along with increased 
cytotoxic activity against B cells, thereby exerting their influences by both suppressing helper T 
cells and killing pathogenic B cells (410). 
 
CD8
+
CD39
+
 Tregs: CD39, an ectonucleotidase, presents at the surface of different immune cells 
and catalyzes conversion of extracellular ATP or ADP to AMP (411). ATP is a potent activator 
of immune cells and inflammation, thus the presence of CD39 deprives cells of an important 
energy source and favors the formation of a potent inhibitor of effector function. CD39 has been 
found on CD4
+
CD25
+
 Tregs and involves in their regulatory activity (412, 413). A recent study 
has shown that it also participates in mediating the suppressive activity of CD8
+
 Tregs (414). 
Besides, intratumoral CD8
+
 Treg-mediated suppression has been associated with CD39 
expression, suggesting that CD39-mediated inhibition constitutes a prevalent hallmark of their 
function. 
 
CD8
+
CD38
+
 Tregs: CD38, similar as CD39, is another ectonucleotidases that strongly 
influences the adaptive immunity (415). In the absence of CD38, NOD mice developed 
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accelerated autoimmune diabetes, and CD38
-/-
 mice showed an impaired regulatory T cell 
development (416). In human, the detection of anti-CD38 autoantibodies has been associated 
with chronic autoimmune thyroiditis, Graves’ disease and Type I diabetes (417, 418). Previous 
study showed that high expression of CD38 on CD4
+
Foxp3
+
 T cell subpopulation correlated with 
strongest regulatory properties of CD4
+
 Tregs (419). Moreover, regulatory CD8
+
 T cells with the 
memory-like phenotype of CD8
+
CD38
high
CD44
+
CD122
+
CD62L
high
 also showed suppressive 
function on CD4
+
 effector T-cell proliferation in a cell-cell contact dependent, TGF-β and 
granzyme B independent manner (420). CD8
+
CD38
high
 T cell-treated MOG-induced EAE mice 
showed reduced clinical score and disease severity compared to mice that received CD8
+
CD38
-
 
T cells, suggesting the potential role of CD8
+
CD38
high 
T cells in inhibiting excessive immune 
responses. 
 
1.6.2 Summary 
 
Although CD4
+
 Treg subsets have been more extensively studied in the last decade, growing 
interest is presently devoted to CD8
+
 Treg subsets. A wide array of CD8
+
 Treg subpopulation has 
been characterized both in mice and human. These cells are involved in physiological 
mechanisms that guarantee immune homeostasis and protect immune system from autoimmune 
reactions. Notably, Tregs have both positive and negative functions in the immune system. Other 
than the positive aspects of Tregs, including suppression of autoimmune responses, maintenance 
immune homeostasis, as well as tolerance in xenotransplantation, negative aspects of Tregs have 
also been widely studied. For example, some infectious agents can manipulate Tregs to avoid the 
host’s immune responses; or in cancer scenario, Tregs can provide help to suppress the body’s 
cytotoxic immune response to neoplastic cells. Therefore, immune homeostasis, which results 
from the controlled balance between effector and regulatory immune responses, determines the 
fate of an immune response. 
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CHAPTER 2 HYPOTHESIS 
 
Hypothesis I. With the targeting role of exosomal pMHC-I complexes, HER2-specific exosome-
targeted CD4
+
 T cell-based vaccine (HER2-TEXO) can stimulate efficient HER2-specific CD8
+
 
CTL responses and antitumor immunity in double transgenic HER2/HLA-A2 mice with HER2-
specific self-immune tolerance. 
 
Hypothesis II. Similar to natural CD4
+
CD25
+
 Tregs, in vitro activated polyclonal CD8
+
CD25
+
 
Tregs may have immunosuppressive effect. With the targeting role of pMHC-II complexes, 
redirecting antigen specificity to non-specific polyclonal CD8
+
CD25
+
 Tregs by OVA323-339 and 
MOG35-55 peptide pulsing can enhance the suppressive effects on OVA-specific tumor model and 
MOG-induced EAE model.  
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CHAPTER 3 OBJECTIVES 
 
For testing hypothesis I, objectives are: 
i. Generation of OVA-TEXO vaccine as well as OVA-(K
b-/-
)TEXO, (4-1BBL
-/-
)TEXO, (OX40L
-
/-
)TEXO and (CD40L
-/-
)TEXO, lacking pMHC-I, 4-1BBL, OX40L and CD40L, respectively. 
ii. Assessment of the role of pMHC-I and costimulatory 4-1BBL, OX40L and CD40L in 
OVA-TEXO-stimulated CTL response and memory development. 
iii. Assessment of critical role of exosomal pMHC-I complexes in targeting OVA-TEXO cells 
to cognate CD8
+
 T cells ex vivo in mouse lymph nodes by two-photon microscopy. 
iv. Generation of HER2-TEXO vaccine using ConA-stimulated CD4
+
 T cells with uptake of 
HER2-expressing DC-released exosomes. 
v. Assessment of HER2-TEXO-stimulated HER2-specific CTL responses and antitumor 
immunity against HLA-A2/HER2-expressing B16 melanoma in double transgenic HLA-
A2/HER2 mice with HER2-specific self-immune tolerance. 
 
For testing hypothesis II, objectives are: 
i. Purification and expansion of polyclonal CD8+CD25+ Tregs in culture using CD3/CD28 
microbeads. 
ii. Phenotypic characterization of CD8+CD25+ Tregs.  
iii. Functional characterization of CD8+CD25+ Treg-mediated suppression in vitro. 
iv. Functional characterization of CD8+CD25+ Treg-mediated suppression in vivo in OVA-
specific animal tumor model. 
v. Comparison of OVA323-339- and MOG35-55-pulsed CD8
+
CD25
+
 Treg-mediated 
suppression to CD8
+
CD25
+
 Treg-mediated suppression in vivo in OVA-specific animal 
tumor model and in MOG-induced EAE model. 
vi. Assessment of critical role of exosomal pMHC-II complexes in targeting OVA-TEXO cells 
to cognate CD4
+
 T cells ex vivo in mouse lymph nodes by two-photon microscopy. 
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CHAPTER 4 MATERIALS AND METHODS 
 
4.1 Materials  
 
4.1.1 Reagents 
 
Table 4.1 lists the chemicals used in this dissertation. All of the reagents are molecular biology 
or research grade. Table 4.2 lists Abs labeled with fluorescein isothiocyanate (FITC), 
phycoerythrin (PE), PE-Cy5 or biotin. Table 4.3 lists the commercially available kits used in this 
dissertation. 
 
Table 4.1 List of chemicals and reagents 
 
Reagents Suppliers 
α-MEM Gibco 
λ HindIII DNA Ladder New England Biolabs 
Agar Invitrogen 
Agarose Invitrogen 
AIM-V medium Gibco 
Ammonium Chloride EM Sciences 
Ampicillin Sigma 
Anti-biotin MicroBeads Miltenyi Biotec 
Bacto-tryptone BD Biosciences 
BSA Sigma 
Calcium chloride Sigma 
Cesium chloride Sigma 
CFA Sigma 
CFSE Invitrogen 
CMTMR Invitrogen 
Collagenase Worthington Biochemical 
dNTP mix (dATP, dCTP, dGTP, dTTP) Invitrogen 
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Reagents Suppliers 
DMEM Gibco 
Dynabeads® Mouse T-Activator CD3/CD28 Invitrogen 
G418 Invitrogen 
Gentamicin Gibco 
Glycerol BDH Inc 
GM-CSF R&D Systems 
HER2369-377 (KIFGSLAFL) Synthesized by New England Peptide 
HindIII Restriction Enzyme New England Biolabs 
Hygromycin Invitrogen 
IL-2 Peprotech 
IL-4 R & D Systems 
Kanamycin EM Sciences 
Lipofectamine2000 Invitrogen 
LS column Miltenyi Biotec 
Mouse anti-biotin MicroBeads Miltenyi Biotec 
Mouse CD4 (L3T4) MicroBeads Miltenyi Biotec 
Mouse CD8 (Ly-2) MicroBeads Miltenyi Biotec 
MOG35-55 (MEVGWYRSPFSRVVHLYRNGK) Anaspec 
Mut1 (FEQNTAQP) Anaspec 
NEBuffer 2.1 New England Biolabs 
OVAI (OVA257-264, SIINFEKL) Anaspec 
OVAII (OVA323-339, ISQAVHAAHAEINEAGR) Anaspec 
pcDNA3.1(+)neo plasmids Invitrogen 
PacI Restriction Enzyme New England Biolabs 
PmeI Restriction Enzyme New England Biolabs 
Poly-D-Lysine/Laminin coated culture slides BD Biosciences 
ProLong Gold antifade reagent Invitrogen 
RPMI-1640 Gibco 
Quick-Seal tube (12.5 mL) Beckman Coulter 
Slide-A-lyzer dialysis cassettes Thermo Fisher Scientific Inc. 
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Reagents Suppliers 
SYBR® Safe DNA Gel Stain Invitrogen 
T4 DNA ligase New England Biolabs 
Taq DNA polymerase Qiagen 
ThiolTracker
TM
 Violet Invitrogen 
XbaI Restriction Enzyme  New England Biolabs 
100 bp Plus Opti-DNA Marker Applied Biological Materials Inc. 
2-ME Bio-Rad 
3.8 μm diameter aldehyde/sulfate latex beads Interfacial Dynamics 
 
Table 4.2 List of antibodies 
 
Antibodies Clone Suppliers 
Anti-H2-K
b
/OVAI (pMHC-I) 25-D1.16 eBioscience 
Anti-human HER2 24D2 Biolegend 
Anti-human HLA-A2 BB7.2 Santa Cruz Biotechnology 
Anti-mouse CD103 M290 BD Biosciences 
Anti-mouse CD11c HL3 BD Biosciences 
Anti-mouse CD20 AISB12 eBioscience 
Anti-mouse CD25 7D4 BD Biosciences 
Anti-mouse CD28 37.51 BD Biosciences 
Anti-mouse CD317 (BST-2) 120G8.04 Dendritics 
Anti-mouse CD4 GK1.5 BD Biosciences 
Anti-mouse CD40 HM40-3 BD Biosciences 
Anti-mouse CD40L MR1 Biolegend 
Anti-mouse CD44 IM7 BD Biosciences 
Anti-mouse CD45R/B220 RA3-6B2 BD Biosciences 
Anti-mouse CD8 53-6.7 eBioscience 
Anti-mouse CD80 16-10A1 BD Biosciences 
Anti-mouse CTLA-4 UC10-4F10-11 BD Biosciences 
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Antibodies Clone Suppliers 
Anti-mouse GITR DTA-1 BD Biosciences 
Anti-mouse Granzyme B NGZB eBioscience 
Anti-mouse OX40L RM134L Biolegend 
Anti-mouse perforin eBioOMAK-D eBioscience 
Anti-mouse PKCθ C-19 Santa Cruz Biotechnology 
Anti-mouse I-A
b
 AF6-120.1 BD Biosciences 
Anti-mouse IgG  Jackson Immunoresearch 
Anti-mouse talin 8D4 Sigma 
Anti-mouse 4-1BBL TKS-1 eBioscience 
Anti-goat IgG  Jackson Immunoresearch 
Streptavidin-FITC  BD Biosciences 
Streptavidin-PE  BD Biosciences 
Streptavidin-PE-Cy5  BD Biosciences 
 
Table 4.3 List of kits 
 
Commercial kits Suppliers 
EasySep™ Mouse CD4+ T Cell Isolation Kit Stemcell 
EasySep™ Mouse CD8+ T Cell Isolation Kit Stemcell 
ELISA Kits for IL-2 BD Biosciences 
Fixation and Permeabilization Solution Kit with BD GolgiStop™ BD Biosciences 
Mouse Regulatory T Cell Staining Kit #3 eBioscience 
GranToxiLux OncoImmunin, Inc. 
QIAprep Spin Miniprep Kit Qiagen 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR purification Kit Qiagen 
RNeasy Plus Mini Kit Qiagen 
RT
2
 First Strand Kit Qiagen 
RT
2
 SYBR Green qPCR Mastermixes Qiagen 
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4.1.2 Cell lines 
 
The highly metastatic B16 mouse melanoma BL6-10 and BL6-10OVA tumor cells were cultured 
in alpha-minimum essential medium (α-MEM). BL6-10HER2 tumor cells were cultured in α-MEM 
plus 1 mg/mL G418. BL6-10HLA-A2/HER2 tumor cells were cultured in α-MEM plus 1 mg/ mL 
G418 and 0.5 mg/mL hygromycin. Human embryonic kidney cells (HEK293) express early 
region-1 (E1) of adenovirus (AdV), which helps the growth and amplification of replication 
deficient AdV. These cells were purchased from the Microbix, and cultured in Eagle's minimal 
essential medium (EMEM). 
 
All culture media were supplemented with 10% (v/v) fetal calf serum (FCS) and 30 µg/mL 
gentamicin reagent. c-PEG solution and 1× citric saline solution were used for BL6-10 and 
HEK293 cell passage, respectively. Cells were cultured in a humidified incubator at 37 ºC with 
5% CO2 saturation. Viable cells were counted using Trypan blue stain using a haemocytometer. 
  
4.1.3 Bacterial cells 
 
Escherichia coli (E. coli), DH5α strain (New England Biolabs), was routinely used for 
expression-vector propagation. E. coli, BJ5183 strain (Stratagene), was used for the homologous 
recombination in AdV vector construction. Both cells were grown in Lysogeny broth (LB) at 37 
ºC on a shaker. Medium was supplemented with selective antibiotic, ampicillin (100 µg/mL) or 
kanamycin (50 µg/mL), depending on the expression vector’s resistance gene. After 
transformation, transformed bacterial cells were selected by plating them on selective LB-agar 
plates containing appropriate selective antibiotics. Plates were incubated overnight at 37 ºC.  
 
4.1.4 Animals 
 
Wild-type (C57BL/6) female mice with H2-K
b
 background, OVA-specific TCR-transgenic OTI 
(transgenic for αβTCR specific for OVA-peptide 257-264 in the context of H-2Kb) and OTII 
(transgenic for αβTCR specific for 323-339 OVA-peptide in the context of I-Ab) mice, CD11c-
DTR mice, various gene KO mice (H-2K
b-/-
, I-A
b-/-
, CD40L
-/-
, CD40
-/-
, 4-1BB
-/-
, OX40L
-/-
 and 
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OX40
-/-
) and transgenic HLA-A2 mice were obtained from the Jackson Laboratory. 4-1BBL
-/-
 
mice were obtained from Amgen. Homozygous OTII/H-2K
b-/-
, OTII/CD40L
-/-
, OTII/4-1BBL
-/-
 
and OTII/OX40L
-/-
 mice were generated by backcrossing the designated gene KO mice onto the 
OTII background. The transgenic (Tg) HER2 (H-2K
b
) mice (421) with HER2-specific self-
immune tolerance were obtained from Dr. Wei-Zen Wei (Wayne State University). The double 
transgenic HLA-A2/HER2 mice were generated by backcrossing male HER2 mice with female 
HLA-A2 mice. All mice used in the experiments were 6-8 weeks old and were treated according 
to the animal care committee guidelines of the University of Saskatchewan. 
 
4.2 Methods 
 
4.2.1 Molecular biology experiments 
 
4.2.1.1 General molecular biology techniques 
 
General molecular biology techniques used in this dissertation were based on the protocols 
described in Molecular Cloning, a Laboratory Manual by Sambrook et al. (422) and Sambrook 
and Russel (423) with few modifications. 
 
4.2.1.1.1 Restriction enzyme digestion 
 
The restriction enzymes HindIII and XbaI were purchased from New England Biolabs. DNA 
digestions were performed according to the manufacturer’s guidelines. Briefly, around 1 µg of 
DNA was digested using 1 unit of specific restriction enzyme in 1× recommended NEBuffer 2.1 
for 1 hour at 37 ºC. 
 
4.2.1.1.2 Agarose gel electrophoresis 
 
Agarose gels were prepared in varying concentration, from 0.7% (w/v) to 2% (w/v), in Tris-
acetate EDTA (TAE) buffer, depending on the size of the DNA band to be visualized. 10,000× 
dilution of SYBR® Safe DNA Gel Stain was used in the gel to stain DNA. Samples were mixed 
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with loading buffer and loaded on the gel along with DNA markers. For optimal resolution, gels 
were run between 90 to 110 volts in TAE buffer for varying times. Bands were visualized under 
UV trans-illuminator gel documentation system (Bio-Rad). 
 
4.2.1.1.3 Purification of linear DNA fragments 
 
For further downstream applications, PCR products were purified using QIAquick PCR 
purification Kit. DNA fragments from agarose gel were purified using QIAquick Gel Extraction 
Kit. The method was followed as per the procedure provided by manufacturer. Typically, DNA 
was eluted in 20 µL of sterile water to facilitate the subsequent ligation or transfection 
procedures. 
 
4.2.1.1.4 DNA ligation 
 
DNA ligation was performed using T4 DNA ligase in supplied ligation buffer. Typically, a 20 
µL ligation reaction consists of 50 ng of vector DNA, at least 150 ng of purified insert DNA with 
1-5 units of T4 DNA ligase in 1× ligation buffer. Ligation reactions were performed overnight at 
4 ºC. 
 
4.2.1.1.5 Heat shock transformation 
 
100 µL competent cells (DH5α or BJ5183) were mixed with plasmid DNA or DNA ligation 
products and kept on ice for 30 min. The sample was heat shocked at 42 ºC for 90 sec by quickly 
placing the sample into a water bath. The sample was then placed on ice for at least 2 min. 
Transformed bacteria cells were then cultured in 500 µL LB medium at 37 ºC for 45 min. Cells 
were then added onto selective LB-agar plates to get individual bacteria clone, and cultured at 37 
ºC for 12-16 hrs. 
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4.2.1.1.6 Plasmid DNA purification 
 
To screen positive recombinant colonies after transformation, single isolated colonies were 
selected. For recombinant BJ5183 colonies, a tiny single colony was selected. The colonies were 
further cultured to amplify copies of recombinant plasmid DNA in LB broth with selective 
antibiotic overnight. Cells were pelleted the next day, plasmids were isolated using QIAprep 
Spin Miniprep Kit according to the manufacturer’s protocol. Finally, purified plasmid DNA was 
quantified using Nanodrop (Thermo-Scientific). 
 
4.2.1.1.7 DNA sequencing 
 
Automated sequencing was performed at the sequencing facilities located in Plant 
Biotechnology Institute of the National Research Council of Canada in Saskatoon, Canada. 
Sequences were then analyzed through Blast on NCBI. 
 
4.2.1.2 Construction of pcDNA3.1/HER2 vectors 
 
The human HER2690aa cDNA fragments coding for the extracellular and transmembrane domains 
of human HER2 were amplified by PCR using PCR2.1/HER2 plasmids carrying full length 
human HER2 3768 bp cDNA (GenBank accession no. NM_004448) as templates, and 
HER2690aa-F (5’-CTT AAG CTT GCC ACC ATG GAG CTG GCG GCC TTG TG-3’) and 
HER2690aa-R (5’-GAG TCT AGA GTC TCC GCA TCG TGT ACT TC-3’) as primers under 
conditions [1 cycle at 94 ºC (2 min) and then 72 ºC (7 min) followed by 30 cycles at 94 ºC (50 
sec), 58 ºC (50 sec) and 72 ºC (2 min)]. The PCR reaction products were analyzed on 1% agarose 
gel electrophoresis with SYBR® Safe DNA Gel staining. Then the about 2070 bp HER2690aa 
cDNA fragments were inserted into pcDNA3.1(+)neo plasmids containing neomycin (G418) 
resistance gene at HindIII and XbaI sites. The recombinant eukaryotic expression vector 
pcDNA3.1(+)neo/HER2690aa (termed pcDNA3.1/HER2 hereafter) were further identified by 
PCR, double enzyme digestion and DNA sequencing analysis, respectively. 
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4.2.1.3 AdVHER2 construction 
  
The overall method for construction of recombinant replication-incompetent Ad5E1- and E3-
deleted adenovirus expressing human HER2690aa as reported by He et al. in 1998 (424). To 
develop a more efficient gene delivery system, we used RGD-modified pAdEasy-1 (425) as an 
adenoviral backbone plasmid, which contains an integrin-binding motif RGD sequence in the HI 
loop of adenoviral fiber, in the construction of human HER2690aa-expressing recombinant 
adenovirus. In brief, the 2070 bp HER2690aa fragments released from recombinant eukaryotic 
expression plasmids pcDNA3.1/HER2 by double enzyme digestion with HindIII and XbaI were 
inserted into pShuttle-CMV transfer (shuttle) plasmid at HindIII and XbaI sites to form 
recombinant transfer vector pShuttle-CMV/HER2690aa. After homologous recombination of 
pShuttle-CMV/HER2690aa or control pShuttle-CMV and pAdEasy-1 (RGD) in E.coli BJ5183 
bacteria, the recombinant pAdEasy-HER2690aa (termed AdVHER2 hereafter) or control blank 
adenovirus were subsequently linearized by PacI digestion and transfected into HEK293 cells for 
replication-deficient AdVHER2 production (Figure 4.1). 
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Figure 4.1 Schematic representation of AdEasy system and AdV production (adapted from 
Qbiogene, Inc)  HER2690aa gene was cloned into pShuttle-CMV vector before homologous 
recombination with the Ad5 backbone gene. pShuttle-CMV-HER2690aa was linearized by PmeI 
restriction enzyme, and then transformed into E. coli BJ5183 containing the backbone vector, 
pAdEasy-1. Homologous recombination between the two vectors in E. coli BJ5183 cells resulted 
in adenoviral vector pAdEasy-HER2690aa. Resulting recombinant vector was linearized by PacI 
digestion and transfected into HEK293 cells for replication-deficient AdVHER2 production. 
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4.2.1.4 Production of AdVHER2 
 
To produce AdVHER2, PacI linearized recombinant adenoviral DNA vector (4 μg) was added into 
500 μL EMEM. Lipofectamine2000 (16 μL) was added into another 500 μL EMEM medium. 
Each mixture was incubated at room temperature for 5 min. These two mixtures were then 
further mixed and kept at room temperature for 20 min. The DNA : liposome mixture solution 
was added to HEK293 cells plated at a cell density of 1x10
6
 cells per well in 6-well plate. Cells 
were incubated in 2 mL EMEM medium at 37 ºC in a CO2 incubator. Medium was replaced by 
EMEM with 10% FCS after 4 hrs. Cells were continually monitored for 7-10 days for formation 
of plaques. Cell culture medium was refreshed as required. When cytopathic effects (CPE) were 
apparent and extensive, cells with medium were subjected five rounds of freeze/thaw cycles 
performed at -80 ºC and 37 ºC, respectively, resulting in generation of the initial crude viral 
lysates. Crude viral lysates were used to infect more HEK293 cells in T75 flasks. Infected cells 
went through further freeze/thaw cycles. The supernatants were collected and used as the source 
of the virus for further infection of HEK293 cells in T175 flasks.  
 
4.2.1.5 Purification of AdVHER2 
 
When more than 50% CPE was observed in the last step of amplification, entire cells were 
harvested in phosphate-buffered saline (PBS) or serum-free EMEM and subjected to five rounds 
of freeze and thaw cycles as mentioned above. Subsequently, samples were centrifuged at 300 g 
for 10 min followed by 10,000 g for 30 min twice at 4 ºC to remove as much cell debris as 
possible, which otherwise may interfere with virus purification. After centrifugation, 
supernatants were collected for discontinuous cesium chloride (CsCl) density-gradient 
ultracentrifugation. It was performed using Quick-Seal centrifuge tubes layered with 1.25 g/mL 
CsCl and 1.40 g/mL CsCl gradient solutions. Viral lysate was layered slowly above the density 
gradient solutions and subjected to ultracentrifugation at 235,000 g at 20 ºC for 2 hrs. The lower 
viral band was collected and layered on a 1.34 g/mL CsCl gradient solution and centrifuged 
again at 235,000 g for about 18 hrs at 20 ºC. After centrifugation, the opalescent band was 
collected. Salts presented in the purified AdV samples were removed by dialysis using slide-A-
lyzer dialysis cassettes following the manufacturer’s instructions. Finally, the concentration of 
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the AdV was determined by spectrophotometry at A260 as described by Xiang and Wu et al. 
(426). Optical density of 1 is equivalent to 1×10
10
 plaque forming unit (PFU)/mL. The virus was 
stored in sterile 10% (v/v) glycerol at -80 ºC until use. 
 
4.2.1.6 Reverse transcriptase (RT)-PCR 
 
The expression of adenovirus-mediated human HER2690aa transgene in HEK293 cells or bone 
marrow-derived dendritic cells (BM-DCs) was determined by RT-PCR. The ratio of adenovirus 
to target cells is called multiplicity of infection (MOI) in the following experiments. Briefly, 
HEK293 cells or BM-DCs were infected with AdVHER2 or control AdV at the MOI of 10 
(HEK293) or 100 (BM-DCs). The medium containing PBS without adenovirus was used as a 
cell control (PBS control). After 48 hrs of infection, the AdVHER2-, AdV-infected or uninfected 
HEK293 cells or BM-DCs were harvested, washed in PBS, and then subjected to RT-PCR. Total 
cellular RNAs were extracted using RNeasy Plus Mini Kit following the manufacturer’s 
guidelines. Sample concentration and purity was determined using Nanodrop (Thermo 
scientific). cDNA was synthesized immediately using RT² First Strand Kit. The PCR reactions 
were performed using cDNA as template and primers specific for human HER2690aa, human 
housekeep gene β-actin (F, 5’-TGC GTG ACA TTA AGG AGA AG-3’; and R, 5’-CTG CAT 
CCT GTC GGC AAT G-3’) or mouse housekeep gene GAPDH (F: 5’-TGC ACC ACC AAC 
TGC TTA-3’; and R: 5’-GGA TGC AGG GAT GAT GTT C-3’) under conditions [1 cycle at 94 
ºC (2 min) and then 72
 
ºC (7 min) followed by 30 cycles at 94
 
ºC (50 sec), 58
 
ºC (50 sec) and 72
 
ºC (2 min)]. 
 
4.2.1.7 Preparation of transgenic tumor cell lines 
 
The BL6-10 melanoma cells were dispensed into 24-well culture plates at 2×10
4
 cells/mL of 
growth medium per well. After 24 hrs of incubation, cells could usually be 70% confluent at the 
time of transfection. The BL6-10 tumor cells were then transfected with eukaryotic expression 
plasmids pcDNA3.1/HER2 expressing human HER2690aa or control plasmids pcDNA3.1(+)neo 
using Lipofectamine2000 transfection reagent according to manufacturer’s instructions. Briefly, 
1 μg of pcDNA3.1/HER2 or pcDNA3.1(+)neo plasmid DNA and 2 μL of Lipofectamine2000 
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were diluted in 50 μL serum-free α-MEM medium without antibiotics, respectively. The diluted 
DNA solution was then mixed gently with diluted Lipofectamine2000 solution, and incubated at 
room temperature. After 30 min of incubation, the DNA-Lipofectamine complex (100 μL) plus 
200 μL of serum-free α-MEM medium was added into each well containing BL6-10 tumor cells 
which has been washed with serum-free α-MEM medium 2 times. After another 6 hrs of 
incubation, the 300 μL of fresh growth medium were then supplemented into each well. 24 or 48 
hrs after transfection, cells were plated at a ration of 1:6 into selection medium (α-MEM medium 
with 10% FBS and 1 mg/mL G418). The transfectants were selected for 2-3 weeks in the 
selection medium. Then the G418-resistant polyclonal cells were plated at a density of 1 
cell/well in a 96-well tissue culture plate in selection medium. After a few days of growth, only 
wells with single colony per well were selected. The selected monoclone was further determined 
by RT-PCR and flow cytometric analysis. BL6-10HLA-A2/HER2 double transgenic tumor cells were 
constructed by transfecting pcDNA3.1/HLA-A2 or control pcDNA3.1(+)hygro plasmids 
containing hygromycin resistance gene into BL6-10HER2 tumor cells using Lipofectamine2000 as 
described above. The hygromycin and G418 double-resistant clones were selected and 
maintained in growth medium with 0.5 mg/mL hygromycin and 1 mg/mL G418. To screen the 
BL6-10HLA-A2/HER2 double transgenic tumor cells, HLA-A2 and HER2690aa transgene expression 
in resulting hygromycin and G418 double-resistant clones were further determined by RT-PCR 
and flow cytometric analysis. 
 
4.2.1.8 Real-time PCR 
 
The preparation of CD8
+
CD25
+
 Tregs and naive CD4
+
 T cells will be described in Section 4.2.2. 
CD8
+
CD25
+
 Tregs were cultured with naive CD4
+
 T cells at 1:1 ratio in culture medium 
containing IL-4 (10 ng/mL) for 16 hrs since IL-4 can promote T-cell survival (427). CD8
+
CD25
+
 
Tregs-treated CD4
+
 T cells were then purified by CD4-microbeads. Total cellular RNAs were 
extracted from naive CD4
+
 or CD8
+
CD25
+ 
Treg-treated CD4
+
 T cells (428) using RNeasy Plus 
Mini Kit according to manufacturer’s guidelines. Sample concentration was determined using 
Nanodrop (Thermo scientific). cDNA was synthesized immediately using RT² First Strand Kit. 
Real-time PCR was carried out with RT² SYBR Green qPCR Mastermix using a StepOnePlus 
Real-time PCR system (Applied Biosystems). A panel of primers specific for T-cell anergy-
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associated genes were synthesized (429). Expression of each gene was normalized to β-actin. 
The primers were as follows: β-actin: F-GTGAC GTTGA CATCC GTAAA GA; R-GCCGG 
ACTCA TCGTA CTCC; Grail: F-GCGCA GTCAG CAAAT GAA; R-TGTCA ACATG 
GGGAA CAACA; Ikaros: F-GCTGG CTCTC GGAGG AG; R-CGCAC TTGTA CACCT 
TCAGC; Casp3: F-ACGCG CACAA GCTAG AATTT; R-CTTTG CGTGG AAAGT GGAGT; 
EGR2: F-TCAGT GGTTT TATGC ACCAG C; R-GAAGC TACTC GGATA CGGGA G; Grg4 
F-TCACT CAAGT TTGCC CACTG; R-CACAG CTAAG CACCG ATGAG; Itch: F-GTGTG 
GAGTC ACCAG ACCCT; R-GCTTC TACTT GCAGC CCATC. The fold induction represents 
the ratio of mRNA expression in CD8
+
CD25
+
 Treg-treated CD4
+
 T cells to that in naive CD4
+
 T 
cells.  
 
4.2.2 Cell generation 
 
4.2.2.1 Generation of BM-DCs 
 
BM-DCs were generated from C57BL/6 as described previously (430). Bone marrow cells from 
the femorae and tibiae of normal C57BL/6 mice were depleted of red blood cells (RBCs) with 
0.85% (w/v) Tris-NH4Cl buffer on day 1 and plated in Dulbecco's modified Eagle’s medium 
(DMEM) plus 10% FCS, GM-CSF (20 ng/mL) and IL-4 (20 ng/mL). On day 3, the nonadherent 
granulocytes, T and B cells were gently removed. Old medium was replaced with fresh medium. 
On day 5, proliferating aggregates of DCs were observed. Fresh medium was added if necessary. 
On day 6, cells slightly adherent to the plate were observed and these cells were pulsed with 0.4 
mg/mL OVA in FCS-free AIM-V medium plus lipopolysaccharide (LPS) (1μg/mL) overnight. 
The resultant DCs were referred to as DCOVA. The DCOVA from H-2K
b-/-
, 4-1BBL
-/-
, OX40L
-/-
 
and CD40L
-/-
 KO mice were termed (K
b-/-
)DCOVA, (4-1BBL
-/-
)DCOVA, (OX40L
-/-
)DCOVA, and 
(CD40L
-/-
)DCOVA, respectively. HLA-A2/HER2 mouse BM-DCs were transfected with AdVHER2 
for 1 hour at 37 ºC in DC culture medium at a MOI of 100 (302), then the medium was replaced. 
DCs were cultured for another 24 hrs to achieve optimal transgene expression. These DCs were 
termed DCHER2.  
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4.2.2.2 Generation of spleen derived DCs (sDCs)  
 
Briefly, spleens were digested in DMEM containing 1 mg/mL collagenase for 45-60 min at 37 
ºC. After removing the RBCs using 0.85% (w/v) Tris-NH4Cl buffer, cells were re-suspended in 
AIM-V
®
 medium plus OVA protein (0.4 mg/mL), GM-CSF (20 ng/mL) and 2-mercaptoethanol 
(2-ME) (50 μM), and incubated at 37 ºC for 90 min. Nonadherent cells were then removed by 
gently washing three times with pre-warmed PBS, used medium was kept for culturing adherent 
cells overnight. Adherent cells were further purified
 
by incubating them with the biotin-
conjugated
 
anti-CD11c Ab followed by anti-biotin microbeads according to the company’s 
instruction (21), and termed sDCOVA.  
 
4.2.2.3 Purification of EXOs 
 
EXOs were isolated as described previously (431). Briefly, supernatants from BM-DCs cultured 
overnight in FCS-free AIM-V medium containing OVA (0.4 mg/mL) were subjected to four 
successive centrifugations at 300 g for 10 min to remove cells, 10,000 g for 30 min twice to 
remove cellular debris and 136,000 g for one hour to pellet the EXOs. The pellets were washed 
twice in a large volume of PBS and recovered by centrifugation at 136,000 g for another one 
hour. The amount of exosomal protein recovered was measured using Nanodrop (Thermo 
scientific). EXOs derived from DCOVA, (K
b-/-
)DCOVA, (4-1BBL
-/-
)DCOVA, (OX40L
-/-
)DCOVA, and 
(CD40L
-/-
)DCOVA were referred to as EXOOVA, (K
b-/-
)EXOOVA, (4-1BBL
-/-
)EXOOVA, (OX40L
-/-
)EXOOVA, and (CD40L
-/-
)EXOOVA, respectively. EXOs purified from culture supernatants of 
DCHER2 were termed EXOHER2. 
 
4.2.2.4 CD4+ TEXO vaccine preparation  
 
Transgenic OTII mice spleens were collected aseptically and single cell suspensions were 
prepared. RBCs were depleted using 0.85% (w/v) Tris-NH4Cl buffer, and splenocytes were 
cultured in Roswell Park Memorial Institute medium (RPMI)-1640 containing 10% FCS, IL-2 
(20 U/mL) and ConA (1 mg/mL) for 3 days. ConA-activated CD4
+
 T cells were purified using 
Mouse CD4 (L3T4) microbeads according to the manufacture’s instructions. ConA-T cells 
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derived from OTII/H-2K
b-/-
, OTII/4-1BBL
-/-
, OTII/OX40L
-/-
 and OTII/CD40L
-/-
 mice were 
termed (K
b-/-
)T, (4-1BBL
-/-
)T, (OX40L
-/-
)T and (CD40L
-/-
)T cells, respectively. ConA-T cells 
were incubated with EXOOVA and EXOHER2  (15 g/1×10
6
 T cells) at 37 ºC for 3 hrs and were 
termed OVA-TEXO and HER2-TEXO, respectively. (K
b-/-
)T, (4-1BBL
-/-
)T, (OX40L
-/-
)T and 
(CD40L
-/-
)T cells that had internalized (K
b-/-
)EXOOVA, (4-1BBL
-/-
)EXOOVA, (OX40L
-/-
)EXOOVA, 
and (CD40L
-/-
)EXOOVA were termed (K
b-/-
)TEXO, (4-1BBL
-/-
)TEXO, (OX40L
-/-
)TEXO and (CD40L
-
/-
)TEXO , respectively.  
 
4.2.2.5 Naive T cell preparation 
 
The naive polyclonal CD8
+
 or OTI CD8
+
 T cells were prepared from splenocytes of C57BL/6 or 
transgenic OTI mice using EasySep
TM
 Mouse CD8
+
 T cell isolation kits according to 
manufacturer’s protocol. Naive CD4+ T cells were prepared from splenocytes of C57BL/6 mice 
using EasySep
TM
 Mouse CD4
+
 T cell isolation kits according to manufacturer’s protocol. 
 
4.2.2.6 Preparation of CD8+CD25+ Tregs 
 
Naive CD8
+
CD25
+
 Tregs were purified from C57BL/6 mouse splenocytes by using EasySep
TM
 
Mouse CD8
+
 T-cell isolation kits, followed by biotin-labeled anti-CD25 Ab and anti-biotin 
microbeads. Those cells were further amplified in culture using Dynabeads® Mouse T-Activator 
CD3/CD28 at a ratio of 1:1 for 4-6 days in the presence of IL-2 (100 U/mL) and 2-ME (50 μM). 
The amplified CD8
+
CD25
+
 Tregs were incubated in medium containing OVAI-, OVAII- and 
MOG-peptide (12 µM) for 3 hrs, and termed Tr/OVAI-, Tr/OVAII- and Tr/MOG-cells, respectively. 
CD8
+
CD25
+
 (perforin
-/-
)Tregs were purified from perforin KO mouse splenocytes as described 
above.  
 
4.2.3 In vitro T-cell proliferation assay 
 
Naive CD4
+
 and CD8
+
CD25
+
 Treg-treated CD4
+
 T cells (1×10
5
 cells/well) were incubated in 
anti-CD3 and anti-CD28 Ab-coated plate, respectively. One day subsequently, the supernatants 
were assayed for IL-2 secretion using ELISA kits (178). In another experiment, sDCs (1×10
5
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cells/well) and their 2-fold dilutions were cultured with a constant number of naive CD4
+
 or 
CD8
+
CD25
+
 Treg-treated CD4
+
 T cells (1×10
5
 cells/well) in culture medium containing anti-
CD3 Ab (2 g/mL) and IL-2 (100 U/mL) (351). After 48 hrs, 3H-thymidine incorporation was 
determined by liquid scintillation counting.  
 
4.2.4 Flow cytometry staining 
 
4.2.4.1 EXO staining 
 
FITC conjugated Abs were used for the EXOs staining. About 1 μL of 1:50 diluted FITC-
conjugated Abs were added to the 20-40 μg EXOs re-suspended in 100 μL PBS, and incubated 
for 30 min on ice. The samples were further diluted with PBS (final volume 300-400 μL) and 
analyzed by flow cytometry. Expression profiles are presented in histograms of fluorescence 
intensity (Log10) of FITC on X-axis (analyzed for CD11c, CD40, CD80, 4-1BBL, OX40L and 
pMHC-I expression) and the number of EXOs on the Y-axis. A total of 30,000 events were 
analyzed by flow cytometry for each marker. 
 
4.2.4.2 Tetramer staining assay 
 
C57BL/6 or various gene KO mice (6 mice/group) were injected intravenously (i.v.) with 
DCOVA, OVA-TEXO or OVA-TEXO with a specific molecular deficiency (3×10
6
 cells/mouse). To 
assess recall responses, immunized mice were boosted i.v. with DCOVA (0.5×10
6
 cells/mouse) on 
day 30 after the primary immunization. Six or four days after the primary immunization or the 
boost, peripheral blood samples were incubated with PE-H-2K
b
/OVA257–264 and FITC-anti-CD8 
Ab for 30 min at room temperature, and analyzed by flow cytometry. 
 
C57BL/6 mice (8 mice/group) were i.v. immunized with sDCOVA (2×10
6
 cells/mouse), sDCOVA 
plus CD8
+
CD25
+
 Tregs, Tr/OVAI-cells or Tr/OVAII-cells (3×10
6
 cells/mouse), respectively. Six days 
after immunization, mice tail blood samples were analysis as described above. 
 
 68 
4.2.4.3 Assessment of CTL responses by CD44 expression and IFN-γ secretion 
 
HLA-A2/HER2 mice (6 mice/group) were i.v. injected with HER2-TEXO (3×10
6 
cells/mouse). 
Six days after the immunization, HLA-A2/HER2 mouse blood samples were collected for 
staining of FITC-anti-CD8 and PE-anti-CD44 (T-cell activation marker) Abs.  
 
Intracellular IFN-γ secretion was also analyzed using fixation and permeabilization solution kit 
with BD GolgiStop (432). Briefly, blood samples were collected and diluted 1:1 using RPMI-
1640 with 10% FCS. Cells were further stimulated with 10 μM of HER2369-377 peptide 
(KIFGSLAFL) for 5 hrs in the presence of 0.7 μL GolgiStop/mL diluted blood in U-bottom 
culture plates. RBCs were then depleted using 0.85% (w/v) Tris-NH4Cl lysis buffer. Stimulated 
cells were washed with PBS, stained with anti-CD8-FITC Abs at room temperature for 20 min 
followed by washing with PBS twice. Each sample was then fixed and permeabilized with 
500μL cytofix/cytoperm solution at room temperature for 20 min. Samples were washed twice in 
1× wash buffer and stained with PE-anti-IFN-γ Ab on ice for 30 min.  Finally, samples were 
washed twice and analyzed by flow cytometry. Flow cytometry profiles are presented as dot-
scatter plots. In each dot-scatter plot, X-axis represents fluorescence intensity of FITC (CD8 
molecule expression) and Y-axis represents fluorescence intensity of PE (IFN-γ+ lymphocytes). 
The value in each plot represents percentage of IFN-γ+ CD8+ T cells in total CD8+ population. 
 
4.2.4.4 Assessment the impact of CD8+CD25+ Tregs on effector CD8+ T cells 
 
Effector CD8
+
 T cells (also referred to as target CTLs) were prepared from OTI transgenic mice. 
Splenocytes were cultured in RPMI-1640 medium containing IL-2 (20 U/mL) and ConA (1 
mg/mL) for 3 days. The ConA-activated effector OTI T cells were then purified using Mouse 
CD8 (Ly-2) microbeads. To assess the impact of CD8
+
CD25
+
 Tregs on effector CD8
+
 CTLs, 
purified CD8
+
 OTI CTLs were co-cultured with or without CD8
+
CD25
+
 Tregs at 1:1 ratio for 16 
hrs. Cell mixtures were then stained with PE-Cy5-anti-CD8 and PE-Tetramer Abs followed by 
FITC-anti-perforin or FITC-anti-Granzyme B staining after cell membrane permeabilized with 
Cytofix/Cytoperm solutions. CD8
+
 and Tetramer double-positive population was gated for 
analysis of perforin and granzyme B expression by flow cytometry.  
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4.2.5 Cytotoxicity assays  
 
C57BL/6 mouse splenocytes were labeled with either high (3.0 µM) or low (0.6 µM) 
concentrations of Carboxyfluorescein succinimidyl ester (CFSE). CFSE
high
 and CFSE
low
 cells 
were then pulsed with OVAI (OVA257-264, SIINFEKL) and irrelevant Mut1 (FEQNTAQP) 
peptides, and served as internal OVA-specific target and control cells, respectively. These 
peptide-pulsed target cells were i.v. co-injected at 1:1 ratio into mice immunized with OVA-TEXO 
or OVA-TEXO with various molecule deficiency (3×10
6
 cells/mouse) six days after the 
immunization. Sixteen hrs later, the residual antigen-specific CFSE
high
 and control CFSE
low
 
target cells remaining in the recipients' spleens were analyzed by flow cytometry (176). This in 
vivo cytotoxicity assay was also performed in sDCOVA (2×10
6 
cells/mouse) with or without 
CD8
+
CD25
+
 Treg, Tr/OVAI and Tr/OVAII Tregs (3×10
6
 cells/mouse) injected C57BL/6 mice six 
days after immunization. 
 
In another cytotoxicity assay, the potential killing effect of CD8
+
CD25
+
 Tregs on ConA-
stimulated target CTLs was assessed. Target CTLs were labeled with TFL2 (cell dye) using 
GranToxiLux Plus kit, and then incubated with CD8
+
CD25
+
 Tregs or (perforin
-/-
)Tregs for 45 
min. Cell permeable fluorogenic granzyme-B substrate was subsequently added to the cell 
mixture followed by flow cytometry to detect cell apoptosis by assessment of granzyme-B 
substrate cleavage.  
 
4.2.6 Imaging analysis 
 
4.2.6.1 Electron microscopic analysis of EXOs 
 
Purified EXOs were fixed in 4% (w/v) para-formaldehyde. They were loaded on carbon-coated 
formvar grids and incubated for 20 min in a moist chamber. Later, the samples were washed 
twice with PBS and fixed in 1% (w/v) glutaraldehyde for 5 min. The samples were then washed 
three times with PBS and stained with aqueous uranyl for 10 min. EXOs were finally examined 
with a JEOL 1200EX electron microscope at 60 KV. 
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4.2.6.2 Confocal microscopic analysis of IS formation 
 
OVA-TEXO cells were loaded with 5 μM ThiolTracker™ Violet for 30 min at 37 ºC. Cells were 
allowed to adhere to the Poly-D-Lysine/Laminin coated culture slide for 30 min in RPMI-1640 
containing 10% FCS. Naive OTI CD8
+
 T cells (1:1 ratio) were added to the culture slides and co-
cultured with OVA-TEXO cells for another 3 hrs. Cells were fixed and permeabilized at 4 ºC for 
12 hrs in the dark and stained with goat anti-PKCθ Ab followed by Cy5-conjugated anti-goat 
IgG. Finally, slide was mounted with ProLong Gold antifade reagent and analyzed using a Carl 
Zeiss LSM 510 confocal microscope with a 25× objective. Similarly, OVA-TEXO cells were 
labeled with 5 μM 5-(and-6)-(((4-Chloromethyl)Benzoyl)Amino)Tetramethylrhodamine 
(CMTMR) to assess the expression of talin. Fixed and permeabilized cell conjugates were 
stained with mouse anti-talin Ab followed by FITC-conjugated anti-mouse IgG.  
 
4.2.6.3 Two-photon imaging and data analysis 
 
C57BL/6 mice were i.v. injected with CFSE-labeled (5 μM, 30 min, 37 ºC) OVA-TEXO (10-
15×10
6
 cells) or OVA-(K
b-/-
)TEXO cells. 24 hrs later, equal amounts of CMTMR-labeled (5 μM, 
30 min, 37 ºC) naive OTI CD8
+
 T cells were transferred into the same recipient mouse. To 
compare the dynamics of antigen-specific OTI with polyclonal CD8
+
 T cells, 10-15×10
6
 
unlabeled OVA-TEXO were injected into the C57BL/6 mouse. 24 hrs later, CFSE-labeled naive 
OTI CD8
+
 T cells and CMTMR-labeled naive polyclonal CD8
+
 T cells were co-injected into the 
same mouse. In order to rule out the effect of host APCs, CD11c-DTR mice (express DT 
receptor under CD11c promoter) were also used as recipient mice. CD11c
+
 APCs were deleted 
by injection of DT (100 ng/mouse, i.p.). Neutralization Abs anti-CD20 (AISB12) and anti-
CD317 (120G8) (300 g/mouse) were i.p. injected to delete B cells and pDCs. 24 hrs later, 
unlabeled OVA-TEXO were injected followed by CFSE-labeled naive OTI CD8
+
 T cells and 
CMTMR-labeled naive polyclonal CD8
+
 T cells as described above. Inguinal lymph nodes were 
collected 3 hrs later and then immobilized in an imaging chamber continuously perfused with 
RPMI-1640 bubbled with 95% O2 and 5% CO2 at 37 ºC. Imaging was performed with a two-
photon laser-scanning microscope (Olympus BX51WIF fitted with a LUMPLFL/IR 40× W/0.8 
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NA Olympus objective lens). Samples were excited with a MaiTai Ti-Saphire laser tuned to a 
wavelength of 800 nm so as to equally excite both fluorophors. CFSE and CMTMR fluorescence 
emissions were acquired with the use of selective emission bandpass 535 nm (50 nm bandpass) 
and 610 nm (75 nm bandpass) filters. 
 
To visualize DC-T cellular interactions, 5×10
6
 DsRed-expressing sDCOVA derived from 
transgenic DsRed mice were injected into footpads of C57BL/6 recipient mouse followed by i.v. 
injection of 5×10
6
 CFSE-labeled OTII CD4
+
 T cells one day later. To assess the influence of 
Tregs, 5×10
6
 CD8
+
CD25
+
 Tregs or Tr/OVAII cells were i.v. injected one day before the injection 
of sDCOVA. Mouse popliteal lymph node imaging was performed in an imaging chamber 6 hrs 
subsequent to adoptive transfer of CD4
+
 T cells by TPM (179). Samples were excited with a 
MaiTai Ti-Saphire laser tuned to a wavelength of 850 nm. CFSE and DsRed fluorescence 
emissions were acquired with the use of selective emission bandpass 535 nm (50 nm bandpass) 
and 610 nm (75 nm bandpass) filters. 
 
Images were collected with typical voxel size of 0.587 × 0.587 × 3-5 μm and volume dimension 
varied in each case. Imaris ×64 (Bitplane, Zurich, Switzerland) was used for four-dimensional 
image analysis and automated tracking of cells. The confinement ratio corresponded to the ratio 
of the distance between the initial and final positions of each cell to the total distance covered by 
the same cell. The duration of individual new contact formed during the imaging session was 
quantitated by individual inspection of each time slice at each z-slice level in the 4D imaging 
data set. 
 
4.2.7 Tumor protection study 
 
To examine antitumor protective immunity, C57BL/6 mice (6 mice/group) were i.v. injected 
with OVA-TEXO or OVA-TEXO with a specific molecular deficiency (3×10
6
 cells/mouse). Thirty 
days after the immunization, mice were i.v. challenged with 0.5×10
6
 OVA-expressing BL6-
10OVA melanoma cells. The mice were euthanized three weeks after tumor cell challenge, and the 
lung metastatic tumor colonies were counted in a blind fashion. Metastase on freshly isolated 
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lungs appeared as discrete, black-pigmented foci in BL6-10OVA tumors. Metastatic foci that were 
too numerous to count were assigned an arbitrary value of  > 300 (176). 
 
To examine the protective antitumor immunity, transgenic HLA-A2 and HLA-A2/HER2 mice (8 
mice/group) were i.v. injected with HER2-TEXO (3×10
6 
cells/mouse), respectively. ConA-T cells 
were used as a control. Six days after immunization, mice were s.c. challenged with 0.2×10
6 
BL6-10HLA-A2/HER2 tumor cells. Mice were monitored for tumor growth. For ethical reason, mice 
bearing tumor with 1 cm in diameter were sacrificed.  
 
C57BL/6 mice (8 mice/group) were injected i.v. with sDCOVA (2×10
6 
cells/mouse) with or 
without co-injection of CD8
+
CD25
+
 Treg, Tr/OVAI or Tr/OVAII (3×10
6
 cells/mouse). To assess the 
antitumor immunity, immunized mice were s.c. challenged with 0.1×10
6
 BL6-10OVA cells 7 days 
subsequent to the immunization. Mice were monitored for tumor growth. For ethical reason, 
mice bearing tumor with 1 cm in diameter were sacrificed. 
 
4.2.8 EAE Induction 
 
EAE was induced in C57BL/6 mice (10 mice/group) by s.c. injection over 4 sites in the flank 
with MOG35-55 peptide (200 µg/mouse) emulsified in complete freund’s adjuvant (CFA) 
containing 0.6 mg mycobacterium tuberculosis (MT) (433). To assess the suppressive effect, 
5×10
6
 CD8
+
CD25
+
 Tregs or Tr/MOG -cells were i.v. injected into each mouse one day before and 
two days after MOG peptide immunization. Mice were examined daily for clinical signs. Mice 
were scored on scale of 0 to 5: 0, no clinical sign; 0.5, partially limp tail; 1, limp/flaccid tail; 2, 
moderate hind limb weakness; 2.5, one hind limb paralyzed; 3, both hind limbs paralyzed; 3.5, 
hind limbs paralyzed and weakness in forelimbs; 4, forelimbs paralyzed; 5, moribund/death 
(433).   
 
4.2.9 Statistical analyses 
 
Statistical analyses were carried out using Prism software (GraphPad Software Inc.) to perform 
Log rank test to compare mouse survival between groups (302). Student t test was performed to 
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determine the significance of differences between groups. A value of p < 0.05 was considered 
statistically significant.  
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CHAPTER 5 RESULTS 
 
5.1 A novel T cell-based vaccine capable of stimulating long-term functional CTL memory 
against B16 melanoma via CD40L signaling  
 
Our previous work have shown that ConA-stimulated CD4
+
 T cells derived from OVA-specific 
TCR transgenic OTII mice can internalize OVA-pulsed, DC-released EXO (EXOOVA) via 
TCR/MHC and LFA-1/CD54 interactions. EXOOVA-loaded CD4
+
 T cells can be used as OVA-
TEXO-cell vaccines capable of stimulating CD8
+
 T-cell priming via IL-2 and CD80 costimulatory 
signaling. In this section, we further assessed (i) the formation of immunological synapses 
between CD4
+
 TEXO and cognate CD8
+
 T cells; (ii) the critical role of exosomal pMHC-I 
complexes in interaction of CD4
+
 TEXO cells with cognate CD8
+
 T cells ex vivo by two-photon 
microscopy. Furthermore, we assessed the potential role of other costimulatory molecules such 
as CD40L, 4-1BBL and OX40L in OVA-specific EXO-targeted T cell-based vaccine-induced 
CD8
+
 CTL responses and antitumor immunity against OVA-expressing B16 melanoma cell line.  
 
5.1.1 OVA-TEXO cell form immunological synapse (IS) with CD8
+
 T cells leading to efficient 
CTL responses via exosomal pMHC-I targeting 
 
C57BL/6 BM-DCs were in vitro pulsed with OVA protein overnight. OVA-pulsed DCs 
(DCOVA)-released exosomes (EXOOVA) were purified from DCOVA culture supernatants by 
differential ultracentrifugation and subjected to electron microscopic analysis. As shown in 
Figure 5.1A, EXOOVA showed a typical exosomal characteristic of “saucer” or round shape with 
a diameter 40-100 nm. DCOVA and EXOOVA were then stained with a panel of Abs and analyzed 
by flow cytometry. The relative size of EXOOVA to 3.8 μm diameter aldehyde/sulfate latex beads 
was shown in Figure 5.1B. DCOVA expressed CD11c (DC marker), costimulatory molecules 
CD40 and CD80, and pMHC-I complexes, whereas EXOOVA also displayed these molecules, but 
in a much less extent (Figure 5.1C). OVA-TEXO cells derived from ConA-stimulated OTII CD4
+
 
T lymphocytes (ConA-T) upon uptaking of EXOOVA, expressed CD11c, CD40, CD80 and 
pMHC-I (Figure 5.1D), however, they did not express pMHC-I if using (K
b-/-
)EXOOVA (released 
from OVA protein pulsed K
b
 knockout BM-DCs) (Figure 5.1E).  
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Figure 5.1 Flow cytometric analysis.  (A) Electron micrograph of BM-DCs released EXOs. 
Bar, 100 nm. (B) Relative distribution of EXOOVA in the presence of 3.8 μm diameter beads. SS: 
side scatter; FS: forward scatter. Flow cytometric analysis of various molecules expressed on (C) 
DCOVA, EXOOVA, (D) OVA-TEXO and (E) pMHC-I expression on OVA-(K
b-/-
)TEXO.  Samples 
were stained with a panel of Abs (solid lines) or isotype-matched irrelevant Abs (dotted lines). 
One representative experiment of two is shown. 
 
Since EXOs harbor many immune molecules including pMHC complexes and costimulatory 
molecules, OVA-TEXO with acquired exosomal molecules may have a potent effect in stimulating 
T cell responses. To examine the stimulatory effect, C57BL/6 or I-A
b-/-
 mice were immunized 
with OVA-TEXO or DCOVA (used as a positive control). CD8
+
 T-cell response was assessed using 
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FITC-anti-CD8 Ab and PE-H-2K
b
/OVA257-264 tetramer staining by flow cytometry on day 6 after 
the immunization. Both OVA-TEXO and DCOVA vaccinations induced in vivo OVA-specific CD8
+
 
T cell responses in C57BL/6 mice (Figure 5.2A). However, OVA-TEXO cells but not DCOVA 
were also capable of inducing CD8
+
 T cell responses in I-A
b-/-
 mice lacking classical MHC II 
(Figure 5.2B), indicating that OVA-TEXO could directly stimulate CD8
+
 T cell responses 
independent of CD4
+ 
T-cell help. Since OVA-specific TCRs of the cognate CD8
+
 T cells are 
recognized by OVA-specific pMHC-I complex, we assumed that it is the exosomal pMHC-I that 
targets OVA-TEXO to cognate naive CD8
+
 T cells in vivo, leading to direct stimulation of cognate 
CD8
+
 T cells. To assess this assumption, C57BL/6 mice were immunized with OVA-(K
b-/-
)TEXO 
lacking pMHC-I expression. We demonstrated that OVA-(K
b-/-
)TEXO lacking pMHC-I expression 
completely lost the ability to stimulate OVA-specific CTL responses (Figure 5.2A), indicating 
that OVA-TEXO cells directly stimulate CD8
+
 T-cell responses via exosomal pMHC-I targeting. 
 
When the TCR complex recognizes MHC-associated peptide on an APC, several T cell surface 
proteins and intracellular signaling molecules are rapidly mobilized to the site of T cell-APC 
contact. This region of physical contact between T cell and APC forms a bull’s-eye-like structure 
that is called an IS or a supramolecular activation cluster (SMAC). Since the formation of IS 
between APCs and T cells is a critical event for controlling T cell activation (434), we sought to 
determine whether, similar to DCs, CD4
+
 OVA-TEXO cells form IS with cognate CD8
+
 T cells. 
OVA-TEXO cells (stained with ThiolTracker™ Violet or CMTMR) were co-cultured with naive 
OTI CD8
+
 T cells for 3 hrs. Cell mixtures were fixed, permeabilized and stained with either 
PKCθ (435, 436) (hallmark of a mature IS) or talin (435, 436) (located in the peripheral SMAC) 
Ab. Using confocal microscopy, we found a polarized and condensed contact region of PKCθ 
(red; Figure 5.2C) and talin (green; Figure 5.2D) molecules formed between OVA-TEXO and 
cognate CD8
+
 T cell, indicating the formation of mature IS. 
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Figure 5.2 OVA-TEXO cells form IS with cognate CD8
+
 T cells leading to efficient CTL 
responses via exosomal pMHC-I targeting. On day 6 after immunization of (A) C57BL/6 mice 
or (B) I-A
b-/-
 mice with OVA-TEXO or OVA-(K
b-/-
)TEXO, tail-blood samples were stained with 
PE-H-2K
b
/OVA257-264 tetramer and FITC-anti-CD8 Ab, and then analyzed by flow cytometry. 
Values in each panel represent the percentage of OVA-specific CD8
+
 T cells to the total CD8
+
 T-
cell population with standard deviation in parenthesis. One representative experiment of two is 
shown. OVA-TEXO stained with (C) ThiolTracker™ Violet (blue) or (D) CMTMR (red) were co-
cultured with unlabeled OTI CD8
+
 T cells for 3 hrs. Cell mixtures were fixed and stained with 
(C) PKCθ Abs (red) or (D) talin Abs (green). Images were obtained with a 25× objective. 
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5.1.2 Visualization of interactions between CD4+ OVA-TEXO and cognate CD8
+
 T cells ex 
vivo 
 
To investigate the CD4
+
 OVA-TEXO/CD8
+
 T (CD4
+
 T-CD8
+
 T) cell interactio, C57BL/6 mice 
were i.v. injected with CFSE-labeled OVA-TEXO followed by the injection of CMTMR-labeled 
OTI CD8
+
 T cells. Upon exposure to OVA-TEXO cells (green), naive OTI CD8
+
 T cells (red) 
quickly formed tight conjugates with both stationary and motile OVA-TEXO assessed by TPM 
(Figure 5.3B; sMovie 5.1). To those low motility clusters, cognate CD8
+
 T cells stayed in a 
close proximity to stationary CD4
+
 OVA-TEXO cells. While in highly motile conjugates, OVA-
TEXO cells always moved in front of CD8
+
 T cells and made turns first, suggesting that the 
conjugated pair is led by OVA-TEXO cells. The pathways of an OVA-TEXO and a CD8
+
 T cell 
remained interconnected during the recording period (Figure 5.3C; sMovie 5.2), indicating that 
CD4
+
 OVA-TEXO cells directly interact with the cognate CD8
+
 T cells ex vivo. Although motile 
conjugates were largely monogamous, polygamous conjugates consisting of one OVA-TEXO cell 
sandwiched by two CD8
+
 T cells were also observed (Figure 5.3D; sMovie 5.3).  
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Figure 5.3 Dynamics of OVA-TEXO/CD8
+
 T-cell interactions in intact lymph nodes. (A) 
Experimental protocol. C57BL/6 mice received i.v. injection of CFSE-labeled OVA-TEXO, 
followed by the injection of CMTMR-labeled OTI CD8
+
 T cells 24 hrs later. Inguinal lymph 
nodes were imaged in T-zone region by TPM 3 hrs later. (B) Cognate CD8
+
 T cells (red) formed 
tight conjugates with both stationary (circle) and motile (arrow) OVA-TEXO cells (green). (C) 
Cognate CD8
+
 T cells (red) followed OVA-TEXO cells (green) in their migration. The pathways of 
an OVA-TEXO (green/grey line) and a CD8
+
 T cell (red/grey line) remaining interlocked for 30 
min are shown. (D) Time-lapse images of one OVA-TEXO (green) sandwiched by two CD8
+
 T 
cells (red). White points represent the center of cells. The pathways of one OVA-TEXO (green 
line) and two CD8
+
 T cells (red line) remaining interlocked for 30 min are shown.  
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5.1.3 Visualization of the targeting role of OVA-TEXO exosomal pMHC-I  
 
Previous results showed that OVA-TEXO’s pMHC-I complexes are critical in targeting their 
stimulatory effect to cognate CD8
+
 T cells in vivo. To visually monitor the critical effect of 
exosomal pMHC-I, we also used OVA-(K
b-/-
)TEXO cells lacking pMHC-I expression in TPM 
study. We didn’t observe long lasting interactions between CD4+ OVA-(Kb-/-)TEXO and CD8
+
 T 
cells (Figure 5.4B, left panel; sMovie 5.4). The mean velocity of OTI CD8
+
 T cells increased 
from 5.28 μm/min to 11.38 μm/min (Figure 5.4C) and the confinement ratio increased from 0.40 
to 0.50 (p < 0.01) (Figure 5.4D), indicating that OVA-specific pMHC-I complexes control the 
motile behavior and assure the ability of OVA-TEXO cells in forming stable conjugates with 
CD8
+
 T cells. Interactions between OVA-(K
b-/-
)TEXO and OTI CD8
+
 T cells were only 
intermittent (most of contacts lasted less than 5 min), while OVA-TEXO cells established long-
lasting contacts with CD8
+
 T cells (70% of contacts lasted more than 5 min) (Figure 5.4E), 
further confirming the important role of pMHC-I in targeting OVA-TEXO cells to cognate CD8
+
 
T cells ex vivo. 
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Figure 5.4 Migration dynamics of naive OTI CD8
+
 T cells in the presence of OVA-TEXO or 
OVA-(K
b-/-
)TEXO cells. (A) Experimental protocol. CFSE-labeled OVA-TEXO and OVA-(K
b-/-
)TEXO were injected into the C57BL/6 recipient mice, respectively. 24 hrs later, equal amounts of 
CMTMR-labeled naive OTI CD8
+
 T cells were injected, respectively. Inguinal lymph nodes 
were imaged in T-zone region by TPM 3 hrs later. (B) Tracks of OTI CD8
+
 T cells in the present 
of OVA-TEXO (right panel) or OVA-(K
b-/-
)TEXO (left panel). Individual cells are displayed as 
color-coded tracks to represent increasing time from blue (start of imaging) to yellow (end of 
imaging). Tracks are overlaid after normalizing their starting coordinates. (C) Velocity 
measurements of naive OTI CD8
+
 T cells. (D) Confinement ratio: corresponded to the ratio of 
the distance between the initial and final positions of each cell to the total distance covered by 
the same cell. (E) Contact times: durations of contact between OVA-TEXO or OVA-(K
b-/-
)TEXO 
and OTI CD8
+
 T cells. Data were pooled from five independent experiments. *, p < 0.01. 
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To determine whether the formation of stable conjugates was due to antigen specificity, 
unlabeled OVA-TEXO cells were injected into the C57BL/6 mouse. 24 hrs later, equal amounts of 
CMTMR-labeled polyclonal CD8
+
 T cells (red) and CFSE-labeled OTI CD8
+
 T cells (green) 
were co-injected into the same mouse. The intranodal migration behavior of the antigen specific 
or non-specific naive CD8
+
 T cells in the presence of OVA-TEXO was highly different (sMovie 
5.5). To rule out the involvement of host APCs in affecting the different behaviors of two types 
of T cells, CD11c-DTR/EGFP mice were used as the recipient mice. In addition to DT treatment 
that depleted CD11c-DTR macrophages/myeloid DCs (437), neutralization Abs AISB12 and 
120G8 were also administered to deplete B cells and pDCs (438) one day before adoptive 
transfer of unlabeled OVA-TEXO cells. As shown in Figure 5.5B, DT treatment deleted 
CD11c
high
GFP
+
 DTR-DCs completely, as well as a complete depletion (> 99%) of B220
+
 cells in 
AISB12- and 120G8 Ab treatment (B220 expressed on both B cells and pDCs) (Figure 5.5C). 
Similar results were obtained with all treatments, resembling initial observations in untreated 
animals. Polyclonal CD8
+
 T cells (red) exhibited a highly motile migration (8.87 μm/min) 
covering large areas, whereas OVA-specific OTI CD8
+
 T cells (green) showed a slower (5.15 
μm/min) and much more confined movement (p < 0.01) (Figure 5.5D-F; sMovie 5.6). Using 
CD11c-DTR/EGFP mice without DT and neutralization Abs treatment as the recipient mice 
showed that there were no direct interactions between local CD11c-positive cells and naive OTI 
CD8
+
 T cells (data not shown), indicating that OVA-TEXO is the reason behind different 
migration behaviors of CD8
+
 T cells. 
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Figure 5.5 Dynamics of OTI CD8
+ 
and polyclonal CD8
+
 T cells in the presence of OVA-
TEXO cells. (A) Experimental protocol. DT, anti-CD20 Ab and anti-CD317 Ab were 
administered to deplete CD11c-positive cells, B cells and pDCs one day before adoptive transfer 
of unlabeled OVA-TEXO cells. 24 hrs later, equal amounts of CMTMR-labeled polyclonal CD8
+
 
T cells (red) and CFSE-labeled OTI CD8
+
 T cells (green) were co-injected into the treated 
CD11c-DTR/EGFP recipient mouse. Inguinal lymph nodes were imaged in T-zone region by 
TPM 3 hrs later. (B) C57BL/6 or CD11c-DTR/EGFP mouse was i.p.-treated with DT. 
Splenocytes were stained with PE-CD11c Ab and analyzed by flow cytometry one day post 
treatment. Panel represents the mean percentage of GFP
+
CD11c
high
 DCs in the total cell 
population assessed, and values in parentheses represent the standard deviation. (C) Histograms 
demonstrate depletion of B220
+
 cells in mice with treatment of anti-CD20 and anti-CD317 Abs 
(black) compared with treatment of isotype control Abs (grey). (D) Automated tracking 
polyclonal CD8
+
 T (lower left) and OTI CD8
+
 T cells’ (lower right) migration. Tracks are 
overlaid after normalizing their starting coordinates. (E) Velocity measurements of polyclonal or 
OTI CD8
+
 T cells in the presence of OVA-TEXO cells. (F) The confinement ratio corresponded to 
the ratio of the distance between the initial and final positions of each cell to the total distance 
covered by the same cell. Data were pooled from five independent experiments. *, p < 0.01. 
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5.1.4 CD40L, 4-1BBL and OX40L signaling are dispensable in priming of effector CD8+ 
CTL responses 
 
Other costimulatory molecules, such as 4-1BBL and OX40L, have also been found to express on 
DCOVA. Similarly, they displayed in a much less extend on EXOOVA as expected (Figure 5.6A). 
As shown in Figure 5.6B, (CD40L
-/-
)TEXO, (4-1BBL
-/-
)TEXO or (OX40L
-/-
)TEXO cells lacked 
expression of the respective molecule compared with OVA-TEXO cells. We previously 
demonstrated that the CD80 costimulation played an important role in OVA-TEXO-initiated CD8
+
 
T-cell responses (181). To assess the potential role of other costimulators such as CD40L, 4-
1BBL and OX40L, C57BL/6 mice were immunized with (CD40L
-/-
)TEXO, (4-1BBL
-/-
)TEXO or 
(OX40L
-/-
)TEXO cells. We found that (CD40L
-/-
)TEXO, (4-1BBL
-/-
)TEXO and (OX40L
-/-
)TEXO-
stimulated OVA-specific CD8
+
 T-cell responses assessed 6 days after the immunization were 
similar to responses observed in mice immunized with OVA-TEXO cells (2.30%) (Figure 5.6C), 
indicating that CD40L, 4-1BBL and OX40L signaling are not involved in OVA-TEXO-induced 
CD8
+
 T-cell priming. This was further confirmed by our assessment of CTL priming in C57BL/6 
or gene KO mice immunized with OVA-TEXO cells, showing that there was also no significant 
difference between C57BL/6 and gene KO groups (Figure 5.6D). To assess the effector function 
of primed CD8
+
 T cells, we performed the in vivo cytotoxicity assay. In the assay, OVAI 
peptide-pulsed/CFSE
high
 and irrelevant Mut1 peptide-pulsed/CFSE
low
 mouse splenocytes (which 
served as OVA-specific and control target cells, respectively) were i.v. co-injected at 1:1 ratio 
into C57BL/6 mice immunized with OVA-TEXO or OVA-TEXO with various molecule deficiency 
6 days after the immunization. 16 hrs later, the residual OVA-specific CFSE
high
 and control 
CFSE
low
 target cells remaining in the recipients' spleens were analyzed by flow cytometry. We 
found that 88% of the OVA-specific CFSE
high
 target cells, but none of the irrelevant control 
Mut1 peptide-pulsed (CFSE
low) target cells were killed in 16 hrs following target cells’ transfer 
in OVA-TEXO-immunized mice (Figure 5.6E), indicating that OVA-TEXO can efficiently 
stimulate CD8
+
 T-cell differentiation into CTL effectors, further confirming that CD40L, 4-
1BBL and OX40L signaling by CD4
+
 OVA-TEXO cells is dispensable for priming effector CD8
+
 
CTL responses. 
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Figure 5.6 CD40L, 4-1BBL and OX40L signaling by OVA-TEXO are not involved in effector 
CD8
+
 T-cell priming. (A) Flow cytometric analysis of 4-1BBL and OX40L expression on 
DCOVA and EXOOVA. (B) OVA-TEXO or OVA-TEXO with various molecule deficiency were 
stained with a panel of Abs (solid lines) or isotype-matched irrelevant Abs (dotted lines) and 
analyzed by flow cytometry. One representative experiment of two is shown. (C) C57BL/6 or 
(D) gene KO mice were immunized with DCOVA, OVA-TEXO or OVA-TEXO with indicated 
molecular deficiencies. Six days after the immunization, tail-blood samples were stained with 
PE-H-2K
b
/OVAI peptide tetramer and FITC-anti-CD8 Ab, and analyzed by flow cytometry. 
Values in each panel represent the percentage of OVA-specific CD8
+
 T cells to the total CD8
+
 T-
cell population with standard deviation in parenthesis. (E) In vivo CD8
+
 T cell cytotoxicity assay. 
OVA-specific CFSE
high
 and irrelevant CFSE
low
 splenocytes were i.v. injected into OVA-TEXO or 
gene KO OVA-TEXO-immunized C57BL/6 mice 6 days after immunization. 16 hrs later, the 
percentage of residual CFSE
high
 (H) and CFSE
low
 (L) target cells remaining in the recipients' 
spleens was analyzed by flow cytometry. One representative experiment of two is shown. 
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5.1.5 CD40L-, but not 4-1BBL- or OX40L-induced signaling is required for functional CTL 
memory development  
 
To assess whether CD8
+
 CTLs are functional memory cells, mice were further boosted with 
DCOVA 30 days after the immunization, when OVA-TEXO-stimulated effector CD8
+
 CTLs 
became memory T cells. We found over 20-fold increase in boosted CD8
+
 T cells 4 days after 
the boost in mice previously immunized with OVA-specific OVA-TEXO, (OX40L
-/-
)TEXO and (4-
1BBL
-/-
)TEXO cells (p > 0.05) (Figure 5.7B). Interestingly, there was no increase in boosted 
CD8
+
 T cells in mice previously immunized with (CD40L
-/-
)TEXO cells (p < 0.05) (Figure 5.7B), 
suggesting that CD40L-, but not 4-1BBL- and OX40L-signaling by OVA-TEXO cells is required 
for functional CD8
+
 T-cell memory development. This was further confirmed by our finding that 
CD40
-/-
 CTLs in CD40
-/-
 mice, which were primed by OVA-TEXO also had defect in recall 
responses (Figure 5.7D). To assess the antitumor immunity, the immunized mice were further 
challenged with OVA-expressing B16 melanoma cell line BL6-10OVA 30 days after the primary 
immunization. OVA-TEXO, (OX40L
-/-
)TEXO and (4-1BBL
-/-
)TEXO-immunized mice were 
significantly more protected against BL6-10OVA tumor challenge than (CD40L
-/-
)TEXO-
immunized ones (p < 0.01) (Figure 5.7E), confirming the loss of functional CTL memory is 
derived from (CD40L
-/-
)TEXO immunization. 
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Figure 5.7 CD40L signaling by OVA-TEXO is involved in CD8
+
 T-cell memory development. 
(A) Experimental protocol. C57BL/6 mice were immunized with OVA-TEXO or OVA-TEXO with 
indicated molecular deficiencies. Tail-blood samples were analyzed on Day 6 and Day 30 for 
OVA-specific memory CTLs by flow cytometry. All above immunized mice were further 
boosted with DCOVA. Four days after the boost, tail-blood samples of immunized mice were 
analyzed for OVA-specific memory CTL recall responses by flow cytometry.  (B) Values in 
each panel represent the percentage of OVA-specific CD8
+
 T cells to total CD8
+
 T-cell 
population with standard deviation in parenthesis. *, p > 0.05 and **, p < 0.05 vs cohorts of 
OVA-TEXO group (Student t test).  (C) Experimental protocol. C57BL/6 or CD40 KO mice were 
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immunized with OVA-TEXO. Tail-blood samples were analyzed at day 6 and day 30 for OVA-
specific memory CTLs by flow cytometry. All above immunized mice were further boosted with 
DCOVA. Four days after the boost, tail-blood samples of immunized mice were analyzed for 
OVA-specific memory CTL recall responses by flow cytometry. (D) Values in each panel 
represent the percentage of OVA-specific CD8
+
 T cells to total CD8
+
 T-cell population with 
standard deviation in parenthesis. **, p < 0.05 vs cohorts of C57BL/6 mice (Student t test). (E) 
Lung metastatic BL6-10OVA melanoma in immunized mice. The OVA-TEXO, (CD40L
-/-
)TEXO, (4-
1BBL
-/-
)TEXO or (OX40L
-/-
)TEXO cells immunized mice were challenged with BL6-10OVA tumor 
cells at day 30 following the primary immunization, and mice were sacrificed three weeks 
subsequent to challenge. Lungs with black tumor nodules are displayed. *, p < 0.01 vs cohorts of 
OVA-TEXO group (Mann-Whilney-U test). One representative experiment of two is shown.  
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5.2 HER2-specific CD4+ T cell-based vaccination stimulating CTL responses leading to 
antitumor immunity in HLA-A2/HER2 mice 
 
Since the success of DC-released exosome-targeted T cell-based vaccines in OVA-specific 
antitumor immunity, we applied this vaccine strategy to HER2 tumor antigen. In this section, we 
first constructed a recombinant human HER2-expressing adenovirus and established a HER2 
transgenic B16 melanoma cell line. We then examined HER2-specific CD8
+
 CTL responses and 
antitumor immunity by HER2-specific EXO-targeted T cell-based vaccine in double transgenic 
HLA-A2/HER2 mice with HER2-specific self-immune tolerance. 
 
5.2.1 AdVHER2 construction 
  
To construct recombinant adenovirus-expressing human HER2 690aa, we firstly obtained the 
human HER2690aa 2070 bp cDNA fragments (Figure 5.8B, lane 1) from pcDNA3.1/HER2 
plasmids by HindIII and XbaI digestion. The released fragments were subcloned into pShuttle-
CMV transfer plasmid at HindIII and XbaI sites, and identified by PCR (Figure 5.8C, lane 2) 
and double enzyme digestion (Figure 5.8D, lane 4). The recombinant transfer plasmid pShuttle-
CMV/HER2690aa or control pShuttle-CMV was then transformed into BJ5183 bacteria containing 
backbone plasmids RGD-pAdEasy-1 for homologous recombination. The RGD-pAdEasy-1-
pShuttle-CMV/HER2690aa or control RGD-pAdEasy-1-pShuttle-CMV (termed RGD-
pAd/HER2690aa and RGD-pAd hereafter) homologous recombinant adenoviral plasmids were 
screened by comparison of plasmid size with pShuttle-CMV/HER2690aa (pShuttle-CMV) and 
RGD-pAdEasy-1. RGD-pAd/HER2690aa (Figure 5.8E, right panel, clone #6) and RGD-pAd 
(Figure 5.8E, left panel, clone #5) plasmids were then abundantly amplified in E.coli DH5α 
bacteria and purified by QIAprep Spin Miniprep Kit. To confirming HER2690aa fragments in the 
RGD-pAd/HER2690aa homologous recombinant adenoviral plasmids, PCR analysis was further 
performed (Figure 5.8F, lane 2). Both of PacI-digested RGD-pAd/HER2690aa and RGD-pAd 
released 4.5 kb fragment of ori and kanamycin (Kana) resistance gene (Figure 5.8G, lane 1 and 
2), suggesting the homologous recombination happened at replication origin sites between 
transfer plasmid pShuttle-CMV/HER2690aa or pShuttle-CMV and adenoviral backbone plasmid 
RGD-pAdEasy-1. 
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Figure 5.8 Construction of AdVHER2 adenoviral vector. (A) Schematic representation of AdV 
vectors. The E1/E3-deleted replication-deficient AdV vectors are under the regulation of the 
cytomegalovirus (CMV) early/immediate promoter/enhancer. The AdV vectors include AdVnull 
without any transgene expression and AdVHER2 expressing transgene human HER2690aa. ITR, 
inverted terminal repeat (B) The 2070 bp human HER2690aa cDNA fragments (lane 1) were 
released from pcDNA3.1neo/HER2690aa plasmids by double digestion with HindIII and XbaI. (C) 
The human HER2690aa cDNA fragments were amplified by PCR using recombinant pShuttle-
CMV/HER2690aa (lane 2) or pShuttle-CMV control plasmids (lane 1) as templates and primer 
sets specific for human HER2690aa. (D) The recombinant plasmids pShuttle-CMV/HER2690aa 
(lane 4) or pShuttle-CMV control plasmids (lane 2) were digested with HindIII and XbaI or not 
(lane 3 and lane 1). (E) Identification of RGD-pAd/HER2690aa by molecular weight. Kana-
resistant clone derived plasmids from pShuttle-CMV/HER2690aa (right, clone # 1-6) or pShuttle-
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CMV transformed in BJ5183 containing RGD-pAdEasy-1 (left, clone # 1-6) were resolved in 
0.7% TAE-agarose gel electrophoresis with SYBR® Safe DNA Gel staining. (F) HER2690aa 
cDNA fragments were amplified by PCR using RGD-pAd/HER2690aa (lane 2) or RGD-pAd 
control plasmids (lane 1) as templates and primer sets specific for human HER2690aa. The 
reaction products in (B-D, F) were resolved in 1% TAE-agarose gel electrophoresis with 
SYBR® Safe DNA Gel staining. M, 100 bp Plus Opti-DNA Marker. (G) Identification of RGD-
pAd/HER2690aa by PacI digestion. The RGD-pAd/HER2690aa (lane 2) or RGD-pAd control 
plasmids (lane 1) were digested with PacI. The reaction products were resolved in 0.7% TAE-
agarose gel electrophoresis with SYBR® Safe DNA Gel staining. M, λ HindIII DNA marker.  
 
5.2.2 Adenovirus-mediated human HER2690aa transgene expression 
 
After homologous recombination of pShuttle-CMV/HER2690aa or control pShuttle-CMV with 
RGD-pAdEasy-1 in E.coli BJ5183 bacteria, recombinant adenoviruses AdVHER2/690aa (termed 
AdVHER2 hereafter) and control AdV blank adenovirus were subsequently abundantly amplified 
in HEK293 cells, and purified by CsCl density-gradient ultracentrifugation. HLA-A2/HER2 
mouse BM-DCs transfected with AdVHER2 at MOI of 100 (302) were termed DCHER2. 24 hrs 
after infection, total cellular RNAs derived from AdVHER2- or AdV-infected HEK293 and BM-
DCs, as well as uninfected HEK293 and BM-DCs were analyzed by RT-PCR, respectively. As 
shown in Figure 5.9A, abundant amounts of human HER2690aa transcriptional expression were 
found in AdVHER2-infected HEK293 and BM-DCs but not in AdV-infected or uninfected control 
cells. Flow cytometric analysis (Figure 5.9B) showed the translational expression of adenovirus-
mediated human HER2690aa on the surfaces of AdVHER2-infected HEK293 and DCHER2 cells. 
Above data indicate that the constructed AdVHER2 harboring human HER2690aa gene can 
functionally direct human HER2690aa transgene expression in mammalian cells such as HEK293 
cells and BM-DCs. 
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Figure 5.9 Adenovirus-mediated human HER2690aa transgene expression. The HEK293 cells 
and BM-DCs were infected with AdVHER2 or AdV blank adenovirus at the MOI of 10 (HEK293) 
or 100 (BM-DCs). The adenovirus-mediated human HER2690aa transgene expression was then 
determined by RT-PCR and flow cytometry, respectively. (A) Total cellular RNAs were 
extracted using RNeasy Plus Mini Kit. cDNA was synthesized immediately using RT² First 
Strand Kit. PCRs were conducted using primer sets specific for human HER2690aa and internal 
control human housekeep gene β-actin or mouse housekeep gene GAPDH, respectively. (B) The 
AdVHER2- or AdV-infected HEK293 and BM-DC cells (solid lines) and uninfected HEK293 and 
BM-DC control cells (dotted lines) were stained with mouse anti-human CD340 (ErbB2/HER2) 
monoclonal Ab (clone 24D2) followed by FITC-conjugated anti-mouse IgG secondary Ab, and 
analyzed by flow cytometry. 
 93 
5.2.3 Establishment of transgenic tumor cell lines 
 
To select an optimal BL6-10HER2 transgenic tumor cell line stably and highly expressing human 
HER2690aa, total 10 G418-resistant monoclones derived from G418-resistant BL6-10-
pcDNA3.1/HER2 or mock BL6-10-pcDNA3.1(+)neo transfectants were employed to expanded 
and then subjected to RT-PCR and flow cytometric analysis. As shown in Figure 5.10A, 
significant transcriptional amount of transgene HER2690aa were found in 9 G418-resistant BL6-
10-pcDNA3.1/HER2 clones (clone #1, 2, 4, 5, 6, 7, 8, 9 and 10) but not in clone #3, suggesting 
that clone #3 derived from the resistance to G418 of BL6-10 tumor cells themselves. 
Furthermore, flow cytometric analysis (Figure 5.10B) showed that only clone #1, 4 and 10 
among above 9 clones stably expressed high translational levels of transgene HER2690aa on the 
surface of BL6-10 tumor cells, whereas others expressed either moderate or undetectable levels 
of HER2690aa. In addition, no detectable amount of HER2690aa at both transcriptional and 
translational levels was found in BL6-10-pcDNA3.1 (+)neo or BL6-10 control tumor cells 
(Figure 5.10). The data indicated that a human HER2690aa-transgenic BL6-10 tumor cell line 
(BL6-10HER2) with stable and high expression of human HER2690aa was successfully established. 
BL6-10HLA-A2/HER2 double transgenic tumor cells were constructed by transfecting 
pcDNA3.1/HLA-A2 or control pcDNA3.1 (+) hygro plasmids containing hygromycin resistance 
gene into BL6-10HER-2 tumor cells. Flow cytometric analysis (Figure 5.10C) revealed the Hygro 
and G418 double-resistant clone stably exhibited high levels of human HER2690aa and moderate 
levels of HLA-A2 on the surface of BL6-10HLA-A2/HER2 transgenic cells. No detectable amount of 
HLA-A2 or HER2 was found in BL6-10 control tumor cells. Above data indicate the successful 
establishment of a human HER2690aa and HLA-A2 double-transgenic BL6-10 (BL6-10HLA-
A2/HER2) tumor cell line with stable and high expression of both human HER2690aa and HLA-A2. 
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Figure 5.10 Establishment of BL6-10HLA-A2/HER2 transgenic cell line. (A) RT-PCR analysis of 
human HER-2690aa transgene transcriptional expression in BL6-10HER2 tumor cells. Total cellular 
RNAs were obtained from G418-resistant pcDNA3.1neo/HER2- or pcDNA3.1neo-transfected 
BL6-10 monoclones and untransfected BL6-10 control cells. PCRs were conducted using primer 
sets specific for HER2690aa and internal control housekeep gene GAPDH, respectively. (B) The 
G418-resistant pcDNA3.1neo/HER2- and pcDNA3.1neo-transfected BL6-10 monoclone cells 
(solid lines) or untransfected BL6-10 control cells (dotted lines) were stained with anti-HER2 
Abs, and analyzed by flow cytometry. (C) BL6-10HLA-A2/HER2 tumor cells were stained with anti-
HER2, anti-HLA-A2 Ab (solid lines) or irrelevant isotype-matched control Ab (dotted lines), and 
analyzed by flow cytometry. One representative experiment of two is shown. 
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5.2.4 HER2-TEXO vaccine stimulates CTL responses leading to antitumor immunity in 
double transgenic HLA-A2/HER2 mice 
 
AdVHER2 transfected BM-DCs can express DC-derived molecules, such as CD11c, CD40 and 
CD80, as well as HER2. Whereas EXOHER2 derived from the culture supernatants of BM-DCHER2 
can only express them in a less extent (Figure 5.11A). ConA-T cells generated from double 
transgenic mice were incubated with EXOHER2 and termed HER2-TEXO, which also expressed 
CD11c, CD40, CD80 and HER2. The stimulatory effect of HER2-TEXO was evaluated in double 
transgenic mouse HLA-A2/HER2 generated by crossing male HER2 with homozygous female 
HLA-A2 mice. After HLA-A2/HER2 mice were immunized, CD8
+
 CTL responses were 
assessed by using nonspecific FITC-anti-CD8 and PE-anti-CD44 Abs staining by flow 
cytometry. HER2-TEXO more efficiently stimulated the upregulated expression of T-cell 
activation marker CD44 on CD8
+
 T cells than ConA-T cells (p < 0.05) (Figure 5.11B upper 
panel). HER2-specific CD8
+
 T cell responses were further quantified by intracellular IFN-γ 
staining assay. 4.16% CD8
+
 T cells in HER2-TEXO-immunized mice produced IFN-γ after 
HER2369-377 peptide stimulation, which is significantly more than that in ConA-T-immunized 
mice (0.42%) (p < 0.05) (Figure 5.11B lower panel), indicating that HER2-TEXO vaccine 
stimulates HER2-specific CTL responses.  
 
In animal studies, HLA-A2 and HLA-A2/HER2 mice were immunized with HER2-TEXO and 
ConA-T, respectively, followed by BL6-10HLA-A2/HER2 tumor cell challenge. All 8/8 (100%) mice 
immunized with HER2-TEXO had complete antitumor immune protection in transgenic HLA-A2 
mice (Figure 5.11E). Furthermore, HER2-TEXO vaccine was capable of protecting 2/8 (25%) 
mice from BL6-10HLA-A2/HER2 tumor challenge, and the remaining 6/8 (75%) mice immunized 
with HER2-TEXO had significantly prolonged survival than mice immunized with the control 
ConA-T (p < 0.05) (Figure 5.11F), indicating that HER2-TEXO can stimulate CTL responses, 
leading to partially protective immunity against HLA-A2/HER2-expressing BL6-10HLA-A2/HER2 
tumor challenge in double transgenic HLA-A2/HER2 mice with HER2-specific self immune 
tolerance.  
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Figure 5.11 HER2-TEXO vaccine stimulates CTL responses and antitumor immunity in 
HLA-A2/HER2 mice. (A) Flow cytometric analysis of various molecules expressed on DCHER2, 
EXOHER2 and HER2-TEXO. Samples were stained with a panel of Abs (solid lines) or isotype-
matched irrelevant Abs (dotted lines). One representative experiment of two is shown. Six days 
after HER2-TEXO immunization, tail-blood samples were stained with FITC-anti-CD8 and (B) 
PE-anti-CD44 or (C) PE-anti-IFN-γ Abs, and then analyzed by flow cytometry. Values represent 
the percentage of HER2-specific CD8
+
 T cells to total CD8
+
 T-cell population with standard 
deviation in parenthesis. *, p < 0.05 vs cohorts of ConA-T cells (Student t test). (D) 
Experimental protocol. (E) HLA-A2 and (F) HLA-A2/HER2 mice were immunized with HER2-
TEXO or control ConA-T cells, respectively. Six days after immunization, mice were s.c. 
challenged with BL6-10HLA-A2/HER2 tumor cells. Tumor growth was monitored daily and mice 
were sacrificed when tumors grew to 1 cm in diameter. *, p < 0.05 vs cohorts of ConA-T cells 
(Log rank test). One representative experiment of two is shown.  
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5.3 Redirecting antigen-specificity by peptide/MHC-II arming to nonspecific CD8+CD25+ 
Tregs for enhanced immunosuppression  
 
Unlike CD4
+
CD25
+
 Tregs, the critical cellular and molecular mechanisms responsible for 
CD8
+
CD25
+
 Treg-mediated suppression remain largely unknown. In this section, we assessed 
immunosuppressive effects and potential mechanisms of in vitro expended CD8
+
CD25
+
 Tregs. 
In addition, antigen-specific pMHC complex-armed CD8
+
CD25
+
 Tregs were further assessed 
their enhanced inhibitory effects in both OVA-specific tumor model and MOG-induced EAE 
model. 
 
5.3.1 CD8+CD25+ T cells express some of Tregs’ markers 
 
CD4
+
CD25
+
 and CD8
+
CD25
+
 T cells were first analyzed using regulatory T cell staining kit. As 
shown in Figure 5.12A, CD4
+
CD25
+
 and CD8
+
CD25
+
 T cells accounted for 7.12% and 0.43% 
of total CD4
+
 T cell and CD8
+
 T cell population in mouse splenocytes, respectively, which is 
consistent with previous reports (351, 439). Both CD4
+
CD25
+
 and CD8
+
CD25
+
 T cells expressed 
Foxp3. Purified CD8
+
CD25
+
 double positive T cells were then expanded in vitro using 
CD3/CD28 beads for 4-6 days, and analyzed by flow cytometry. CD8
+
CD25
+
 Tregs expressed 
Treg markers such as cell-surface CD25, CD103, GITR, CTLA-4, as well as intracellular 
perforin and granzyme B (Figure 5.12B). In addition, they also expressed cell surface CD28. 
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Figure 5.12 Phenotypic characterization of CD8
+
CD25
+
 Tregs. (A) Flow cytometric analysis 
of Foxp3 expression on CD4
+
CD25
+
 and CD8
+
CD25
+
 T cells. C57BL/6 mouse splenocytes were 
stained with PE-anti-CD25 and FITC-anti-CD4 or -CD8 Abs, and then stained with PE-Cy5-
anti-Foxp3 Ab after cell membrane permeabilized with Cytofix/Cytoperm solutions. The stained 
cells were analyzed by flow cytometry. Naive CD4
+
CD25
+
 and CD8
+
CD25
+
 T cells in boxes 
were gated for analysis of Foxp3 expression. (B) In vitro expanded CD8
+
CD25
+ 
Tregs were 
stained with FITC Abs for different molecules (solid lines) or FITC-conjugated isotype-matched 
irrelevant Abs (dotted lines), and analyzed by flow cytometry. 
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5.3.2 Immune suppression of CD8+CD25+ Tregs  
 
To assess the immune suppression of CD8
+
CD25
+
 Tregs, C57BL/6 mice were i.v. immunized 
with sDCOVA with co-injection of CD8
+
CD25
+
 Tregs. CTL responses were examined using 
mouse blood samples by flow cytometry. sDCOVA stimulated PE-H-2K
b
/OVAI tetramer-positive 
CD8
+
 T cell responses, accounting for 1.82% in total CD8
+
 T-cell population in C57BL/6 mice. 
However, PE-H-2K
b
/OVAI tetramer-positive CD8
+
 T-cell responses in mice with co-injection of 
CD8
+
CD25
+ 
Tregs significantly dropped from 1.82% to 1.17% in the total CD8
+
 T-cell 
population (p < 0.05) (Figure 5.13B), indicating that CD8
+
CD25
+
 Tregs are capable of 
suppressing in vivo sDCOVA-stimulated OVA-specific CD8
+
 T-cell responses. Next, in vivo 
cytotoxicity assay was performed to assess whether CD8
+
CD25
+
 Tregs suppress CD8
+ 
T-cell 
differentiation into effector CD8
+
 CTLs. As shown in Figure 5.13C, 82.7% of the OVA-specific 
CFSE
high
 target cells, but none of the irrelevant control Mut1 peptide-pulsed CFSE
low
 target cells 
were killed over 16 hrs after transfer of target cells into mice immunized with sDCOVA, while the 
injection of CD8
+
CD25
+
 Tregs significantly reduced the loss of CFSE
high 
target cells to 57.9% 
(Figure 5.13C), indicating that CD8
+
CD25
+
 Tregs efficiently inhibit in vivo effector CTL 
responses. To assess whether CD8
+
CD25
+
 Tregs suppress antitumor immunity, animal studies 
was performed. As shown in Figure 5.13D, all PBS control mice died of tumor within 25 days 
after s.c. inoculation of BL6-10OVA tumor cells, whereas 8/8 of sDCOVA-immunized mice (100%) 
were protected from BL6-10OVA cell challenge. However, the administration of CD8
+
CD25
+
 
Tregs significantly reduced sDCOVA-induced antitumor immunity and 4/8 (50%) of mice died of 
tumor (p < 0.05), indicating that CD8
+
CD25
+
 Tregs also suppress in vivo CTL-mediated 
antitumor immunity. 
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Figure 5.13 Immune suppression of CD8
+
CD25
+
 Tregs. (A) Experimental protocol. C57BL/6 
mice were i.v. immunized with sDCOVA with or without CD8
+
CD25
+
 Tregs. (B) Blood samples 
were assessed for OVA-specific CTL responses using PE-tetramer and FITC-CD8 staining by 
flow cytometry. Values in each panel represent the percentage of OVA-specific CD8
+
 T cells to 
total CD8
+
 T-cell population with standard deviation in parenthesis. *, p < 0.05 vs cohorts of 
sDCOVA group (Student’s t test). (C) In vivo cytotoxicity assay. 16 hrs after target cell delivery, 
the residual OVAI peptide-pulsed CFSE
high
- and the control Mut1 peptide-pulsed CFSE
low
-target 
cells remaining in the spleens of above immunized mice were sorted and analyzed by flow 
cytometry. The value in each panel represents the percentage of OVA-specific CFSE
high
 and 
control CFSE
low
 target cells remaining in the spleens. *, p < 0.05 vs cohorts of sDCOVA group 
(Student’s t test). One representative experiment of two is shown. (D) In animal studies, 7 days 
after immunization, mice were s.c. challenged with BL6-10OVA tumor cells. Tumor growth was 
monitored daily for 60 days. *, p < 0.05 vs cohorts of sDCOVA group (Log rank test).  
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5.3.3 CD8+CD25+ Tregs induce naive CD4+ T-cell anergy  
 
CD4
+
CD25
+
 Tregs have been reported to play inhibitory role via rendering naive T cells 
functional anergic (440). However, the molecular phenotype of these anergic T cells is not well 
characterized. To assess the effect of CD8
+
CD25
+
 Tregs on naive T cells, naive CD4
+
 T cells 
were incubated with CD8
+
CD25
+
 Tregs and phenotypically characterized. CD8
+
CD25
+
 Treg-
treated CD4
+
 T cells showed similar level of Grail, Grg4, Caspase 3, Itch and Ikaros, but 4-fold 
higher of anergic early growth response 2 (EGR2) compared with naive CD4
+
 T cells (Figure 
5.14A) by real time-PCR analysis using DNA primers specific for a panel of T cell anergy-
associated genes (429). In addition, CD8
+
CD25
+
 Treg-treated CD4
+
 T cells were stimulated in 
anti-CD3 and anti-CD28 Ab-coated wells. As shown in Figure 5.14B, CD8
+
CD25
+
 Treg-treated 
CD4
+
 T cells secreted significantly lower level of IL-2 (0.07 ng/mL) than control naive CD4
+
 T 
cells (0.53 ng/mL). 
3
H-thymidine incorporation assay was also performed to determine the extent 
of cell division that occurred in response to CD8
+
CD25
+
 Tregs treatment. As shown in Figure 
5.14C, the primary naive CD4
+
 T cells proliferated upon DC stimulation in a dose-dependent 
manner. However, CD8
+
CD25
+
 Treg-treated CD4
+
 T cells completely lost their capacity for 
cellular proliferation, consistent with the hyporesponsive state of T-cell anergy. 
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Figure 5.14 CD8
+
CD25
+
 Tregs anergize naive CD4
+
 T cells. (A) cDNA was synthesized from 
total cellular RNAs isolated from naive CD4
+
 T cells or CD8
+
CD25
+
 Treg-treated CD4
+
 T cells. 
Real time-PCR was carried out using a panel of primers specific for β-actin, Grail, Ikaros, Casp3, 
EGR2, Grg4 and Itch. Values of fold induction (the ratio of mRNA expression in CD8
+
CD25
+
 
Treg-treated CD4
+
 T cells to that in naive CD4
+
 T cells) were the mean ± SD (standard 
deviation) of three independent experiments. (B) Naive CD4
+
 or CD8
+
CD25
+
 Treg-treated CD4
+
 
T cells were incubated in anti-CD3 and anti-CD28 Ab-coated wells. Supernatants were collected 
and analyzed for IL-2 secretion by ELISA. (C) Naive CD4
+
 or CD8
+
CD25
+
 Treg-treated CD4
+
 T 
cells were incubated with sDCs in the presence of anti-CD3 Ab and IL-2 in an in vitro 
3
H-
thymidin incorporation assay. The levels of 
3
H-thymidine incorporation into the cellular DNA 
were determined by liquid scintillation counting. Each point represents the mean of triplicates. 
One representative experiment of two in the above different experiments is shown.
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5.3.4 CD8+CD25+ Tregs downregulate CTL perforin expression and induce perforin-
mediated CTL apoptosis 
 
Since CD4
+
CD25
+
 Tregs were reported to inhibit CTL killing effect (237) and involved in 
cytolytic effect on target cells (441), we assume that the above in vitro CD8
+
CD25
+
 Treg-
induced inhibition could be a result of either modulation of CTL killing activity or killing-
activity to target cells. To assess our assumption, CD8
+
CD25
+
 Tregs were incubated with CTLs 
followed by assessment of intracellular perforin and granzyme B expression on target CTLs. 
CD8
+
CD25
+
 Treg-treated CTLs were found to decrease perforin (not granzyme B) expression 
(Figure 5.15A) when compared with untreated CTLs. CD8
+
CD25
+
 Tregs were also incubated 
with TFL2-labeled CTLs followed by assessment of target cell apoptosis. CD8
+
CD25
+
 Tregs 
induced apoptosis in 17.2% Treg-treated CTLs (Figure 5.15B), while spontaneous apoptosis was 
seen in only 3.7% untreated CTLs. However, (perforin
-/-
)Tregs lacking perforin expression lost 
their killing effect on CTLs (Figure 5.15B), indicating that CD8
+
CD25
+
 Tregs kill target CTLs 
via perforin-mediated apoptosis.  
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Figure 5.15 Effect of CD8
+
CD25
+
 Tregs on CTLs. (A) ConA-stimulated OTI CD8
+
 CTLs were 
co-cultured with or without CD8
+
CD25
+
 Tregs overnight. Cell mixtures were stained with PE-
Cy5-anti-CD8 and PE-Tetramer Abs, and then stained with FITC-anti-perforin or granzyme B 
Ab after cell membrane permeabilized with Cytofix/Cytoperm solutions. The stained cells were 
analyzed by flow cytometry. CTLs in boxes were gated for analysis of perforin or granzyme B 
expression. (B) CD8
+
CD25
+
 Tregs or CD8
+
CD25
+
 (perforin
-/-
)Tregs were incubated with TFL2 
(cell dye)-labeled CTLs for 45 min. Cell permeable fluorogenic granzyme-B substrate was 
subsequently added followed by flow cytometric analysis. CD8
+
CD25
+
 Tregs’ killing effect was 
assessed by the ability of target CTLs cleaving granzyme-B substrate using flow cytometry. *, p 
< 0.05 vs cohorts of CTL only group (Student’s t test). One representative experiment of two is 
shown. 
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5.3.5 CD8+CD25+ Tregs with OVA-specific pMHC-II arming enhance their inhibition of 
CTL responses and antitumor immunity 
 
Previous work demonstrated that polyclonal CD4
+
 T cells, after uptake of DCOVA-released 
exosomes, became capable of stimulation of OVA-specific CTL responses via exosomal pMHC-
I targeting (431). To assess whether pMHC-I or the pMHC-II complexes are involved in 
enhanced suppression, we pulsed CD8
+
CD25
+
 Tregs with OVAI- and OVAII-peptide to form 
functional pMHC-I-expressing CD8
+
CD25
+
 Tr/OVAI- and pMHC-II-expressing CD8
+
CD25
+
 
Tr/OVAII-cells, respectively. Interestingly, only CD8
+
CD25
+
 Tr/OVAII, but not CD8
+
CD25
+
 Tr/OVAI 
cells (Figure 5.16B) showed significantly enhanced suppression to sDCOVA-induced CTL 
responses (p < 0.05) compared with CD8
+
CD25
+
 Tregs, indicating that CD8
+
CD25
+
 Tregs with 
OVA-specific pMHC-II arming enhance their inhibition of CTL responses. Similarly, 
CD8
+
CD25
+
 Tr/OVAII, but not CD8
+
CD25
+
 Tr/OVAI cells, also demonstrated an enhanced effect on 
suppressing CD8
+
 T cells differentiation into effector CTLs response (Figure 5.16C), and 
antitumor immunity in C57BL/6 mice (Figure 5.16D) compared with CD8
+
CD25
+ 
Tregs (p < 
0.05). 
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Figure 5.16 CD8
+
CD25
+
 Tregs with OVA-specific pMHC-II arming enhance their 
antitumor immunity. (A) Experimental protocol. C57BL/6 mice were immunized with sDCOVA 
plus CD8
+
CD25
+
 Tregs, CD8
+
CD25
+
 Tr/OVAI or CD8
+
CD25
+
 Tr/OVAII cells. (B) Blood samples 
were assessed for OVA-specific CTL responses using PE-tetramer and FITC-CD8 staining by 
flow cytometry. Values in each panel represent the percentage of OVA-specific CD8
+
 T cells to 
total CD8
+
 T-cell population with standard deviation in parenthesis. *, p < 0.05 vs cohorts of 
sDCOVA plus Treg group (Student’s t test) (C) In vivo cytotoxicity assay. 16 hrs after target cell 
delivery, the residual OVAI peptide-pulsed CFSE
high
- and the control Mut1 peptide-pulsed 
CFSE
low
-target cells remaining in the spleens of the above immunized mice were sorted and 
analyzed by flow cytometry. The value in each panel represents the percentage of OVA-specific 
CFSE
high
 and control CFSE
low
 target cells remaining in the spleens. *, p < 0.05 vs cohorts of 
sDCOVA plus Treg group (Student’s t test). (D) In animal studies, 7 days after immunization, 
mice were s.c. challenged with BL6-10OVA tumor cells. Tumor growth was monitored daily for 
60 days. *, p < 0.05 vs cohorts of sDCOVA plus Treg group (Log rank test). One representative 
experiment of two is shown. 
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5.3.6 CD8+CD25+ Tregs with OVA-specific pMHC-II arming reduce cognate CD4+ T-cell 
interaction with sDC ex vivo 
 
Tregs have previously been shown to regulate DC-CD4
+
 T cell interaction during priming (235, 
236), we therefore hypothesized that armed CD8
+
CD25
+
 Tregs destabilized sDC-CD4
+
 T cell 
interaction more efficiently than regular CD8
+
CD25
+
 Tregs. To investigate this possibility, 
recipient mice were adoptively transferred with CD8
+
CD25
+
 Tregs and CD8
+
CD25
+
 Tr/OVAII 
cells, respectively. One day later, mice were i.v. injected with DsRed fluorescent protein-
expressing sDCOVA (red) derived from transgenic DsRed mice followed by i.v. injection of 
CFSE-labeled CD4
+
 T cells (green). Recipient mice that did not receive Tregs were considered 
as positive control. Imaging assay was then performed in mouse popliteal lymph nodes to 
analyze CD4
+
 T-cell motility by TPM. No significant change of CD4
+
 T-cell dynamics was 
found in mice with or without co-injection of CD8
+
CD25
+
 Tregs (data not shown). In contrast, 
the presence of CD8
+
CD25
+
 Tr/OVAII cells resulted in a less confined migration pattern (Figure 
5.17B; sMovie 5.7-5.8), and a slight but statistically significant increase of CD4
+
 T cell 
velocities (4.47 μm/min versus 5.25 μm/min) (p < 0.05) (Figure 5.17C). The quality of T-DC 
interaction was also measured by the contact duration. Contacts detectable throughout a 
complete 40-min imaging period were defined as stable ones. All other interactions were 
considered as transient contacts. The analysis of the duration of individual transient T-DC 
interaction showed that transient contacts lasted shorter in the presence of pMHC-II-armed Tregs 
(median contact duration 7.5 min versus 14.7 min; Figure 5.17D). Therefore, our data indicate 
that CD8
+
CD25
+
 Tregs with OVA-specific pMHC-II arming reduce cognate CD4
+
 T-cell 
interactions with sDCs ex vivo.  
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Figure 5.17 CD4
+
 T-cell dynamics in the presence pMHC-II armed Tregs. (A) Experimental 
protocol. Unlabeled CD8
+
CD25
+
 Tr/OVAII-cells were adoptively transferred into recipient mice 
one day before. The mice were injected in footpad with DsRed-sDCOVA (red) followed by i.v. 
injection of CFSE-CD4
+
 T cells (green) one day later. Popliteal lymph nodes were imaged in T-
zone region by TPM 6 hrs later. (B) Migration behavior of CFSE-labeled OTII CD4
+
 T cells 
(green) in the absence of unlabeled CD8
+
CD25
+
 Tregs (left) or in the presence of CD8
+
CD25
+
 
Tr/OVAII (right) cells. Individual cells are displayed as color-coded tracks to represent increasing 
time from blue (start of imaging) to yellow (end of imaging). Tracks are overlaid after 
normalizing their starting coordinates (lower panel). (C) Average velocities of OTII CD4
+
 T 
cells. Each dot represents an individual cell; bars indicate median values. *, p < 0.05 between 
cohorts of no Tregs and Tr/OVAII group (Student’s t test). (D) Duration of transient contacts 
between OTII CD4
+
 T cells and sDCOVA in the absence of CD8
+
CD25
+
 Tregs or in the presence 
of pMHC-II-armed Tr/OVAII cells. Transient contacts of individual T cells were grouped into four 
categories with regard to the contact duration. Data shown are representative from one of at least 
three independent experiments. 
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5.3.7 Providing CD8+CD25+ Tregs with pMHC-II complexes enhance their EAE-inhibiting 
capacity 
 
To induce mild EAE, we only administered MOG35-55 peptide plus CFA/MT, but not pertussis 
toxin (442). Treated-mice developed EAE with clinical scores (Figure 5.18). To assess the 
potential immunosuppressive effect, CD8
+
CD25
+
 Tregs were applied to the MOG peptide-
injected EAE mice. Tregs only slightly, but not statistically significantly inhibited MOG peptide-
induced EAE. When MOG-specific pMHC-II-armed CD8
+
CD25
+
 Tr/MOG cells were applied to 
EAE mice, the immunosuppression was significantly stronger in regards to clinical scores 
assessed in EAE mice with injection of Tr/MOG cells than that in EAE mice with injection of 
Tregs (p < 0.05), indicating that arming CD8
+
CD25
+
 Tregs with MOG-specific pMHC-II 
complexes enhance their inhibition of EAE. 
 
 
Figure 5.18 CD8
+
CD25
+
 Tr/MOG cells in MOG peptide induced EAE. (A) Experimental 
protocol. Wild-type C57BL/6 mice were immunized with MOG35-55. CD8
+
CD25
+
 Tregs or 
MOG-specific pMHC-II-armed CD8
+
CD25
+
 Tr/MOG cells were applied to the MOG peptide-
induced EAE mice one day pre- and two days-post the immunization. (B) C57BL/6 mice 
immunized with CFA only were used as control. The analysis was performed on the raw data 
that included all clinical scores for each mouse at each time point in each group. *, p < 0.05 vs 
cohorts of MOG CD8
+
CD25
+
 Treg group (Student’s t test).  
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CHAPTER 6 DISCUSSIONS 
 
Vaccines that are capable of stimulating effector and memory CD8
+
 CTL responses have been 
extensively studied in an effort to control pathogen-induced diseases and tumor development. 
Stimulation of T-cell responses by APCs involves at least two signaling events: one elicited by 
TCRs recognizing pMHC complexes and another triggered by costimulatory molecular signaling 
such as CD40, CD80, 4-1BBL and OX40L (443). To achieve T cell activation, the formation of 
IS composed of TCR-pMHC complexes, CD28-CD80 and LFA-1-CD54 engagements at the 
interface between an APC and a T cell must occur after initial engagement of TCR molecules 
(434). Monks et al. further showed that, instead of uniform distribution, these proteins clustered 
into segregated three-dimensional domains within the cell contacts (435). The condensed central 
distribution and essential role in TCR-triggered T-cell activation (444) make PKC-θ a perfect 
marker for IS formation. APCs also provide an additional polarization signal (signal 3), such as 
IL-12 (445), which selectively drives the development of type I or type II immunity, each 
characterized by a distinct microenvironment promoting a particular set of effector mechanisms 
(446, 447). Following the recognition of foreign antigen, CD8
+
 T cells undergo three distinct 
developmental phases: (i) a proliferation (primary) phase, in which naive CD8
+
 T cells undergo 
autonomous clonal expansion and develop into effector CTLs; (ii) a contraction phase, in which 
approximately 95% of the effector CTLs undergo AICD through apoptosis, allowing the 
remaining approximately 5%-10% of the CTLs to develop into memory CTLs; and (iii) a 
maintenance phase, in which memory CTLs survive for a prolonged duration. Unlike their naive 
counterparts, memory CTLs display enhanced responses to subsequent antigen encounters, 
undergo rapid proliferation and have heightened effector functions during recall responses. 
 
Hao et al. (181) showed that ConA-stimulated CD4
+
 T cells derived from OVA-specific TCR 
transgenic OTII mice can internalize OVA-pulsed DC-released EXO (EXOOVA) via TCR/MHC 
and LFA-1/CD54 interactions. EXOOVA-loaded CD4
+
 T cells can be used as OVA-TEXO vaccines 
capable of stimulating CD8
+
 T-cell priming via pMHC-I-mediated targeting and via IL-2 and 
CD80 costimulatory signaling. This mechanism has been further unveiled in this dissertation by 
the finding that OVA-TEXO cells are capable of inducing CD8
+
 T cell responses in I-A
b-/-
 mice, 
indicating that OVA-TEXO could directly stimulate CD8
+
 T cell responses independent of CD4
+ 
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T-cell help. The confocal imaging data in this dissertation also demonstrate the direct evidence 
that, similarly to APCs, OVA-TEXO can also form PKC-θ-composed IS with cognate CD8
+
 T 
cells, which is consistent with previous work by Sumoza-Toledo et al (448), thereby leading to 
the induction of CTL responses. 
 
CD4
+
 T cell’s CD40L signaling has been found to be important in licensing DCs to induce CTL 
responses via DC’s CD40/CD4+ T cell’s CD40L interactions (449). In addition, Munroe et al. 
demonstrated a functional costimulation of T cell’s CD40 via induction of kinase and 
transcription factor activities (450). Furthermore, Bourgeois et al. reported that CD40 deficiency 
had a major impact on the CTL memory responses when re-challenged with the same antigen, 
suggesting that the help of CD4
+
 T-cell to CD8
+
 T-cell involves CD4
+
-CD8
+ 
T cell interactions 
by forming DC-CD4
+
-CD8
+
 T cell clusters (173). However, they did not provide any direct in 
vivo evidence for role of CD4
+
 T cell’s CD40L in CTL memory development. In this study, we 
demonstrate that although CD40L signaling of CD4
+
 OVA-TEXO is not involved in CD8
+
 T cell 
priming, it does play an important role in functional CD8
+
 T cell memory development since 
CD4
+
 (CD40L
-/-
)TEXO-stimulated CD8
+
 T memory cells lose their functional recall responses, 
thereby clearly indicating the critical role of CD4
+
 T cell’s CD40L signaling in CTL memory 
development. 
  
TPM has been widely used in assessment of immune cell interactions in vivo (188), specially the 
interactions between DC-T cells. It has been shown in many cases that CD4
+
 helper T cells 
promote the quality of CD8
+
 T cell responses (451, 452). Using intravital imaging, Beuneu et al. 
(453) showed that recruiting CD8
+
 T cells to DCs was enhanced by the presence of CD4
+
 T cells 
that recognize their cognate peptide on the same DC, thereby suggesting ternary clusters with 
both CD4
+
 and CD8
+
 T cells in direct contact with antigen-bearing DCs. Similarly, Castellino
 
et 
al. (222) demonstrated that the up-regulated expression of CCR5 on naive CD8
+
 T cells 
permitted these cells to be attracted to sites of antigen-specific DC-CD4
+
 T cell interaction where 
the chemokines CCL3 and CCL4 were produced. A variation of this theme was shown by 
Ahmed et al. (179) that DC-primed CD4
+
 T cells were able to directly interact with CD8
+
 T cells 
to prime CTL responses in the absence of DCs. Trogocytosis, a process whereby lymphocytes 
conjugated to APCs extract surface molecules from these cells and express them on their own 
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surface, could be partially explain this CD4
+
-CD8
+
 interaction theme. In this dissertation, 
interactions between OVA-TEXO and OTI CD8
+
 T cells have also been shown ex vivo by two-
photon imaging. Upon exposure to OVA-TEXO, naive OTI CD8
+
 T cells show significantly lower 
velocity (5.15 μm/min) and confined movement compared with those OTI CD8+ T cells exposed 
to OVA-(K
b-/-
)TEXO (11.38 μm/min). Therefore, we provide the first ex vivo evidence on the 
important role of exosomal pMHC-I in targeting OVA-TEXO cells to cognate CD8
+
 T cells. 
Interestingly, we also find that the velocity of polyclonal CD8
+
 T cells (8.87 μm/min) in the 
presence of OVA-TEXO-OTI CD8
+
 T cells conjugates is lower than the velocity of polyclonal 
CD8
+
 T cells (11.38 μm/min) in the presence of OVA-TEXO alone, indicating that help to 
polyclonal CD8
+
 T cells can be provided by antigen specific CD8
+
 T cells responding to OVA-
TEXO cells. In fact, our result is consistent with a previous observation by Hugues et al. (223), 
showing that the nonspecific interactions between polyclonal CD8
+
 T cells and DCs, which 
occurred in the presence of an ongoing antigen-specific CD8
+
 T-cell responses, though much 
shorter than the antigen-specific interactions, were longer than the nonspecific interactions with 
DCs alone.  
 
The transgenic HER2 mice express human HER2 under the whey acidic protein promoter and 
have HER2-specific self-immune tolerance (421). Since there is ∼10% difference between rat 
and human ErbB-2 proteins (454), these mice have become a useful model for evaluation of 
various human HER2-specific antitumor vaccines (455, 456). The double transgenic HLA-
A2/CEA (carcinoembryonic antigen) mice expressing both HLA-A2 and CEA molecules have 
been constructed and extensively used to assess CEA-specific antitumor vaccines (126, 457, 
458). Similarly, we establish, for the first time, the double transgenic HLA-A2/HER2 mice by 
cross-breeding of transgenic HLA-A2 female mice with transgenic HER2 male mice, to assess 
CTL responses and antitumor immunity derived from HER2-TEXO vaccination. We demonstrate 
that HER2-TEXO vaccine is capable of stimulating efficient HER2-specific CTL responses and 
inducing protective immunity against BL6-10HLA-A2/HER2 tumor in vivo in 2/8 double transgenic 
HLA-A2/HER2 mice with HER2-specific self-immune tolerance. In addition, the remaining 6/8 
mice have significantly prolonged survival.  
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Several reports from experimental models and clinical studies have shown that HER2 is an 
immunogenic molecule since it generates antibody responses and activation of HER2-specific 
CD4
+
 helper T cell and CD8
+
 CTL responses (459-462). Vaccines against HER2 have been 
tested in mouse models and in human clinical trials, showing that significant levels of HER2-
specific CTL responses can be generated with active immunization (462, 463). An issue of 
whether tumor antigen-specific vaccines induce autoimmunity since most tumor antigens are 
self-antigens in nature is still controversial. In some animal models, no tumor antigen-specific 
vaccine-induced autoimmunity was demonstrated (464, 465). However, vaccine-induced 
autoimmunity was reported in other melanoma/melanocyte-associated antigen models (466, 
467). These discrepant results may derive from differences of distinct tumor antigens in nature, 
which are targeted in these animal models. Moreover, although some strategies using Tregs’ 
inhibitor in previously vaccinated cancer patients have shown promising results (274, 275), 
autoimmunity is prone to occur due to the inhibition or depletion of Tregs. Thus, the balance 
between antitumor efficacy and autoimmunity pathology should be considered when designing 
vaccines (468). So far, signs of autoimmunity directed against normal tissues have not been 
encountered by various HER2-specific vaccinations (469). In fact, we did not find any clinical 
signs related to autoimmunity six months after HER2-TEXO vaccination administration (data not 
shown). Most probably, it is because the vaccine itself is not strong enough to completely break 
HER2-specific self-immune tolerance. Besides, no Treg inhibitors have been added in this 
vaccine strategy to increase the occurrence of systematic autoimmunity. Therefore, the risk of 
induction of autoimmunity by using HER2-TEXO vaccine is, at present, negligible. 
 
Compared with CD4
+
CD25
+
 Tregs, mechanisms for CD8
+
CD25
+
 Tregs suppression are less 
studied. Cosmi et al. (346) identified a subset of human CD8
+
CD25
+
 thymocytes that shared 
phenotype, functional features, and mechanism of action with CD4
+
CD25
+
 Tregs. Mahic et al. 
(349) found that CD8
+
CD25
-
 T cells up-regulated CD25, Foxp3, GITR, CD28 and CTLA-4 after 
continuous antigen stimulation, and inhibited CD4
+ 
and CD8
+
 T cell proliferation and cytokine 
production via a contact-dependent mechanism. A similar subset has also been found in the 
thymus and periphery of MHC class II-deficient mice by Bienvenu et al. (351), showing that 
CD44, GITR, LFA-1 and intracellular CTLA-4 expressing CD8
+
CD25
+
 T cells suppressed anti-
CD3-stimulated CD25
-
 T cell responses in vitro in a contact-dependent, IL-10-independent 
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manner. However, one study by Mayer et al. pointed out that although both naturally occurring 
and induced CD8
+
Foxp3
+
 T cells expressed bona fide Treg markers including CD25, GITR, 
CTLA-4 and CD103, induced CD8
+
Foxp3
+
 T cells only mildly suppressed T-cell proliferation 
and IFN-γ production (352). In this dissertation, we use natural CD8+CD25+ Tregs expanded in 
vitro with CD3/CD28 microbeads as previously described (470, 471) to study cellular and 
molecular mechanisms of CD8
+
CD25
+
 Treg-mediated immunosuppression. We demonstrate that 
CD8
+
CD25
+
 Tregs express bona fide Treg markers (CD25, CD103, GITR and CTLA-4) and 
CD28, which is partially consistent with recently reported data by Mayer et al.(352). Therefore, 
these CD8
+
CD25
+
 Tregs are phenotypically distinct from some of other CD8
+
 Treg subsets, such 
as CD8
+
CD25
+
CD103
-
 and CD8
+
CD25
+
CD28
-
 Tregs (472). The work conducted by other 
peoples in our lab show that these induced CD8
+
CD25
+
 Tregs inhibit DC-stimulated CD4
+
 and 
CD8
+
 T-cell proliferation in a cell-cell contact-dependent manner, but the inhibitory effect is not 
mediated by the secretion of IL-10, TGF-β or by the expression of CTLA-4, which is consistent 
with previous reported characteristics of CD8
+
CD25
+
 Tregs (351, 473).  
 
The presence of activated Tregs has been reported to affect CTL killing function. Chen et al. 
(474) showed that co-transfer of antigen-specific Tregs with antigen-specific CD8
+
 T cells 
followed by implantation of tumor cells resulted in the failure of CTL-induced tumor rejection. 
Similarly, Mempel et al. (237) showed that the ability of CD4
+
CD25
+
 Tregs regulated CTLs in 
inducing target cell lysis was greatly impaired, which is correlated with impaired release of lytic 
granules. Tregs have also been shown with the expression of perforin and granzyme B, and the 
ability in killing target cells in different experimental settings (441, 475-477). Boissonnas et al. 
(238) further demonstrated Foxp3
+
 Tregs induced the death of DCs through a perforin-dependent 
mechanism, involving direct contacts between Tregs and DCs. In this dissertation, we find that 
CD8
+
CD25
+
 Treg-treated CTLs down-regulate the expression of perforin, which could affect 
CTL function in lysing target cells. On the other hand, since granzyme B only becomes active 
when effector cells are induced in the presence of target cells, measurement of granzyme B 
activity inside target cells provides an extremely early quantitative assessment of cell-mediated 
cellular cytotoxicity. Thus, through the measurement of granzyme B activity in target CTLs, 
CD8
+
CD25
+
 Tregs show direct killing effect to target CTLs via the release of cytolytic granzyme 
B, while the perforin KO CD8
+
CD25
+
 Tregs fail to do so. CD8
+
CD25
+
 Tregs efficiently suppress 
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splenic DCOVA-stimulated CTL responses and antitumor immunity against OVA-expressing 
BL6-10OVA melanoma, while CD8
+
CD25
+
 Tregs lacking perforin only induced weaker inhibitory 
effects (data not shown). Thus CD8
+
CD25
+
 Tregs’ inhibitory effect may be derived from a 
combined actions of modulation of CTLs’ killing activity and direct killing target cells, and the 
impaired killing ability in perforin KO CD8
+
CD25
+
 Tregs is probably because of the poor pore 
formation by perforin in controlling the entry of cytolytic granzyme B. 
 
Adaptive antigen-specific CD4
+
 Tregs such as type 1 T regulatory (Tr1)- and Th3-cells secreting 
IL-10 and expressing antigen-specific TCRs are generated in the periphery by the stimulation of 
TGF-β- or IL-10-producing DCs through the recognition of antigen-specific TCRs by matching 
antigen-specific pMHC-II complexes (478, 479). Those T cells execute the immunosuppression 
in either cell-cell contact dependent or independent fashion (480). In comparison, polyclonal 
CD4
+
CD25
+
 and CD8
+
CD25
+
 Tregs, which express a pool of self-reactive (autoantigen-specific) 
TCRs, are nonspecific. Autoantigen-directed CD4
+
CD25
+
 Treg derived from TCR-transgenic 
mice have been shown to be more efficient at preventing autoimmunity than polyclonal 
CD4
+
CD25
+
 Tregs (481-483), indicating that the augmentation of Treg function in an 
autoantigen-specific manner is likely to be beneficial for treating autoimmunity. Reprogramming 
the specificity of polyclonal CD4
+
CD25
+
 Tregs achieved by introducing antigen-specific TCRs 
(484-486) would thus enhance CD4
+
CD25
+
 Treg-mediated immune suppression. However, some 
critical disadvantages associated with this approach may still limit its clinical use. In addition to 
the complexity of TCR cloning and transduction, the optimal TCR affinity suitable for each 
therapeutic application is difficult to define (487, 488). Sometimes, the excessive TCR-affinity 
could also be detrimental (489, 490). Tregs may also target pathogenic T cells via their 
expression of class II molecules. LaGuern et al. (491) found enhanced Treg function in 
allogeneic transplantation studies using murine class II transfected Tregs. Engineered Tregs that 
coexpressing Foxp3 and class II autoantigen-peptide complexes, have been shown to efficient 
inhibit of autoimmune T cell function and prevent the development of autoimmune arthritis 
(492). 
 
Alternatively, redirecting antigen specificity to non-specific polyclonal T cells can be achieved 
via the acquisition of pMHC complexes. Previous work in our lab demonstrated that polyclonal 
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CD4
+
 and CD8
+
 T cells, when acquiring antigen-specific pMHC-I-expressing EXOs, became 
capable of stimulating antigen-specific CTL responses as these exosomal pMHC-I complexes 
targeted them to cognate CD8
+
 T cells in vivo (431, 493). In this thesis, CD8
+
CD25
+
 Tregs 
weakly express I-A
b
 (data not shown), which is still quite controversial (494), and exert an 
enhanced inhibition of CTL responses and antitumor immunity when pulsed with OVAII-peptide 
for pMHC-II arming (but not OVAI-peptide for pMHC-I arming). This indicates that 
CD8
+
CD25
+
 Tr/OVAII cells expressing pMHC-II enhance their immunosuppressive action because 
of pMHC-II arming, which potentially redirects them in an antigen-specific manner towards 
matching cognate CD4
+
 T cells in vivo. 
 
TPM provides a unique perspective to examine the cellular mechanisms of Treg-mediated 
suppression in vivo. Two imaging studies demonstrated by Tang et al. (236) and Tadokoro et al. 
(235) have provided direct evidence that Tregs interfere with the interactions between antigen-
loaded DCs and their cognate T cells, and the long-lasting interactions between CD4
+
CD25
+
 
Tregs and DCs have also been visualized. To address the potential suppressive role of 
CD8
+
CD25
+
 Tregs, interactions between antigen-loaded DCs (DCOVA) and cognate OTII CD4
+
 T 
cells have been carefully studied in the presence or absence of CD8
+
CD25
+
 Tregs. CD8
+
CD25
+
 
Tregs are unable to alter the CD4
+
 T-DC interaction, which contradicts with previous reports 
(235, 236). This apparent contradiction could be due to the lower potency of polyclonal 
CD8
+
CD25
+
 Tregs (472) used in this dissertation. However, Mempel et al. (237) also 
demonstrated that the presence of Tregs didn’t alter CD8+ CTL recognition and stable 
interactions with antigen presenting B cells, but profoundly inhibited the ability of CD8
+
 CTLs 
in releasing cytolytic granules and lysing the targets. Interestingly, decreased contact duration 
has been observed after the administration of pMHC-II armed CD8
+
CD25
+
 Treg, suggesting 
CD8
+
CD25
+
 Tr/OVAII cells participate in inhibiting T-DC interactions. Our data thus confirm an 
alternative way to constitute antigen specificity to polyclonal Tregs by pMHC-II arming that can 
direct nonspecific CD8
+
CD25
+
 Tregs towards antigen-specific CD4
+
 T cells, possibly leading to 
the inhibition of priming cognate CD4
+
 T cells by DCs. Unfortunately, we fail to detect the 
interaction between CD8
+
CD25
+
 Tr/OVAII cells and cognate CD4
+
 T cells. Moreover, no direct 
CD8
+
CD25
+
 Tr/OVAII-DCs interaction has been observed in our experiment setting, although both 
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antigen-specific (236) and endogenous polyclonal Tregs (238) have been found to directly 
interact with DCs. 
 
EAE is a rodent model that has been valuable for characterization of the immunopathogenic 
processes of human MS. The pathologic correlate of the multifocal neurologic deficit is the 
invasion of immune cells, predominantly T cells and macrophages in the CNS, which attack the 
myelin sheath and lead to disseminated plaque-like demyelination. Both encephalitogenic CD4
+
 
Th1 and Th17 cells have been found to play an important role in EAE (495, 496). In a 
therapeutic context, natural CD4
+
CD25
+
 Treg populations expanded in vitro can be used for 
preventing autoimmune diseases (497, 498). Polyclonal CD4
+
CD25
+
 Tregs, Qa-1/HLA-E 
restricted CD8
+
 Tregs and some CD8
+
CD25
-
 Tregs such as CD8
+
CD122
+
 and CD8
+
LAP
+ 
Tregs 
have also been reported to suppress EAE (335, 360, 403, 499). Moreover, Tregs expressing TCR 
specific for either MBP- or MOG antigen have been shown to be very effective in inhibiting 
primary EAE as well treating relapsing disease (500, 501). In this thesis, we demonstrate that 
CD8
+
CD25
+
 Tregs with pMHC-II arming can significantly suppress EAE, possibly via induction 
of both cell anergy and effector apoptosis.  
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CHAPTER 7 CONCLUSIONS AND FUTURE DIRECTIONS 
 
In summary, our studies demonstrate that nonspecific polyclonal CD4
+
 T cells, when armed with 
HER2 antigen-specific pMHC-I complexes, become capable of stimulating HER2-specific CTL 
responses and antitumor immunity in double transgenic HLA-A2/HER2 mice. Therefore, 
redirecting antigen specificity to nonspecific CD4
+
 T by pMHC complex arming may have great 
impact on development of novel T cell-based vaccines for treatment of HER2-positive breast 
cancer. Since HER2 has also been found to be overexpressed in many other human malignancies 
including ovary, prostate, gastric, lung, bladder and kidney carcinomas (248), our novel HER2-
TEXO vaccine may be useful in treatment of these human cancers.  
 
In addition, our studies also demonstrate that nonspecific polyclonal CD8
+
CD25
+
 Tregs, when 
armed with MOG antigen-specific pMHC-II complexes, become capable of inducing enhanced 
MOG-specific immunosuppression in MOG-induced EAE mice. Many autoantigens, including 
insulin, MBP and collagen type II targeted in autoimmune diseases such as type-I diabetes, MS 
and rheumatoid arthritis, have been defined (502), which makes the generation of pMHC-II-
armed Tregs possible. Since CD4
+
CD25
+
 Tregs demonstrate more potent immunosuppression 
(352) than CD8
+
CD25
+
 Tregs, the principle of this study can thus be more likely applied to 
CD8
+
CD25
+
 Treg-mediated immunotherapy. Therefore, redirecting antigen specificity to 
nonspecific CD8
+
CD25
+
 Tregs by pMHC complex arming may have great impact on 
development of novel immunotherapeutics for treatment of autoimmune diseases, such as MS. 
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SUPPLEMENTARY MOVIE LEGENDS 
 
sMovie 5.1 Migration of naive OTI CD8
+
 T and OVA-TEXO cells. C57BL/6 mouse was 
transferred with CFSE-labeled OVA-TEXO (green) followed by CMTMR-labeled naive OTI 
CD8
+
 T cells  (red) 24 hrs later. Inguinal lymph nodes were immobilized in an imaging chamber 
and imaged in T-zone region by two-photon laser-scanning microscopy. OTI CD8
+
 T cells form 
tight conjugates with both stationary (circle) and motile (arrow) OVA-TEXO. Projection of a time-
lapse series imaged in intact inguinal lymph nodes is shown. Dimensions: 83 μm × 83 μm × 21 
μm × 30 min. 
 
sMovie 5.2 Pathways of naive OTI CD8
+
 T and OVA-TEXO cells. Experiment was conducted 
in the same conditions as described in sMovie 5.1. Naive OTI CD8
+
 T cells (red) move along 
behind OVA-TEXO (green). The pathways of an OVA-TEXO (green/grey line) and a CD8
+
 T cell 
(red/grey line) are remaining bound to each other during the time of imaging. Dimensions: 106 
μm × 106 μm × 18 μm × 30 min. 
 
sMovie 5.3 Polygamous conjugate between naive OTI CD8
+
 T and OVA-TEXO cells. 
Experiment was conducted in the same conditions as described in sMovie 5.1. An OVA-TEXO 
(green) simultaneously interacts with two naive OTI CD8
+
 T cells (red). White points represent 
the central of cells. Images on the right panel show the pathways for each cell type. Dimensions: 
47 μm × 43 μm × 21 μm × 30 min.  
 
sMovie 5.4 Migration of naive OTI CD8
+
 T cells in the presence of OVA-(K
b-/-
)TEXO cells. 
C57BL/6 mouse was transferred with CFSE-labeled OVA-(K
b-/-
)TEXO (green) followed by 
CMTMR-labeled naive OTI CD8
+
 T cells (red) 24 hrs later. Inguinal lymph nodes were 
immobilized in an imaging chamber and imaged in T-zone region by two-photon laser-scanning 
microscopy. Projection of a time-lapse series imaged in intact inguinal lymph nodes is shown. 
Interactions between OVA-(K
b-/-
)TEXO cells and naive OTI CD8
+
 T cells are only intermittent. 
Dimensions: 106 μm × 106 μm × 27 μm × 30 min.  
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sMovie 5.5 Migration of naive OTI and polyclonal CD8
+
 T cells in the presence of OVA-
TEXO cells. Unlabeled OVA-TEXO cells were injected 24 hrs before co-transferring naive OTI 
(green) and polyclonal (red) CD8
+
 T cells to the same recipient C57BL/6 mouse. OTI CD8
+
 T 
cells (green tracks) show slower and much more confined movements than polyclonal CD8
+
 T 
cells (red tracks). Dimensions: 121 μm × 67 μm × 28 μm × 40 min.  
 
sMovie 5.6 Migration of naive OTI and polyclonal CD8
+
 T cells in the presence of OVA-
TEXO and absence of host APCs. CD11c-DTR mouse was treated with DT, anti-CD20 and anti-
pDC Abs to get rid of potential host APCs one day ahead. Unlabeled OVA-TEXO cells were 
injected followed by co-transferring CFSE-labeled naive OTI (green) and CMTMR-labeled 
polyclonal (red) CD8
+
 T cells to the same pre-treated recipient mouse. OTI CD8
+
 T cells (green 
tracks) and polyclonal CD8
+
 T cells (red tracks) show similar migration patterns as described in 
sMovie 5.5. Dimensions: 88 μm × 88 μm × 42 μm × 40 min.  
 
sMovie 5.7 Migratory behavior of OTII CD4
+
 T cells and sDCOVA. DsRed-sDCOVA (red) were 
injected into the footpad of recipient C57BL/6 mouse. One day later, OTII CD4
+
 T cells (green) 
were i.v. injected to the same recipient mouse. Popliteal lymph node imaging was performed 6 
hrs subsequent to the adoptive transfer of OTII CD4
+
 T cells. Dimensions: 200 μm × 200 μm × 
21 μm × 40 min.  
 
sMovie 5.8 Migratory behavior of OTII CD4
+
 T cells and sDCOVA in the presence of 
OVAII-pulsed CD8
+
CD25
+
 Tregs. Unlabeled OVAII-pulsed CD8
+
CD25
+
 Tregs were i.v. 
injected one day before adoptive transfer of DsRed-sDCOVA (red). One day later, OTII CD4
+
 T 
cells (green) were injected to the same recipient mouse. Popliteal lymph node imaging was 
performed 6 hrs subsequent to the adoptive transfer of OTII CD4
+
 T cells. Dimensions: 200 μm 
× 200 μm × 30 μm × 40 min.  
 
 
